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I Abbreviations 
 
aa amino acids 
ab antibody 
ALL acute lymphoblastic leukemia 
AML acute myeloblastic leukemia 
Amp ampicillin 
AP alkaline phosphatase 
AP-2 clathrin adaptor protein complex 2 
APC allophycocyanin 
approx. approximately 
APS ammonium persulfate 
B-NHL B-cell non-Hodgkin’s lymphoma 
bp base pairs 
BSA bovine serum albumine 
cDNA complementary DNA  
cdk cyclin-dependent kinase 
CFP cyan fluorescent protein 
cfu colony forming unit 
Ci Curie 
CIAP calf intestine alkaline phosphatase 
CME clathrin mediated endocytosis 
CoIP co-immunoprecipitation 
d.p.c days post coitum 
DAPI 4’,6-DIAMIDINO-2-PHENYINDOLE, DIALACTATE 
ddH2O double distilled water 
DEPC diethylpyrocarbonate 
DIG digoxigenin 
DMF N,N-dimethylformamide 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
Dox doxycycline 
DTT dithiothreitol 
e.g. example 
EDTA ethylenediaminetetraacetic acid 
EST expressed sequence tags 
FAB French-American-British classification system for acute leukemia 
FACS fluorescence activated cell sorting 
g gram 
GA glutaraldehyde 
GAL4-AD GAL4 transcriptional activation domain 
GAL4-DBD GAL4 DNA binding domain 
GAL4-UAS GAL4 upstream activating sequence 
GAPDH Homo sapiens glyceraldehyde-3-phosphate dehydrogenase 
GFP green fluorescent protein 
GST glutathione S transferase 
HA hemagglutinin 
hnRNP heterogeneous nuclear ribonucleoprotein 
HPRT hypoxanthine guanine phosphoribosyl transferase 
hr(s) hour(s) 
HRP horse radish peroxidase 
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INF interferon 
Intr intron 
IPTG isopropyl β-D thiogalactoside 
kb kilobases 
kD kilodalton 
KH hnRNP K homology domain 
l liter 
LacZ E. coli gene encoding beta-galactosidase 
LB Luria Bertani medium 
LiAc lithium acetate 
M Molar 
m- milli (1 x 10-3) 
MCS multi cloning site 
min minute(s) 
MOPS 3-N-morpholino-propanesulfonic acid 
mRNA messenger RNA 
n nano (1 x 10-9) 
NaAC sodium acetate 
NaOH sodium hydroxide 
NB northern blot 
NHL Non-Hodgkins Lymphoma 
NLS nuclear localization signal 
nt nucleotide 
O/N overnight 
ºC degree Celsius 
OD optical density 
p pico (1 x 10-12) 
PBS phosphate buffer saline 
PCNA proliferating cell nuclear antigen 
PCR polymerase chain reaction 
PE phycoerythrin 
PEG polyethylenglycol 
PFA paraformaldehyde 
PtdIns(4,5)P2 phosphatidylinositol-4,5-bisphosphate 
RNA ribonucleic acid 
RNAse A ribonuclease A 
RT room temperature 
SAP shrimp alkaline phosphatase 
SD synthetic drop out 
SDS sodium dodecylsulfate 
sec second(s) 
SSC saline sodium citrate buffer 
TBE tris-buffered saline 
TE tris-EDTA buffer 
Tm melting temperature 
TNF alpha tumor necrosis factor alpha 
TNFR tumor necrosis factor receptor 
TPA phorbol ester 
U unit 
UTR untranslated region 
V volts 
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vol. volume 
w/v weight per volume 
WB western blot 
WISH whole mount in situ hybridization 
x g gravity (9.81 m/s2) 
X-gal 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
Y2H yeast two hybrid 
YFP yellow fluorescent protein 
YPD yeast extract, peptone, dextrose 
µ- micro (1 x 10-6) 
 
 
Single-letter codes for amino acids 
 
A (Ala) Alanine M (Met) Methionine 
B Asparagine or Aspartic acid N (Asn) Asparagine 
C (Cys) Cysteine P (Pro) Proline 
D (Asp) Aspartic acid Q (Glu) Glutamine 
E (Glu) Glutamic acid R (Arg) Arginine 
F (Phe) Phenylalanine S (Ser) Serine 
G (Gly) Glycine T (Thr) Threonine 
H (His) Histidine V (Val) Valine 
I (Ile) Isoleucine W (Trp) Tryptophan 
K (Lys) Lysine Y (Tyr) Tyrosine 
L (Leu) Leucine Z Glutamine or Glutamic acid 
 
 
Single-letter codes for nucleotides 
 
A Adenine 
G Guanine 
U Uracil 
C Cytosine 
T Thymine 
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1 Introduction 
 
1.1 Chromosomal translocations 
 
It has been over 40 years since chromosome aberrations were first associated with particular 
types of malignancies. Today it is well known that chromosomal abnormalities, such as 
deletions, inversions, and translocations are crucial events in the malignant process. Balanced 
chromosomal translocations, in particular, are frequently observed in human leukemias. These 
lead to the exchange of genetic material between two non-homologous chromosomes (Figure 
1.1) resulting in the fusion of genes located at the translocation breakpoints or leading to the 
deregulated expression of genes close to the translocation breakpoints.  
 
 
Fig: 1.1: Balanced chromosomal translocation. Arrowheads indicate breakpoint regions on both non-
homologous chromosomes. The exchange of chromosome material is depicted by the double-headed arrow. 
 
There are basically two molecular mechanisms used by the translocations to alter gene 
function, (1) the juxtaposition of a coding region from one gene with the promoter of another 
gene, or (2) fusion of two coding regions to create a new chimeric gene that encodes a fusion 
protein (Figure 1.2) (Rowley, 1999; Rowley, 2000; Rowley, 2001). Classic examples of these 
mechanisms are the t(8;14) translocation which juxtaposes the IGH promoter region to the 
MYC coding sequences, resulting in an overexpression of the MYC oncogene in Burkitt’s 
lymphoma (ar-Rushdi et al., 1983; Taub et al., 1982) and the t(9;22) translocation which fuses 
the Abelson tyrosine kinase gene (ABL) with the breakpoint cluster region gene (BCR) 
resulting in the expression of the BCR-ABL fusion protein encoded by the Philadelphia 
chromosome in chronic myeloid leukemia (CML) (Shtivelman et al., 1985). 
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Janet D. Rowley; Nature reviews 2001 
Fig. 1.2: Consequences of balanced chromosomal translocation. Chromosomal translocation results (a) in the 
juxtaposition of regulatory elements of a gene A with the intact coding region of a gene B leading to deregulated 
expression of the last, or (b) combination of the coding region of two different genes forming a new chimeric 
fusion gene leading to the expression of a fusion protein. 
 
In recent years a growing number of chromosomal translocations have been characterized at 
the molecular level, leading to the identification of many genes involved in inducing 
malignant transformation. As a consequence of these efforts, a network of fusion genes has 
emerged where several genes are involved in more than one translocation forming fusion 
genes with several partner genes. The RUNX1 (AML1), ETV6 and MLL genes occupy central 
positions in this network, playing pivotal roles in the pathogenesis of various types of 
leukemias (Figure 1.3) (Bohlander, 2000).  
 
adapted from Bohlander 2000 and 2005 
Fig. 1.3: Fusion gene network of RUNX1, ETV6 and MLL. Leukemia-associated gene fusions are indicated 
by connecting line (not all fusions of PDGFRB and MLL are shown). Genes are grouped into tyrosine kinases: 
purple; genes with a function in endocytosis: red; chromatin control genes: green; transcription factor genes: 
yellow. 
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Translocations involving the core binding factor complex (heterodimer of the RUNX1 and 
CBFβ proteins) are the most frequent AML-associated rearrangements. The RUNX1/MTG8 
(AML1/ETO) fusion gene resulting from the t(8;21) translocation is found in about half the 
cases of AML of FAB subtypes M2, whereas the CBFβ/MYH11 fusion resulting from the 
inversion of chromosome 16 (inv(16)) is strictly found in M4eo. Both rearrangements account 
for approximately 8-12 % of all cases of AML and are associated with relatively good 
prognosis (Schnittger, 2002). RUNX1 is also involved in the t(12;21) translocation fusing with 
ETV6, the resulting ETV6/RUNX1 fusion being the most common fusion gene found in 
childhood B-ALL (Bohlander, 2005).  
Among the most common chromosomal breakpoint regions in human leukemias is the long 
arm of chromosome 11 at band q23, where the mixed linage leukemia gene (MLL) is located  
(Ziemin-van der Poel et al., 1991). In translocations involving the 11q23 band the MLL gene 
can become fused to one of more than 39 different partner genes at other chromosomal 
locations (De Braekeleer et al., 2005). The most frequent fusion products are the MLL/AF4, 
MLL/AF9, MLL/AF6, MLL/AF10, MLL/ELL and MLL/ENL. These can be found in AML, 
ALL and therapy associated leukemia with poor prognosis. In these MLL fusion proteins the 
N-terminal DNA binding domain of MLL is retained whereas the C-terminal SET domain 
responsible for the H3-K4 methylase activity is lost and replaced by the fusion partner. As a 
consequence, the chimeric protein binds to the MLL target genes, which are then differently 
regulated as a result of a gain of function that is associated with the fusion partner proteins. 
MLL is a major regulator of homeobox (HOX) gene expression, directly interacting with HOX 
promoter regions. In leukemias with MLL fusion protein, overexpression of HOX genes are 
found (Daser & Rabbitts, 2004; Daser & Rabbitts, 2005). Some MLL fusion proteins may 
directly target HOX genes for activation by aberrant recruitment of activators (Licht & 
Sternberg, 2005; Slany, 2005). This is also the case in MLL/AF10 positive leukemias. Okada 
and coworkers have beautifully shown that leukemogenisis by MLL/AF10 involves 
upregulation of Hoxa9 mediated through recruitment of histone methyltransferase hDOT1L 
through interaction with the AF10 octapeptide leucine zipper domain. hDOT1L increases H3-
K79 methylation on MLL target genes leading to increased expression of these genes (Okada 
et al., 2005). There is increasing evidence that nuclear interacting partners of MLL have 
transcription activity themselves and belong to important chromatin remodeling and 
transcription modulating complexes, emphasizing the role of epigenetic processes as mediator 
of malignant transformation (Daser & Rabbitts, 2005; Okada et al., 2005; Slany, 2005; Zeisig 
et al., 2005).  
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1.2 The t(10;11)(p13;q14) translocation involving CALM and 
AF10  
 
The rare but recurring t(10;11)(p13;q14) translocation was first characterized at the molecular 
level in the human monocytic cell line U937 (Dreyling et al., 1996). This rearrangement 
results in the fusion of CALM on chromosome 11 band q14 to AF10 on chromosome 10 band 
p13 (Figure 1.4).  
 
t(10;11)(p13;q14)
AF10
CALM
CALM/ 
AF10
AF10/
CALM
10 11 der(10) der(11)
 
Fig. 1.4: The t(10;11)(p13,q14) translocation. This balanced translocation which results in the CALM/AF10 
fusion is found in acute lymphoid and acute myeloid leukemia as well as in malignant lymphoma. 
 
The two reciprocal fusion mRNAs encode fusion proteins of very unequal size. This is due to 
the location of the breakpoints; in the CALM gene the breakpoints are located at the C-
terminus of the gene and the breakpoints in AF10 are located in the N-terminal portion of 
AF10 (Dreyling et al., 1996). The CALM/AF10 fusion encompasses nearly the complete open 
reading frames of both the CALM and AF10 genes whereas the reciprocal AF10/CALM fusion 
essentially encodes for a truncated AF10 protein of 84 amino acids (Figure 1.5). 
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Fig. 1.5: Diagram representing the protein structures of AF10, CALM and the AF10/CALM and 
CALM/AF10 fusion proteins. Arrows indicate the breakpoints in CALM and AF10 described in U937 cell line. 
Other breakpoints found in cells from patients are shown as triangles. There is no apparent correlation between 
breakpoint location and disease phenotype. PHD: plant homeodomain zinc fingers; NLS: nuclear localization 
signal; AT: AT-hook motif; OM: octapeptide motif; LZ: leucine zipper; Q: glutamic acid rich domain; ANTH: 
AP180 N-terminal homology domain. 
 
In patients, the occurrence of CALM/AF10 rearrangement has been observed mainly in 
undifferentiated acute myeloid leukemia (AML) (FAB M0 or M1) or T-cell acute 
lymphoblastic leukemia (ALL) and in malignant lymphoma and carries rather poor prognosis 
(Dreyling et al., 1998; Kumon et al., 1999; Narita et al., 1999). In T-ALL with T-cell receptor 
(TCR) gamma/delta rearrangement the CALM/AF10 fusion is found in up to 30 % of cases 
and constitutes the most frequent rearrangement in this leukemia subtype (Asnafi et al., 2004; 
Asnafi et al., 2005; Asnafi et al., 2003). Recently, cases of more differentiated AML with a 
CALM/AF10 fusion have been reported (FAB M4, M5 and M7) (Abdou et al., 2002; Carlson 
et al., 2000; Jones et al., 2001; Nakamura et al., 2003; Salmon-Nguyen et al., 2000). The 
translocation is observed in younger patients (Dreyling et al., 1998; Kobayashi et al., 1997; 
Kumon et al., 1999; Silliman et al., 1998) and is also associated with mixed-lineage 
immunophenotype with coexpression of lymphoid (T-cell) and myeloid antigens (Kumon et 
al., 1999; Narita et al., 1999). 
In several patients, the t(10;11)(p13;q14) translocation has been described as a sole 
chromosomal abnormality (Abdou et al., 2002; Bohlander et al., 2000; Carlson et al., 2000; 
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Kumon et al., 1999; Narita et al., 1999; Salmon-Nguyen et al., 2000; Silliman et al., 1998) 
implying that the CALM/AF10 fusion plays a crucial role in leukemogenesis. 
It is very likely that the CALM/AF10 fusion transcript and not the reciprocal AF10/CALM 
fusion is critical in the leukemogenic process since it is a constant feature observed in all 
patients with a t(10;11)(p13;q14) whereas the AF10/CALM fusion mRNA can only be 
detected in about half of the patients that carry a CALM/AF10 fusion (Bohlander et al., 2000; 
Carlson et al., 2000; Dreyling et al., 1996; Dreyling et al., 1998; Krause, 2004; Narita et al., 
1999). Indeed, Deshpande et al. could show that the CALM/AF10 fusion gene causes 
aggressive biphenotypic leukemia in a murine bone marrow transplantation model 
(Deshpande, 2005; Deshpande, 2003). 
Very recently Delabesse and coworkers and our group have report that CALM/AF10 positive 
T-ALL are characterized by overexpression of the HOXA and BMI1 genes. The over-
expression of the HOX genes is reminiscent of the HOX gene expression patterns observed in 
leukemias involving rearrangements of the MLL gene (Dik et al., 2005; Krause, 2004). 
The AF10 gene is one of the few MLL partner genes to be independently rearranged with a 
third gene in leukemia (Ayton & Cleary, 2001; Dreyling et al., 1996). It codes for a 1084-aa 
nuclear protein which contains an N-terminal LAP/PHD (leukemia associated protein/plant 
homeodomain) zinc finger motif, an extended LAP/PHD motif, a nuclear localization signal 
(NLS), an AT-hook motif, an octapeptide motif (OM), a leucine zipper (LZ) motif and a 
glutamic acid rich region (Q rich region). AF10 contains sequence motifs common to 
transcription factors and has been suggested to play a role in heterochromatin-mediated 
transcriptional silencing (Debernardi et al., 2002; Linder et al., 2001; Linder et al., 2000; 
Perrin et al., 2003; Perrin & Dura, 2004; Saha et al., 1995).  
CALM codes for a 652-aa ubiquitously expressed protein that shows extensive homologies to 
the neuronal specific endocytic protein AP180 (Morris et al., 1993). It functions as an 
endocytosis adaptor which takes part in the initial stages of coated pit invagination together 
with clathrin, AP-2 and PtdIns(4,5)P2 containing membranes. CALM interacts with the 
clathrin heavy chain through its C-terminal third and with phophoinositides through its ANTH 
domain in the N-terminal third, promoting assembly of clathrin triskelia into clathrin cages in 
vitro (Ford et al., 2002; Ford et al., 2001). Both overexpression or down regulation of CALM 
have been shown to inhibit receptor-mediated endocytosis and impair endosome trafficking in 
the trans golgi network (Huang et al., 2004; Meyerholz et al., 2005; Tebar et al., 1999). The 
phenotype of AP180/CALM mutants of Drosophila (lap mutants) and Caenorhabditis 
elegans (unc11 mutants) and more recently depletion of CALM protein in mammalian cells 
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suggested a role of these proteins in regulating the size of endocytic vesicles during the 
clathrin assembly process (Meyerholz et al., 2005; Nonet et al., 1999; Zhang et al., 1998). 
Evidences that CALM and its involvement in the clathrin mediated endocytosis processes 
play an important role for hematopoiesis, iron uptake- metabolism and growth was provided 
by Klebig and co workers, who have shown that point mutations in the mouse CALM 
homologue Picalm are responsible for abnormalities in hematopoiesis and iron metabolism 
(Klebig et al., 2003). 
To further elucidate the function of CALM and the leukemogenic CALM/AF10 fusion protein 
we searched for CALM interacting proteins using a yeast two-hybrid approach. A novel 
protein, which is strongly expressed in thymus, spleen and colon was identified in this search. 
The corresponding gene was named CATS (CALM interacting protein expressed in thymus 
and spleen). 
2 Material and Methods 
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2 Material and Methods 
 
2.1 Material 
 
2.1.1 Reagents 
 
1-kb-DNA Ladder Invitrogen, Karlsruhe, Germany 
β-Mercaptoethanol Sigma, Taufkirchen, Germany 
[∝-32P]dCTP 3000 µCi/mmol Amersham, Freiburg, Germany 
10X DIG RNA reaction mix Roche, Mannheim, Germany 
Acetic acid Merck, Darmstad, Germany 
Acrylamid Rotiphorese® Gel 30 (37, 5:1) Carl Roth, Karlsruhe, Germany 
Ag501-X8 BioRad Laboratories, Hercules, CA 
Agar Carl Roth, Karlsruhe, Germany 
Agarose ICN Biomedicals Inc. 
Amino acids (yeast two-hybrid) Sigma, Taufkirchen, Germany 
Ammonium acetate (NH4Ac) Sigma, Taufkirchen, Germany 
Ammonium chloride (NH4Cl) solution CellSystems, Vancouver, Canada 
Ammonium persulfate (APS) Sigma, Taufkirchen, Germany 
Ampicillin Na-Salt Pan Biotech, Aidenbach, Germany 
Ampuwa® H2O Fresenius, Bad Homburg, Germany 
Aprotinin Sigma, Taufkirchen, Germany 
BigDye™ terminator mix PE Applied Biosystems, Foster City, CA 
Blocking reagent  Roche, Mannheim, Germany 
BM purple AP substrate Roche, Mannheim, Germany 
Boric acid Carl Roth, Karlsruhe, Germany 
Bovine serum albumin Sigma, Taufkirchen, Germany 
Bromophenol blue Carl Roth, Karlsruhe, Germany 
Calcium chloride (CaCl2) Sigma, Taufkirchen, Germany 
Calf Intestine Alkaline Phosphatase (CIAP) MBI Fermentas, St. Leon-Rot, Germany 
Citric acid Merck, Darmstadt, Germany 
Coomassie® stain solution BioRad, Hercules, CA 
D(+)-Glucose-Monohydrate Merck, Darmstadt, Germany 
Dakocytomation Fluorescent Mounting Medium DakoCytomation, Hamburg, Germany 
DAPI Sigma, Taufkirchen, Germany 
ddH2O Millipore, Eschborn, Germany 
Deoxyribonuclease I, Amplification Grade Invitrogen, Karlsruhe, Germany 
Dextran sulfate Carl Roth, Karlsruhe, Germany 
Diethyl Pyrocarbonate (DEPC) Sigma, Taufkirchen, Germany 
Dimethyl formamide (DMF) Carl Roth, Karlsruhe, Germany 
Dimethyl sulfoxide (DMSO) Merck, Darmstadt, Germany 
Dithiothreitol (DTT) Carl Roth, Karlsruhe, Germany 
dNTP Set, PCR Grade Invitrogen, Karlsruhe, Germany 
DPBS Pan Biotech, Aidenbach, Germany 
ECL™ Plus Western Blotting Detection Reagent Amersham, Freiburg, Germany 
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ECL™ Western Blot Detection reagents Amersham, Freiburg, Germany 
EDTA Carl Roth, Karlsruhe, Germany 
Ethanol Merck, Darmstadt, Germany 
Ethidium bromide Carl Roth, Karlsruhe, Germany 
Fetal bovine serum (FBS) Gibco Invitrogen cell culture, Karlsruhe, Germany 
Ficoll (type 400) Sigma, Taufkirchen, Germany 
Formaldehyde 37 % Carl Roth, Karlsruhe, Germany 
Formamide Carl Roth, Karlsruhe, Germany 
Gelatine Merck, Darmstadt, Germany 
Glutaraldehyde 25 % aqueous solution Sigma, Taufkirchen, Germany 
Glutathione Sigma, Taufkirchen, Germany 
Glutathione-Agarose Sigma, Taufkirchen, Germany 
Glycerin 87 % neoLab, Heidelberg, Germany 
Glycerol Carl Roth, Karlsruhe, Germany 
Glycine Merck, Darmstadt, Germany 
Heparin Sigma, Taufkirchen, Germany 
Herring Testes Carrier DNA denatured  DB Biosciences Clontech, Heidelberg, Germany 
Hydrochloridric acid 37 % Merck, Darmstadt, Germany 
Hydrogen peroxide (H2O2) solution 35 %  Merck, Darmstadt, Germany 
IPTG Roche, Mannheim, Germany 
Isopropanol Carl Roth, Karlsruhe, Germany 
Jung Tissue Freezing Medium™ Leica Instruments, Nussloch, Germany 
Kaisers Glyceringelatine Merck, Darmstadt, Germany 
Kanamycin Pan Biotech, Aidenbach, Germany 
Klenow Fragment MBI Fermentas, St. Leon-Rot, Germany 
Leptomycin B (LMB) Streptomyces sp.  Calbiochem, San Diego, USA 
Leupeptin Sigma, Taufkirchen, Germany 
Levamisole Sigma, Taufkirchen, Germany 
L-Glutamine  Pan Biotech, Aidenbach, Germany 
Lithium acetate Sigma, Taufkirchen, Germany 
Maleic acid Sigma, Taufkirchen, Germany 
Methanol Merck, Darmstadt, Germany 
Milk powder Carl Roth, Karlsruhe, Germany 
MOPS  Carl Roth, Karlsruhe, Germany 
NP40 Roche, Mannheim, Germany 
Oligo (dT)12-18 Primer Invitrogen, Karlsruhe, Germany 
PanScript DNA Polymerase Pan Biotech, Aidenbach, Germany 
Paraformaldehyde Sigma, Taufkirchen, Germany 
Penicillin/streptomycin Pan Biotech, Aidenbach, Germany 
Pepstatin Sigma, Taufkirchen, Germany 
Peptone, meat pancreatic digested Merck, Darmstadt, Germany 
Pfu DNA Polymerase Promega, Mannheim, Germany 
Phenol/chloroform/isoamyl (25:24:1) Invitrogen, Karlsruhe, Germany 
Phenylmethylsulfonylfluorid (PMSF) Sigma, Taufkirchen, Germany 
Platinum® Taq DNA Polymerase Invitrogen, Karlsruhe, Germany 
Polyethylenglycol (PEG) 4000 Merck, Darmstadt, Germany 
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Polyvinylpyrrolidone (PVP) K 30 Carl Roth, Karlsruhe, Germany 
Potassium acetate (KAc) Calbiochem, San Diego, USA 
Potassium chloride (KCl) Calbiochem, San Diego, USA 
Propidium iodide Sigma, Taufkirchen, Germany 
Protein A-Agarose Roche, Mannheim, Germany 
Protein G-Agarose Roche, Mannheim, Germany 
Proteinase inhibitor cocktail Sigma, Taufkirchen, Germany 
Proteinase K Sigma, Taufkirchen, Germany 
Restriction enzymes MBI Fermentas, Germany 
Restriction enzymes NewEngland Biolabs, Schwalbach, Germany 
Ribonuclease A MBI Fermentas, Sigma or Qiagen, Germany 
RNA Ladder, High Range MBI Fermentas, St. Leon-Rot, Germany 
RNA polymerase Roche, Mannheim, Germany 
RNase Away Carl Roth, Karlsruhe, Germany 
RNaseOUT™ Recombinant Ribonuclease Inhibitor Invitrogen, Karlsruhe, Germany 
Roti®-Fect transfection reagent Carl Roth, Karlsruhe, Germany 
Salmon testes DNA  Sigma, Taufkirchen, Germany 
SDS Carl Roth, Karlsruhe, Germany 
SeeBlue® Plus2 pre-stained standard Invitrogen, Karlsruhe, Germany 
Shrimp Alkaline Phosphatase (SAP) MBI Fermentas, St. Leon-Rot, Germany 
Sodium acetate, Anhydrous (NaAC) Calbiochem, San Diego, USA 
Sodium chloride (NaCl) Merck, Darmstadt, Germany 
Sodium citrate Carl Roth, Karlsruhe-, Germany 
Sodium deoxycholate Sigma, Taufkirchen, Germany 
Sodium hydroxide (NaOH) Merck, Darmstadt, Germany 
Sodium phosphate dibasic anhydrous (Na2HPO4) Sigma, Taufkirchen, Germany 
Sodium phosphate monobasic monohydrate (NaH2PO4) Calbiochem, San Diego, USA 
Sucrose Sigma, Taufkirchen, Germany 
SuperScript™ II RNase H- Reverse Transcriptase Invitrogen, Karlsruhe, Germany 
T4 DNA Ligase NewEngland Biolabs, Schwalbach, Germany 
Tris Carl Roth, Karlsruhe, Germany 
Triton X-100 Carl Roth, Karlsruhe, Germany 
tRNA Roche, Mannheim, Germany 
Trypsin-EDTA  Gibco™, Germany 
Tween® 20 Sigma, Taufkirchen, Germany 
X-α- gal Clontech, Heidelberg, Germany 
Yeast extract Sigma, Taufkirchen, Germany 
Yeast nitrogen base without aa Difco, Detroit MI, USA 
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2.1.2 Material and Kits 
 
Blotting paper GB003 and GB002 Schleicher & Schuell, Dassel, Germany 
Cell Strainer 40µm Nylon Falcon® BD Biosciences, Palo Alto, CA 
Column Bulk and RediPack GST Purification Modules Amersham, Freiburg, Germany 
Coverslips Menzel-Gläser®, Braunschweig, Germany  
Cryotube™ vials Nalge Nunc Internacional, Denmark 
DNeasy® Tissue Kit (50) Qiagen, Hilden, Germany 
Dual-Luciferase® Reporter Assay System Promega, Mannheim, Germany 
Electroporation cuvettes 2mm EquiBio, Kent, UK 
Endofree® Plasmid Maxi kit (10) Qiagen, Hilden, Germany 
Eppendorf tubes Eppendorf, Hamburg, Germany 
FACS Polystrene round-bottom tubes Becton Dickinson, Meylan, France 
Filter 0.22µm Millipore, Belford, USA 
Glass beads  Sigma, Taufkirchen, Germany 
Glassware  Schott, Jena, Germany 
Human Multiple Tissue Northern (MTN™) Blot Clontech, Heidelberg, Germany 
Human Multiple Tissue Northern (MTN™) Blot II Clontech, Heidelberg, Germany 
Hybond-N nylon membrane Amersham, Freiburg, Germany 
Hybond™ ECL™ nitrocellulose membrane Amersham, Freiburg, Germany 
Hypercassete™ 18x24 cm Amersham, Freiburg, Germany 
Hyperfilm ECL high performance Amersham, Freiburg, Germany 
JETSorb DNA extraction from Agarose Gels Genomed, Bad Oeynhausen, Germany 
JETSTAR Plasmid Midi Kit Genomed, Bad Oeynhausen, Germany 
Luminometer tube (Disposable Cuvettes 12 mm x 50 mm) Promega, Mannheim, Germany 
Marabu Fixogum Rubber Cement Marabuwerk GmbH, Tamm, Germany 
Megaprime™ DNA labeling system Amersham, Freiburg, Germany 
Microcentrifuge tube (1.5 ml) Eppendorf, Hamburg, Germany 
Microscope slides Menzel-Gläser®, Braunschweig, Germany 
Microspin S-400 HR columns Amersham, Freiburg, Germany 
Mitsubishi thermal papervideo-printer Mitsubishi, Hatfield, UK 
Nescofilm sealing film Carl Roth, Karlsruhe, Germany 
Pipette tips Carl Roth, Karlsruhe, Germany 
Plastic cuvettes for OD Carl Roth, Karlsruhe, Germany 
Plastic ware for cell culture Greiner Labortechnik, Frickenhausen, Germany 
Plastic ware for cell culture Sarstedt, Nümbrecht, Germany 
Plastic ware for cell culture Corning, USA 
Polypropylene conical tubes Becton Dickinson, Meylan, France 
Qiagen RNEasy Mini Kit Qiagen, Hilden, Germany 
QIAquick® Nucleotide Removal Kit (50) Qiagen, Hilden, Germany 
Qiashredder™ columns Qiagen, Hilden, Germany 
Rneasy™ mini kit Qiagen, Hilden, Germany 
Scintillation vials Sigma, Taufkirchen, Germany 
Surgical blade Feather Safety Razor Co. Med. Div., Japan 
Syringe  Braun, Melsungen, Germany 
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2.1.3 Equipment 
 
Axioplan 2 Imaging microscope Carl Zeiss, Jena, Germany  
AxioCam HR digital camera Carl Zeiss, Jena, Germany 
Axiovert 200M microscope Carl Zeiss, Jena, Germany 
BioPhotometer 6131 Eppendorf, Hamburg, Germany 
Centrifuge 5417 C Eppendorf, Hamburg, Germany 
Centrifuge 5417 R Eppendorf, Hamburg, Germany 
Centrifuge RC5B Plus  SORVALL®, Langenselbold, Germany 
Centrifuge RC5C  SORVALL®, Langenselbold, Germany 
Cryotome CM 1850 Leica Microsystems, Wetzlar, Germany 
Electroporator (Easyject Prima)  EquiBio Peqlab, Erlangen, Germany 
FACSVantage SE System BD Biosciences, Palo Alto, CA 
Gel Air™ Drying System BioRad Laboratories, Hercules, CA 
GeneAmp® PCR system 2400 Perkin Elmer, Jügesheim, Germany 
GeneAmp® PCR system 9700 Perkin Elmer, Jügesheim, Germany 
Genetic Analyzer automated sequencer ABI PRISM 310 PE Applied Biosystems, Foster City, CA 
GS Gene Linker™ UV Chamber BioRad Laboratories, Hercules, CA 
Icubator Heraeus Instruments, Langenselbold, Germany 
Innova™ 4400 Incubator Shaker New Brunswick Scientific, Nürtingen, Germany 
InsituPro robot ABIMED, Langenfeld, Germany 
MZ APO stereomicroscope 
JVC KY-F70 digital camera 
Leica Microsystems, Wetzlar, Germany 
JVC Professional Europe, London, UK 
Savant SpeedVac® GMI, Minnesota, U.S.A 
TD-20/20 luminometer Turner Designs, Sunnyvale, CA 
Thermomixer 5436 Eppendorf, Hamburg, Germany 
Tissuemizer  Tekmar-Dohrmann, Manson, OH 
Trans-Blot® SD Semi -Dry Transfer Cell BioRad Laboratories, Hercules, CA 
X-Ray Automatic Processor Curix 60 Agfa, Köln Germany 
 
2.1.4 Software 
 
Software INSITU version 4.020 was used in the InsituPro robot (ABIMED) for automated in 
situ hybridization of whole mount mouse embryos. Images of whole mount embryos were 
recorded using the Leica QWin software (Leica Microsystems Imaging Solutions, Cambridge, 
UK). AxioVision 3.1 (Carl Zeiss, Jena, Germany) was used for capturing images of sectioned 
embryos and the Openlab 3.08 (Improvision, Coventry, UK) for visualizing and photographic 
documentation of cells. Pictures were processed with Adobe Photoshop® 7.0 (Adobe Systems, 
Mountain View, U.S.A) and worked on Macromedia Freehand 10.0 (Freehand Systems, 
USA). The software used for FACS sorting was the CellQuest Version 3.1(f) (BD 
Biosciences, Palo Alto, CA). Mac Vector™ 7.2.3 (Oxford Molecular Group) was used for 
sequence analysis and primers design and AssemblyLIGN™ 1.0.9c (Oxford Molecular Group) 
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for assembling and generating contig sequences. Microsoft Office 2004 for Mac (Microsoft 
Corporation, USA) was used for text editing, table calculations and graphic images, Adobe 
Reader 7.0 (Adobe Systems, Mountain View, U.S.A) was used to covert documents into PDF 
format, and EndNote 8.0 (Thomson) for managing bibliographies. 
 
2.1.5 Buffers and Solutions 
 
All buffers and solution were prepared with ddH2O, unless they had to be RNase-free. In this 
case they were prepared with DEPC-H2O.  
 
E1 resuspension buffer 50 mM 
10 mM 
100 µg/mL 
Tris/HCl pH 8.0 
EDTA 
RNAse A 
Store at 4°C 
 
E2 lysis buffer 200 mM 
1 % 
NaOH 
SDS 
Autoclave, store at RT 
 
E3 neutralization buffer 3 M Potassium acetate pH5.5 
Autoclave, store at RT 
 
10X TE buffer 100 mM 
10 mM 
Tris/HCl  
EDTA 
pH 8.0 or 7.5 (for Y2H experiments) 
 
5X TBE 445 mM 
445 mM 
10 mM 
Tris/HCl pH 8.0 
Boric acid 
EDTA 
 
Blue Juice loading buffer 65 % 
10 mM 
10 mM 
0.3 % 
Sucrose 
Tris/HCl pH 7.5 
EDTA 
Bromophenol blue 
Store at RT 
 
RNA sample buffer (325 µl) 75 µl 
45 µl 
180 µl 
25 µl 
Formaldehyde 37 % 
10X MOPS RNA running buffer 
Formamide 
Ethidium bromide (1 µg/µl) 
 
RNA loading buffer (1 ml) 500 µl 
25 µl 
4 µl 
471µl 
Glycerol (autoclaved) 
10 % Bromophenol blue 
0.25 M EDTA pH 7.4/DEPC-H2O 
DEPC-H2O 
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10X MOPS RNA running 
buffer 
41.8 g 
16.6 ml 
20 ml 
 
MOPS in 800 ml DEPC-H2O, adjust pH 7.0 
3 M NaAC/DEPC-H2O 
0.5 M EDTA/DEPC-H2O 
Add DEPC-H2O to complete 1 l vol., filter sterile 
and store at RT protected from light 
 
Hybridization solution (NB) 5X 
5X 
10 % 
0.5 % 
Denhardt’s solution 
SSC 
Dextran sulfate 
SDS 
 
Stripping solution for NB 5 mM 
2 mM 
0.1X 
Tris/HCl pH 8.0 
EDTA 
Denhardt’s solution 
 
50X Denhardt’s solution  1 % 
1 % 
1 % 
BSA 
Polyvinylpyrrolidone (PVP)  
Ficoll 400 (type 400) 
Filter sterile, aliquot and store at –20°C 
 
DEPC-H2O 0.01 % Diethyl pyrocarbonate (DEPC) in ddH2O 
Mix well, incubate O/N and autoclave 
 
Saline sodium citrate buffer 
(SSC) 20X 
3 M 
0.3 M 
NaCl 
Sodium citrate 
pH 7.0  
Autoclave 
 
10 % SDS 10 % (w/v) Sodium dodecylsulfate 
 
Hybridization solution (RZPD 
filters) 
50 % 
4X 
50 mM 
1 mM 
10 % 
1 % 
50 µg/ml 
10X 
Formamide 
SSC 
Sodium phosphate buffer 
EDTA 
Dextran sulfate 
SDS 
Denature Salmon testes DNA 
Denhardt’s solution 
 
Sodium phosphate buffer  684 ml 
316 ml 
1 M Na2HPO4 
1 M NaH2PO4 
pH 7.2 
 
Phosphate buffer saline (PBS) 80 g 
14.4 g 
2.4 g 
2 g 
800 ml 
NaCl 
Na2HPO4 
NaH2PO4 
KCl 
ddH2O 
adjust pH 7.4 with HCl,  
complete to 1 l vol. and autoclave 
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Stripping solution for WB 62.5 mM 
0.1 M 
2 % 
Tris/HCl pH 6.8 
β-mercaptoethanol  
SDS 
 
RIPA buffer 1X 
1 % 
0.5 % 
0.1 % 
PBS 
Triton X-100 
Sodium deoxycholate 
SDS 
 
1X TBS 10 mM 
150 mM  
Tris/HCl pH 8.0 
NaCl 
 
1X TBST washing buffer 1X 
0.1 % 
TBS 
Tween® 20 
 
Transfer buffer(1 l) 5.82 g 
2.93 g 
0.038 g 
20 % 
Tris 
Glycin 
SDS 
Methanol 
 
10X Tris-Glycine 
electrophoresis buffer 
250 mM 
2.5 M 
1 % 
Tris 
Glycine 
SDS 
 
2X Laemmli sample buffer 10 % 
6 % 
20 % 
0.2 mg/ml 
0.025X 
β-mercaptoethanol 
SDS 
Glycerol 
Bromophenol blue 
Laemmli stacking buffer (optional) 
Store up to 2 month at RT 
 
2.5X Laemmli stacking buffer 0.3 M 
0.25 % 
Tris/HCl pH 6.8 
SDS 
Store up to 1 month at 4°C 
 
FACS buffer 1X 
2 % 
1 mg/l 
PBS 
FBS 
propidium iodide 
 
Ammonium chloride 
solution 
0.8 % 
0.1 mM 
NH4Cl in sterile water 
EDTA 
 
PEG/LiAc solution 8 vol. 
1 vol. 
1 vol.  
50 % PEG 4000 
10X TE buffer 
10X LiAc 
 
10X LiAc solution 1 M Lithium acetate 
Adjust to pH 7.5 with acetic acid and autoclave 
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1X PEG/LiAc 0.2 ml 
0.2 ml 
1.6 ml 
10X TE 
10X LiAc solution 
ddH2O 
Lysis solution for yeast cells 10 mM 
1 mM 
100 mM 
2 % 
1 % 
Tris/HCl pH 8.0 
EDTA 
NaCl 
Triton X-100 
SDS 
 
NETN buffer  
(Purification of GST-fusion 
protein) 
150 mM 
20 mM 
1 mM 
0.5 % 
NaCl  
Tris/HCl pH 8.0 
EDTA pH 8.0 
Triton X-100 
 
High salt washing buffer 
(Purification of GST-fusion 
protein) 
1 M 
20 mM 
1 % 
1 mM 
NaCl 
Tris/HCl pH 7.5 
Triton X-100 
DTT 
 
Elution buffer  
(Purification of GST-fusion 
protein) 
100 mM 
50 mM 
200 mM 
NaCl 
Tris/HCl pH 8.0 
Glutathione 
 
CoIP buffer I 50 mM 
150 mM 
0.5 % 
0.25 % 
1:100 
Tris/HCl pH 7.5 
NaCl 
Triton X-100 
Sodium deoxycholate 
Proteinase inhibitor cocktail, freshly added 
 
CoIP buffer II 50 mM 
0.1 % 
0.05 % 
 
Tris/HCl pH 7.5 
Triton X-100 
Sodium deoxycholate 
 
CoIP buffer 3 10 mM 
50 mM 
0.5 % 
1:100 
 
Tris/HCl pH 8.0 
NaCl 
Triton X-100 
Proteinase inhibitor cocktail, freshly added 
 
2 % Paraformaldehyde (PFA) 1 g 
48 ml 
47-50 µl 
75-90 µl 
PFA 
PBS 
5 M NaOH to dissolve the PFA 
2 M HCl (37 %; diluted 1:5) to adjust pH to 7.4 
complete with PBS to 50 ml vol.  
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Tfb 1  30 mM 
50 mM 
100 mM 
10 mM 
15 % 
KAc 
MgCl2 
KCl 
CaCl2 
Glycerol 
adjust to pH 5.8 (with 0.2 M NaOH), filter 
sterile, aliquot and store at -20°C 
 
Tfb 2 10 mM 
75 mM 
10 mM 
15 % 
MOPS 
CaCl2 
KCl 
Glycerol 
adjust to pH 6.8 (with acetic acid), filter sterile, 
aliquot and store at -20°C 
 
4 % Paraformaldehyde (PFA) 
(100 ml) 
4 g 
100 ml 
~50 µl 
 
~90 µl 
PFA 
PBS-DEPC 
5 M NaOH and heat up to 55°C to dissolve the 
PFA 
2 M HCl (37 %; diluted 1:5) to adjust pH to 7.0  
 
4 % PFA/ 0.1 % GA 1 vol. 
0.1 % 
1 vol. 
4 % PFA 
Glutaraldehyde 
PBT 
PBS-DEPC 30 ml 
15 ml 
955 ml 
5 M NaCl 
1 M Sodium phosphate buffer pH 7.3 
DEPC-H2O 
 
PBT  1X 
0,1 % 
PBS-DEPC 
Tween® 20 
 
Proteinase K buffer 2 mg/ml 
20 mM 
1 mM 
Proteinase K (10 mg/ml stock) 
Tris/HCl pH 7.0 
EDTA 
in DEPC-H2O 
 
Hybridization solution 
(WISH) 
50 % 
5X 
50 µg/ml 
0.1 % 
Deionized formamide 
SSC-DEPC 
Heparin (100 mg/ml stock) 
Tween® 20 
in DEPC-H2O, adjust to pH 6.0 (with 1 M Citric 
acid-DEPC) 
 
SSC/FA/ Tween® 20 2X 
50 % 
0.1 % 
SSC 
formamide 
Tween® 20 
in ddH2O  
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10X TBST (WISH) 8 g 
0.2 g 
25 ml 
10 ml 
NaCl 
KCl 
1 M Tris/HCl pH 7.5 
Tween® 20 
complete with ddH2O to 100 ml final vol. 
 
MAB 100 mM 
150 mM 
 
Maleic acid 
NaCl 
in ddH2O, adjust to pH 7.5 with solid NaOH 
 
MABT 1X 
0.1 % 
MAB 
Tween® 20 
 
RNase solution (TNT) 10 mM 
0.5 M 
0.1 % 
Tris/HCl pH 7.5 
NaCl 
Tween® 20 
in ddH2O 
 
Alkaline phosphatase buffer 
(NTMT) 
100 mM 
50 mM 
100 mM 
0.1 % 
2 mM 
NaCl 
MgCl2 
Tris/HCl pH 9.5 
Tween® 20 
Levamisole 
in ddH2O 
 
Blocking stock solution  
(10 %) 
10 % Blocking reagent  
Dissolve reagent in MAB with shaking and 
heating. After autoclaving add 0.1 % Tween® 20, 
aliquot and store at -20°C 
 
RIPA-DEPC 2.5 ml 
15 ml 
5 ml 
25 ml 
1 ml 
25 ml 
 
10 % SDS-DEPC 
5 M NaCl 
NP40 
10 % Sodium deoxycholate-DEPC 
0.5 M EDTA-DEPC 
1 M Tris/HCl pH 8.0 
Add to 500 ml DEPC-H2O 
 
Deionized formamide 10 g 
100 ml 
BioRad Ag501-X8 
Formamide 
Stir for 1 hr, filtrate and store at -80°C 
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2.1.6 Culture medium 
 
2.1.6.1 Culture medium for bacteria 
 
Luria Bertani (LB) medium was prepared with ddH2O and autoclaved 
LB medium 1 % peptone 
 0.5 % yeast extract 
 1 % NaCl 
 1.5 % agar (for LB agar plates only) 
In order to select transformed cells ampicillin or kanamycin was added to the medium at final 
concentration of 50 µg/ml and 25 µg/ml, respectively.  
LB-agar medium with antibiotic was poured onto Petri dishes and stored at 4° C. 
 
2.1.6.2 Culture medium for yeast 
 
All yeast media and solutions were prepared and handled on sterile conditions. 
YPD medium 20 g/l peptone 
 10 g/l yeast extract 
 20 g/l agar (for YPD agar plates only) 
 950 ml ddH2O, autoclave 
Adjust the pH to 6.5 (with NaOH), if necessary and autoclave. Allow medium reached 
approx. 55°C and add 50 ml of 40 % glucose stock solution. At the same temperature YPD-
agar medium was poured onto Petri dishes and subsequently stored at 4°C. 
 
A combination of a minimal SD base and a dropout (DO) solution were used to produce a 
defined minimal yeast medium lacking one or more specific nutrients. The nutrients were 
added separately for each selective SD/DO medium according to the selection desired. A 10X 
stock dropout solution was prepared lacking amino acids adenine, histidine, leucine, and 
tryptophan.  
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10X DO -Trp, -Leu, 
-His, -Ade 
 
200 mg 
 
Arginine 
 300 mg Isoleucine 
 300 mg Lysine 
 200 mg Methionine 
 500 mg Phenylalanine 
 2000 mg Threonine 
 300 mg Tyrosine 
 200 mg Uracil 
 1500 mg Valine 
 1000 ml  ddH2O, autoclave 
 
SD -Trp, -Leu, 
-His, -Ade  
 
6.7 g 
 
yeast nitrogen base without aa 
 20 g agar (for SD plates only) 
 850 ml ddH2O 
 100 ml 10X dropout solution (-Trp, -Leu, -His, -Ade) 
For SD -Trp, -Leu, -His 
add 
 
200 mg 
 
Adenine 
For SD -Trp, -Leu add 200 mg Adenine, Histidine 
Adjust the pH to 5.8 if necessary and autoclave. Allow medium reached approx. 55°C and add 
50 ml of 40 % glucose stock solution. For SD -Trp, -Leu, -His, -Ade plates supplemented 
with X-α -gal, 1:1000 volume of X-α -gal (20 mg/ml in DMF) was added to the medium. SD-
agar medium was poured onto Petri dishes and subsequently stored at 4°C. 
 
2.1.6.3 Cell culture medium  
 
All cell culture media and solutions were handled on sterile conditions and stored at 4°C. 
Dulbecco´s Modified Eagle medium (DMEM), Roswell Park Memorial Institute culture 
medium (RPMI 1640), antibiotics, L-Glutamine and DPBS were purchased from Pan Biotech, 
Aidenbach, Germany. Fetal bovine serum (FBS) was purchased from Gibco® Invitrogen cell 
culture.  
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2.1.7 Bacterial strain (Escherichia coli) 
 
Strain Usage 
XL1’ Blue host for plasmid amplification 
BL21 host of choice for GST fusion expression. Does not transform well, an alternate strain for cloning and 
maintenance of the vector is needed 
 
2.1.8 Yeast strain 
 
All yeast reporter strains were purchased from DB Biosciences Clontech, Heidelberg, 
Germany 
 
Strain Reporter Transformation markers 
CG 1945 HIS3, lacZ trp1, leu2 
AH 109 HIS3, ADE2, lacZ, MEL1 trp1, leu2 
 
2.1.9 Mouse strain 
 
BALB/c mouse strain was used for whole mount in situ hybridization experiments. Animals 
were obtained from the animal facility of the GSF-Hämatologikum, Grosshadern and 
Neuherberg. 
 
2.1.10 Mammalian cell lines 
 
All cell lines are available in the Cell Culture Collection from the Deutsche Sammlung von 
Mikroorganismen und Zellkulturen GmbH (DSMZ), unless discriminated. 
 
2.1.10.1 Murine and rat cell lines  
 
Name Cell type/ Origin 
NIH3T3 swiss mouse embryo fibroblast 
MEF∗ mouse embryonic fibroblast (primary fibroblast from day 15 of the mouse embryo) 
BA/F3 mouse pro B-cells, IL-3 dependent line established from peripheral blood  
TGR∗ rat fibroblast 
∗ courtesy from Dr. Michael Hölzel, GSF, Munich 
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2.1.10.2 Human cell lines 
 
Normal cell lines 
Name Cell type/ Origin 
293T human embryonal kidney 
WI-38∗ human normal embryonic lung fibroblast, cells have a finite lifetime of 50 + or – 10 population doublings. 
Growth of the cells is enhanced by addition of TNF alpha to the medium  
JB4∗∗ T-cell line, stimulated bimonthly 
TYRF8∗∗ T-cell line, HLA-A2-restricted tyrosinase peptide specific cytotoxic clone. Cells are stimulated bimonthly 
with IL-2-secreting HLA-A 0201-positive and tyrosinase-positive melanoma cells 
∗ courtesy from Dr. Michael Hölzel, GSF, Munich; ∗∗ courtesy from Dr. Elfriede Nössner, GSF, Munich 
 
Tumor cell lines 
Name Cell type/ Origin 
HELA human cervix carcinoma 
U2OS∗ human osteogenic sarcoma, p53 wild type 
SaOS human osteogenic sarcoma, p53 null 
T98G∗ human glioblastoma multiforme, cells enter a viable G1 arrest state when deprived of serum or when crowded 
∗ courtesy from Dr. Michael Hölzel, GSF, Munich 
 
B-cell leukemia and B-cell lymphoma cell lines 
Name Cell type/ Origin 
NALM6 human B-cell precursor leukemia 
Granta 519 human B-cell lymphoma 
HBL-2∗ human mature B-cell line derived from B-NHL (diffuse large cell), carries t(11;14)(q13;q32) leading to 
alteration of the BCL1 and IGH genes 
JeKo-1 human B-cell lymphoma established from the peripheral blood of a 78-year-old woman with B-cell non-
Hodgkin’s lymphoma (B-NHL), specifically mantle cell lymphoma 
Karpas 422 human B-cell lymphoma established from the pleural effusion of a 73-year-old woman with B-NHL 
NCEB-1∗ human mature B-cell line derived from B-NHL (diffuse centroblastic-centrocytic), carries t(11;14)(q13;q32) 
leading to alteration of the BCL1 and IGH  
∗ courtesy from Dr. Martin Dreyling, CCG-Leukemia, Grosshadern, Munich 
 
T-cell leukemia and T-cell lymphoma cell lines 
Name Cell type/ Origin 
JURKAT human T cell leukemia, immature T cell line established from the peripheral blood of a 14-year-old boy with 
ALL  
MOLT-4 human T cell leukemia, immature T cell line established from the peripheral blood of a 19-year-old man 
with ALL 
HUT 78∗ human mature T-cell line established from the peripheral blood of a 53-year-old male with cutaneous T-cell 
lymphoma (Sézary syndrome). Cells carry the t(2;8)(q34;q24) leading to TCL4-MYC fusion gene 
∗ courtesy from Dr. Elfriede Nössner, GSF, Munich 
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Myeloid leukemia cell lines 
Name Cell type/ Origin 
HL-60 human acute myeloid leukemia established from the peripheral blood of a 35-year-old woman with AML 
(FAB M2). Cells can be used for induction of differentiation studies (responsive to DMSO, TPA and other 
reagents), carry amplified c-myc gene and lack wild type p53 
KASUMI-1 human acute myeloid leukemia. Cell line established from the peripheral blood of a 7-year-old Japanese 
boy with AML (FAB M2). Cells carry the t(8;21) ETO-AML1 fusion gene 
U937 human histiocytic lymphoma. Cells express markers and properties of monocytes and carry the t(10;11) 
leading to CALM-AF10 fusion gene 
K-562 erytroid cell line. Cells carry the t(9;22) leading to BCR-ABL fusion gene 
 
2.1.11 Plasmids  
 
 
2.1.12 Constructs 
 
pGADGH-CATSv2CT Joachim Gläsner, Institute für Humangenetik, Göttingen, Germany 
pGEX4T-2- CATSv2CT Joachim Gläsner, Institute für Humangenetik, Göttingen, Germany 
YFP-CALM/AF10 Alexandre Krause, CCG Leukemia, GSF, Munich, Germany 
pGBKT7-CALM (1-408) Britta Kaltwasser, CCG Leukemia, GSF, Munich, Germany  
GAL4-CALM (1-652) Sigrun Bartels, Institute für Humangenetik, Göttingen, Germany 
pGBT9-CALM (1-335) Sigrun Bartels, Institute für Humangenetik, Göttingen, Germany 
pAS2-CALM (1-294) Sigrun Bartels, Institute für Humangenetik, Göttingen, Germany 
pAS2-CALM (1-221) Sigrun Bartels, Institute für Humangenetik, Göttingen, Germany 
YFP-Nucleostemin Michael Hölzel, GSF, Munich, Germany 
YFP-Nucleophosmin Angus Lamond, University of Dundee, Dundee, UK 
YFP-HAX1 Luciana Fontanari Krause, CCG Leukemia, GSF, Munich, Germany 
YFP-SIVA Luciana Fontanari Krause, CCG Leukemia, GSF, Munich, Germany 
pBluescript II KS (+/-) Cloning vector, Stratagene, La Jolla, USA 
pGEM®-T Easy Cloning vector with 3’-T overhangs at insertion site for direct cloning of PCR 
products, Promega, Madison, USA 
pGBT9; pGBKT7 Expression of GAL4-DBD (amino acids 1-147) fusion proteins in the yeast system, 
DB Biosciences Clontech, Heidelberg, Germany 
pGADGH; pGADT7 Expression of GAL4-AD (amino acids 768-881) fusion proteins in the yeast system. 
DB Biosciences Clontech, Heidelberg, Germany  
pEGFP-; pECFP-; pEYFP-C1 Expression of green (GFP), cyan (CFP) or yellow (YFP) fluorescent fusion proteins, 
DB Biosciences Clontech, Heidelberg, Germany 
pGEX-4T2 Expression of GST fusion proteins in bacterial cells. Vector contains a tac promoter 
for protein expression upon IPTG induction, Amersham Pharmacia Biotech 
pM1 Expression of GAL4-DBD (1-147) fusion proteins in the mammalian system. The 
hybrid protein is targeted to the cell’s nucleus by the GAL4 NLS, DB Biosciences 
Clontech, Heidelberg, Germany 
pGAL4LUC Reporter plasmid encoding the luciferase gene under the transcriptional control of the 
GAL4-binding sites  
pGAL45tkLUC Reporter plasmid encoding the luciferase gene under the transcriptional control of the 
Herpes simplex virus thymidine kinase promoter and 5 GAL4-binding sites, (Netzer et 
al., 2001) 
pRL-null Co-reporter vector encoding the Renilla luciferase protein, Promega, Madison, USA 
pUC18-HA tag Provides a COOH-terminal HA tag, (Holzel et al., 2005) 
pRTS-1 Episomal all-in-one plasmid with tight doxycycline-dependent gene expression. The 
bidirectional promoter controls simultaneously the expression of both GFP and the 
gene of interest, (Bornkamm et al., 2005) 
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2.1.13 Oligonucleotides 
 
All nucleotides were synthesized by Metabion GmbH, Martinsried, Munich, at the 
concentration of 100 pmol/µl. 
 
CATS specific primers 
Oligonucleotide Sequence Position at CATS 
sequence*,1 
Tm 
°C 
CATSE1F1(364) 5'-AAGAGTGCTTTGGGTGCCG-3' Exon 2 (343-361) 56-60 
CATSE4R1(784) 5'-TGAATGAGAGAGACGATGTCACC-3' Exon 5 (785-763)  56-60 
CATSE5R1(828) 5'-CGGTCAGACAGGGCTTGTTTC-3' Exon 6 (1116-1096)  56-60 
FhCATSXhoI 5'-CTACCTCGAGAGATGGCTTCTCGGTGGC-3' Exon 2 (74-91)  55 
RhCATSHindIII  5'-CATTAAGCTTGCAGGCACTTCCTCAGTC-3' Exon 5 (804-787)  55 
hCATS774-793 5'-GGAAGAGAGTGGTGACATCG-3' Exon 4/5 (753-772)  58 
hCATSI4F1 5'-AACCTGCCCTTCCTCCAGAAC-3' Intr 4 (9997-10017)1  56 
hCATSf SalI 635(ex3) 5'-TATAGTCGACACTCCTCAACAGAGCCCCTC-3' Exon 3 (635-654)  55 
hCATSr SalI 909(ex6) 5'-TATAGTCGACCCCAGGGGTACTGACGACTCC-3' Exon 6 (1198-1178) 55 
hCATS 5’ ORF BglII 5’-GAAGATCTATGGCTTCTCGGTGGC-3' Exon 2 (76-91) 55 
hCATS 3’ ORF XhoI 3’-CCGCTCGAGGCAGGCACTTCCTCAGTC-3' Exon 5 (804-787) 55 
hCATSATGf(PUC18) 5'-Pho-GCCACCATGGCTTCTCGGTGGCAG-3' Exon 2 (76-93) 60 
hCATS∆TGAv1r(PUC18) 5'-Pho-GTCATGAATGAGAGAGACGATGTC-3' Exon 5 (789-766) 60 
hCATS∆TGAv2r(PUC18) 5’-Pho-CGGGGAAGCATAGACATCC-3' Exon 6 (1153-1135) 60 
*human CATS cDNA (Figure: 3.2), 1AC055872.2nt89161-101255 (BAC clone)  
 
Cats specific primers 
Oligonucleotide Sequence Position at CATS 
sequence*,1 
Tm 
°C 
mCATSF113 5’-AAACTGGACCAAGCACATGGCG-3’ Exon 2 (270-291) 60 
mCATSF364 5'-TCCAGAGCCAGAGCAGCAAG-3' Exon 2 (501-520)  60 
mCATSR630 5'-CAGACTCCCTCCTTAGCCGC-3' Exon 3 (805-786)  60 
mCATS F552 5'-GAAGAACACTCGGCTATGC-3' Exon 3 (690-708) 55 
mCATSE1R(133) 5’-ATGCCCTGCCACTGAGACGC-3’ Exon 2 (308-289) 63 
F10-3T319 5’-GTTTCCAGACTCAGAACTATC-3’ Exon 6 (1351-1331) 55 
mCATSR886 5’-GGAAGTTCATGGGTTTGGGGTAG-3’ Exon 6 (1065-1045) 62 
mCATSR942 5’-GCCAAATCCCTGTTAGCAGTGC-3’ Exon 6 (1121-1099) 60 
mCATS 5’ORF EcoRI 5’-CCGGAATTCACATGGCGTCTCAGTGGCAG-3' Exon 2 (284-303) 55 
mCATS 5’ORF XhoI 5'-CTACCTCGAGACATGGCGTCTCAGTGGCAG-3' Exon 2 (284-303) 55 
mCATS 3’ORF Not I 5'-CTAGCGGCCGCATGCTTGCTGTCCTCATTCACG-3' Exon 5 (994-973) 55 
mCATS3’ORFΔTGAXhoI 5'-AATCTCGAGTTCACGGATAAGGGAGACGG-3' Exon 5 (978-959) 55 
mCATS Int.1 L02H-4 5'-TGTGTGGTGTGTCCAAGAGC-3' Intr 2 (3765-3784)1 60 
mCATS Ex.4 f 5'-TAGAGACGCACAGTGGAACCTC-3' Intr 5 (6471-6492)1 60 
mCATS 3’UTR-R1 5'-TCAGACTCAGACCCACTGTC-3' 3’Cats (7667-7648)1 56 
mCATS 3’UTR-F1 5'-ACCCCACACTGACACCGTAG-3' 3’Cats (7223-7242)1 60 
mCATS 5’UTR-R1 5'-CGGAGCAGACTTAGCAATCC-3' Intr 1 (2532-2513)1 60 
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mCATS 5’UTR-F1 5'-CACAGTAGTTCAGGGAGATTTG-3' 5’Cats (268-289)1 56 
mCATS 5’UTR-R2 5'-ATCACTGTTACCGACCAGC-3' Exon 1 (217-199) 56 
mCATS 5’UTR-F2 5'-TTGGAGATTTGGTCTGG-3' 5’Cats (694-710)1 52 
mCATS 5’UTR-R3 5'-GCTCTACGCATCTTTCAATC-3' 5’Cats (1660-1641)1 55 
mCATS 5’UTR-F3 5'- CCCTGCTACTGTTAGTGAGTG-3' 5’Cats (1022-1042)1 55 
mCATSInt.3r 5’-CCCTGTGGTTTTCTTACTCC-3’ Intr 5 (6326-6307)1 56 
mCATSInt.1r 5’-CAGTGTGGTAACTCAGCAGG-3’ Intr 2 (4605-4586)1 56 
mCATSInt.2f 5’-AGACATCTGGAAGACCGAGG-3’ Intr 3 (5290-5309)1 59 
*Murine cDNA IMAGp998H174619Q2 clone, 1L02EcoRI-2 (murine genomic clone) 
 
PCBP-1 specific primers 
Oligonucleotide Sequence Position at the cDNA 
sequence* 
Tm °C 
PCBP1XhoIf 5'-CTACCTCGAGCCATGGATGCCGGTGTGACTG-3' (176-196) 56 
PCBP1HindIIIr 5’- ATTAAGCTTGCAGAAAGGGGTTATTGAGGGAAC-3’ (1282-1259) 56 
PCBP1seq0fw 5’-TGTCCGGAGAGAATCATC-3’ (337-354) 54 
PCBP1seq1fw 5’-AGTGCGGCTCCCTGATTG-3’ (500-517) 62 
PCBP1seq2fw 5’-CTAGATGCCTACTCGATTC-3’ (832-850) 50 
*GenBank acc. Nr.: NM_006196 
 
KIS specific primers 
Oligonucleotide Sequence Position at the cDNA 
sequence* 
Tm °C 
FKISXhoI  5'-CTACCTCGAGCTTAACCCACACCGATGGC-3' (132-150) 56 
KISXhoI5’new  5’-CTACCTCGAGCTTTACCCACACCGATGGC-3’ (132-150) 56 
RKISHindIII 5’-CATTAAGCTTGGAATAACCCAAGAAATGGAAG-3’ (1460-1439) 56 
KISseq1fw 5'-TTCTCCAAATGTGCCATC-3' (445-462) 55 
KISseq2fw 5’-GCAGAGTGATACAGAATGTACC-3’ (784-805) 54 
KISseq3fw 5’-TGAATGTGCTGGATGATG -3’ (1122-1139) 54 
*GenBank acc. Nr.: NM_175866/AJ536197 
 
Control primers 
Oligonucleotide Sequence Position at the cDNA sequence* Tm °C 
HPRT fw 5’-GGGGGCTATAAGTTCTTTGC-3’ Exon 3 (295-314) 60 
HPRT rev 5’-TCCAACACTTCGAGAGGTCC-3’ Exon 6 (606-587) 60 
hGAPDHforward 5’-GCACCACCAACTGCTTAGCACC-3’ Exon 7 (530-551) 60 
hGAPDHreverse  5’-GTCTGAGTGTGGCAGGGACTC-3’ Exon 9 (1166-1146) 60 
mGAPDHf 5’-CATCACCATCTTCCAGGAGC-3’ (271-290) 60 
mGAPDHr 5’-ATGACGTTGCCCACAGCCTT-3’ (714-695) 60 
INF 5’ 5’-AGAATCTCTCCTTTCTCCTG-3’ (180-199) 56 
INF 3’ 5’-GATCTCATGATTTCTGCTCTG-3’ (565-545) 56 
*GenBank acc. Nr.: NM_013556 (mouse HPRT), NM_002046 (human GAPDH), NM_001001303 (mouse Gapdh), 
NM_002170 (interferon alpha 8) 
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Vector primers 
Oligonucleotide Sequence Position Tm °C 
T7 5’-GTAATACGACTCACTATAGGGC-3’  55 
T3 5’-AATTAACCCTCACTAAAGGG-3’  55 
SP6 5’-AGGTGACACTATAGAATAC-3’  55 
Y2H1 5’-TCATCGGAAGAGAGTAG-3’ (1155-1171 pGBKT7)  55 
Y2H3’AD 5’-AGATGGTGCACGATGCACAG-3’ (2102-2083 pGADT7) 55 
Y2H2-729-751 5’-CGTTTGGAATCACTACAGGGATG-3’ (1799-1821 pGADT7) 55 
M13/pUCRevSeqP 5’-AGCGGATAACAATTTCACACAGG-3’ (2187-2209) 55 
pGEX5’ 5’-GGGCTGGCAAGCCACGTTTGGTG-3’ (869-891) 55 
5’pME18S-FL3 5’-CTTCTGCTCTAAAAGCTGCG-3’ (774-793)  
3’pME18S-FL3 5’-CGACCTGCAGCTCGAGCACA-3’   
pEGFPC-1240-1258 5’-AAAGACCCCAACGAGAAGC-3’ (1240-1258) 55 
pUC18-M13fwd 5’-GCGGATAACAATTTCACACAGG-3’ (2188-2209) 55 
pUC18-M13rev 5’-GTAAAACGACGGCCAGTGC-3’ (2358-2340) 55 
pEBNA_Sfi+55bp (rev) 5’-AATCAAGGGTCCCCAAACTC-3’ (1752-1733) 55 
*GenBank acc. Nr.: U55763 (pEGFP-C1), U13854 (pGEX-4T2) 
 
2.1.14 Antibodies 
 
Name Company dilution 
Anti-GFP rabbit IgG fraction Molecular Probes, Inc. 1:5000 
CALM (S-19, G-17 and C-18) Santa Cruz Biotechnology, Inc. 1:1000 
GAL4 (DBD) (RK5C1) Santa Cruz Biotechnology, Inc. 1:1000 
mouse monoclonal HAX-1 BD Pharmingen, Heidelberg 1:3000 
SIVA (C-20) Santa Cruz Biotechnology, Inc. 1:2000 
CD3-12 Dr. Elizabeth Kremmer, GSF, Munich 1:10 
CD4-PE labeled  BD Pharmingen, Heidelberg 1:100 
CD8-APC labeled  BD Pharmingen, Heidelberg 1:100 
Anti-β-Actin clone AC-15 Sigma® 1:2000 
Mac1 (CD11b)-APC labeled BD Pharmingen, Heidelberg 1:250 
Gr-1-PE labeled BD Pharmingen, Heidelberg 1:250 
Ter119-PE labeled BD Pharmingen, Heidelberg 1:250 
B220-APC labeled BD Pharmingen, Heidelberg 1:250 
Sca-1-PE labeled BD Pharmingen, Heidelberg 1:250 
c-kit (CD117)-APC labeled BD Pharmingen, Heidelberg 1:250 
Donkey anti-rabbit IgG-HRP conjugated Santa Cruz Biotechnology, Inc. 1:2000 
Donkey anti-goat IgG-HRP conjugated Santa Cruz Biotechnology, Inc. 1:2000 
Sheep anti-mouse IgG-HRP conjugated Chemicon® International 1:1000-3000 
Goat Anti-Rat IgG + IgM -HRP conjugated Jackson ImmunoResearch Laboratories, Inc. 1:3000 
Mouse Anti-Rat IgG-HRP conjugated Jackson ImmunoResearch Laboratories, Inc. 1:2000 
Goat anti-rat IgG + IgM-Cy™3 conjugated Jackson ImmunoResearch Laboratories, Inc. 1:250 
Anti-Digoxigenin-AP conjugate Roche, Mannheim, Germany 1:5000 
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2.1.15 Human cDNA IMAG clones 
 
All IMAG cDNA clones were ordered from the Resource Centre of the German Human 
Genome Project (RZPD, Berlin, Germany). 
Human IMAG cDNA clones are IMAGp998G039611 and IMAGp998D169579 (both cloned 
into pCMV-SPORT6 vector). The murine IMAG cDNA clones are IMAGp998E09899Q2 
(cloned into pT7T3D-Pac vector); IMAGp998F103793Q2 and IMAGp998H174619Q2 (both 
cloned into pME18S-FL3 vector). 
 
2.1.16 Mouse cosmid library 
 
The 129/ ola mouse cosmid library Nr.: 121 as well as the isolated genomic clones were 
ordered from the Resource Centre of the German Human Genome Project (RZPD, Berlin, 
Germany). Library was cloned into Lawrist 7 and kept in the host DH5 alpha . 
 
2.1.16.1 Mouse genomic clones 
 
MPMGc121C1938Q2, MPMGc121C0434Q2, MPMGc121L02225Q2, 
MPMGc121H24352Q2, MPMGc121A14416Q2, MPMGc121I20398Q2, 
MPMGc121D13437Q2, MPMGc121K17553Q2 and MPMGc121P22586Q2. 
 
2.1.17 cDNAs 
 
cDNA from leukemia patient samples used in 3.3.1, were kindly provided by Alexandre 
Krause (CCG Leukemia, GSF, Munich). 
cDNA from leukemic cells derived from CALM/AF10 murine bone marrow transplant model 
(used in 3.3.2) were kindly provided by Aniruhddha Deshpande (CCG Leukemia, GSF, 
Munich). cDNAs were prepared from highly purified B220+/Mac1-, B220+/Mac1+ and B220-
/Mac1+ cells obtained after propagation of a single sorted B220+/myeloid marker- cell from a 
bulk leukemic cell population grown in IL3 supplemented medium. 
 
2.1.18 Cellular lysates 
 
Lysates from serum stimulated T98G (3.10.4) as well as from synchronized HeLa and U2OS 
cells (3.10.5) were kindly provided by Dr. Michael Hölzel (GSF, Munich). 
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2.2 Methods 
 
All molecular biology standard methods were performed according to the ”Molecular 
Cloning” (Sambrook, 1989) with minor or no modifications. 
 
2.2.1 Isolation of Nucleic Acids 
 
2.2.1.1 Mini preparation of plasmid DNA (Miniprep) 
 
Miniprep was employed to isolate small amount of DNA from a large number of clones. First, 
single E. coli colonies were inoculated into 3 ml of LB medium plus selective antibiotics and 
incubated O/N with vigorous shaking at 37°C. From each culture, 1.5 ml was centrifuged for 
5 min at 14 000 rpm and the supernatant removed. Pellet was resuspended in 300 µl of E1 
resuspension buffer and cells were lysed by adding 300 µl E2 lysis buffer followed by 5 min 
incubation at RT. 300 µl of E3 neutralization buffer was added to the lysate, gently mixed and 
reaction was centrifuged for 10 min at 14 000 rpm. The supernatant containing the plasmid 
DNA was transferred to a fresh 1.5 ml tube. DNA was purified by precipitation with 0.7 vol. 
of isopropanol followed by 10 min incubation at -20°C and 20 min centrifugation at 4°C (14 
000 rpm). The DNA pellet was washed with 300 µl 70 % ethanol (10 min; 14000 rpm, 4°C), 
air dried and dissolved in 20-30 µl ddH2O. DNA was stored at -20°C. 
Glycerin stocks were prepared for long-term storage of the bacterial clones. For that 700 µl 
bacterial suspension plus 300 µl glycerin were placed in a fresh 1.5 ml tube, mixed by 
vortexing and stored at -80°C. 
 
2.2.1.2 Midi preparation of plasmid DNA (Midiprep) 
 
In order to isolate larger amount of plasmid DNA Midi preparation was carried out. 
JETSTAR Plasmid Midi Kit (Genomed) was used for clean preparation. Single E. coli colony 
or approx. 5 µl of glycerin stock (2.2.1.1) was inoculated into 50 ml LB medium plus 
selective antibiotics and incubated O/N with vigorous shaking at 37°C. Cells were harvested 
by centrifugation (4 000 rpm for 15 min). Pellet was resuspended in 4 ml E1 solution. For the 
cell lysis, 4 ml of solution E2 was added and the suspension incubated for 5 min at RT. 4 ml 
of solution E3 was added to the reaction and immediately mixed by inversion. The suspension 
was centrifuged for 10 min and the supernatant containing the plasmid DNA was applied to a 
previously equilibrated column (10 ml solution E4 had been applied to the column for 
equilibration). After the suspension has ran through, DNA bound to the column was washed 
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twice with 10 ml solution E5. The DNA was then eluted from the column with 5 ml solution 
E6 and isopropanol precipitated as described above (2.2.1.1). DNA was dissolved in 50 µl 
ddH2O and stored at -20°C after concentration has been determined (2.2.10). 
 
2.2.1.3 Maxi preparation of plasmid DNA (Maxiprep) 
 
Highly purified endotoxin-free DNA plasmid used in transfection experiments (2.2.21) was 
isolated with the Endofree® Plasmid Maxi kit (Qiagen). Single E. coli colony or approx. 5 µl 
of glycerin stock was inoculated into 2 ml LB medium plus selective antibiotics and incubated 
for approx. 6 hrs with vigorous shaking at 37°C. The preculture was diluted 1:500 into a 
larger vol. (250 ml) of selective medium and expanded to saturation at the same condition as 
above. 
The bacterial cells were harvested by centrifugation at 6 000 x g for 15 min at 4°C. The pellet 
was resuspended with 10 ml P1 buffer. For cell lysis, 10 ml of P2 buffer was added, mixed by 
inversion, and the mixture was incubated for 5 min at RT. 10 ml of pre-chilled P3 buffer was 
added, mixed and the reaction was applied into the QIAfilter Cartridge. After 10 min 
incubation at RT, cell lysate was filtered and recovered in a 50 ml tube. 2.5 ml buffer ER was 
added to the lysate, the mixture was mixed and further incubated for 30 min on ice. After that 
the cell lysate was applied into a previously equilibrated column (column was equilibrated 
with 10 ml QBT buffer). Plasmid DNA bound to the column was washed twice with 30 ml 
QC buffer. The DNA eluted with 15 ml QN buffer, precipitated with 0.7 vol. isopropanol, 
incubated 10 min at -20°C and centrifuged at 15 000 x g for 30 min at 4°C. The DNA pellet 
was washed with 15 ml 70% ethanol, further centrifuged (20 min, 15 000 x g, at 4°C), air 
dried and dissolved in 500 µl endotoxin-free buffer (EB). The DNA was stored at -20°C after 
concentration has been determined (2.2.10). 
 
2.2.2 Cleavage of nucleic acids 
 
2.2.2.1 Digestion of DNA with restriction enzymes 
 
For specific digestion of DNA, type II restriction endonucleases are essential. These enzymes 
are capable of recognizing, binding and cleaving short defined nucleotide sequences within 
the target DNA. The restriction of DNA was carried out with defined buffer, when multiple 
enzymes were used, a Five Buffer Plus System such as Y+/Tango™ (MBI Fermentas) was 
required. For single digestion the following components were placed in a 1.5 ml tube.  
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1 µg DNA 
1X appropriate restriction enzyme buffer 
5 U restriction enzyme 
to 20 µl ddH2O 
Reaction was incubated for 2 hrs to O/N at optimal temperature as recommended for each 
enzyme. Alternatively, reactions were scaled up to 50 µl vol. 
 
2.2.2.2 Dephosphorylation of digested DNA 
 
Alkaline phosphatase is capable of removing the phosphate group from the 5’ free end of the 
DNA molecule, preventing ligation of DNA, especially re-ligation of previously restricted 
vectors. The DNA was dephosphorylated as follows: 
1 µg DNA, previously digested (2.2.2.1) and purified (2.2.3 or 2.2.7) 
5 µl 10X alkaline phosphatase buffer 
1 U alkaline phosphatase (CIAP or SAP) 
to 50 µl ddH2O 
Reaction was incubated at 37°C for 1 hr and stopped by heating at 85°C (CIAP) or 70°C 
(SAP) for 15 min. DNA was then purified by ethanol precipitation (2.2.3) 
 
2.2.2.3 Blunting sticky end DNA 
 
Klenow enzyme was used to produce blunt end products, either through its polymerase 
activity used to fill in 3’ recessed ends in the presence of dNTPs or through its 3’-5’ 
exonuclease activity used to cleave protruding 3’ overhangs from digested DNA (2.2.2.1). 
The reaction was carried out as follows: 
0.1-4 µg DNA, previously digested (2.2.2.1) and purified (2.2.3 or 2.2.7) 
0.5 µl 2mM dNTP mix 
0.5 µl Klenow Enzyme (10 U/µl) 
2 µl 10X Klenow buffer 
to 20 µl ddH2O 
The mixture was incubated for 10 min at 37°C. Reaction was stopped by heat inactivation at 
70°C for 10 min. DNA was then purified by ethanol precipitation (2.2.3) and used for ligation 
(2.2.4). 
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2.2.3 Precipitation of DNA 
 
Acid nucleic were purified from buffers used in previous reactions (e.g. digestion, 
dephosphorylation, sequencing, etc.) through ethanol precipitation. Reaction was carried out 
mixing 1 vol. of DNA sample, with 2.5 vol. of ethanol and 1:10 vol. of 5 M NaAc pH 5.2. 
Reaction was incubated at -20°C for 10 min and centrifuged at 14 000 rpm for 20 min at 4°C. 
DNA pellet was washed with 50-200 µl 70  % ethanol, centrifuged at 14 000 rpm for 10 min 
at 4°C, air dried and diluted in the desired vol. of ddH2O. Purified DNA was used for 
subsequent reactions or stored at -20°C. 
 
2.2.4 Ligation 
 
Both vector and restriction fragment (insert) were restricted (2.2.2) in a way to have 
compatible ends. Vector and insert were used at proportion 3:1 in the ligation reaction as 
described below: 
30 ng restricted vector DNA (2.2.2) and purified (2.2.3 or 2.2.7) 
90 ng insert  
4 µl 5X T4 DNA ligase buffer 
1 µl T4 DNA ligase (5 U/µl) 
to 20 µl ddH2O 
The reaction was incubated for 15 min to 1 hr at RT. 
 
2.2.5 Delivery of plasmid DNA into bacterial cell 
 
2.2.5.1 Preparation of chemically competent cells 
 
An aliquot of frozen cells (E. coli strain BL21) was inoculated into 10 ml LB medium free 
from antibiotics and incubated O/N with vigorous shaking at 37°C. The O/N culture was 
diluted into a larger volume of medium (300 ml) and further incubated for approx. 2-3 hrs 
until culture has reach OD600 0.5-0.7. Bacterial suspension was cooled down on ice and cells 
were harvested by centrifugation. Cell pellet was resuspended with 120 ml Tfb1 (2.1.5) and 
incubated for 10-15 min on ice. Suspension was centrifuged, supernatant was discarded and 
cells were ressupended with 12 ml Tfb2 (2.1.5). Bacterial cells were aliquoted (100 µl vol.), 
frozen in liquid nitrogen and stored at -80°C. All centrifugation steps were carried out at  
4000 rpm for 10 min at 4°C. 
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2.2.5.2 Transformation 
 
Chemically competent cells (100 µl aliquot) (2.2.5.1) were mixed with 1 µl plasmid DNA 
(50-100 ng) or 20 µl ligation reaction (2.2.4). Reaction was incubated for 45 min on ice, heat 
shocked for 90 sec at 42°C and placed on ice for 2 more min. 100 µl LB medium was added 
to the reaction, which was incubated for 30 min shaking at 37°C. Cells were subsequently 
stricked onto LB agar plate containing appropriate selective antibiotic. Plates were incubated 
O/N at 37°C. 
 
2.2.5.3 Preparation of electrocompetent cells  
 
O/N culture of E coli strain XL1-blue MRF’, grown as in 2.2.5.1 was diluted into 400 ml LB 
medium and incubated for approx. 2-3 hrs until culture has reach OD600 0.5-0.6. Bacterial 
suspension was cooled on ice and cells were harvested by centrifugation. Pelleted cells were 
washed twice with 40 ml ice cold ddH2O, twice with 20 ml ice cold 10 % glycerol (in ddH2O) 
and finally resuspended in 800 µl of the same solution (ice cold 10 % glycerol in ddH2O). 
Bacterial cells were aliquoted (40 µl vol.) and stored at -80°C. All centrifugation steps were 
carried out at 4 500 rpm for 5 min at 4°C. 
  
2.2.5.4 Electroporation 
 
Electrocompetent cells (40 µl aliquot) (2.2.5.3) were mixed with 1 µl plasmid DNA (50-100 
ng) or 2-7 µl ligation reaction (2.2.4), incubated for 1 min on ice and transferred to a 
previously cooled electroporation cuvett. Cuvett was placed in an electroporator and cells 
were electroporated at 2.5 kV. After electroporation, 1 ml pre warmed LB medium (37°C) 
was immediately added to the cells, the suspension was transferred to a fresh 1.5 ml tube and 
incubated for 1 hr with vigorous shaking at 37°C. Cells were harvested by brief centrifugation 
(15 sec, at 14 000 rpm), resuspended with 50 µl LB medium and stricked onto LB agar plates 
containing appropriate selective antibiotic. Plates were incubated O/N at 37°C. 
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2.2.6 Agarose-gel electrophoresis for DNA 
 
Non-denaturing gel electrophoresis was employed in the separation of restricted DNA, for 
both analysis and isolation of the fragments. The concentration of the gels used was 
determined according to the range of separation of linear DNA in gels containing different 
amounts of agarose as shown below: 
Agarose (%) Range of separation of linear DNA 
0.5 700 bp to 25 kb 
0.8 500 bp to 15 kb 
1.0 250 bp to 12 kb 
1.2 150 bp to 6 kb 
1.5 80 bp to 4 kb 
Gel was prepared by boiling the desired amount of agarose in 50 ml 0.5X TBE (2.1.5). After 
gel has cooled to approx. 50°C, 3 µl ethidium bromide was added. The gel was poured onto a 
horizontal gel bed. DNA samples were loaded on the gel slots with 1 µl Blue Juice loading 
buffer (2.1.5). Nucleic acids ran under electric current (50-120 V) from the negative to the 
positive pole. 
 
2.2.7 Isolation of DNA fragments after gel electrophoresis  
 
DNA fragment was cut out of the gel under UV light (312 nm) with a sterile scapel and 
transfered to a 1.5 ml tube. Gel extraction was performed with JETSorb DNA extraction from 
Agarose Gels (Genomed, Bad Oeynhausen). For each 100 mg gel slice, 300 µl buffer A1 and 
10 µl JETSORB suspension were added. The reaction was incubated at 50°C for 15 min. and 
centrifuged for 1 min at 10 000 x g. The supernatant was discarded and 300 µl of buffer A1 
was added. The pellet was then resuspended and centrifuged once more. 
The same procedure was performed twice, with buffer A2. After the second wash step with 
buffer A2, the pellet was dried at 50°C for 5 min. The DNA was then eluted with 30 µl 
ddH2O, incubated at 50°C for 5 min and centrifuged as before. The supernatant containing the 
purified DNA fragment was transfered to a fresh 1.5 ml tube and was used for subsequent 
reactions such as ligation (2.2.4). 
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2.2.8 Extraction of genomic DNA  
 
Genomic DNA from 293T, HeLa and HL-60 cells (2.1.10.2) was isolated using DNeasy® 
Tissue Kit (Qiagen). For the isolation, 4 x 106 cells were harvested and ressuspended in 200 
µl PBS. In order to obtain RNA-free genomic DNA, cells were incubated with 4 µl RNase A 
(100 mg/ml) for 2 min at RT. Cells were lysated by adding 20 µl of proteinase K (>600 
mAU/ml) and 200 µl of buffer AL, mixing thoroughly by vortexing and incubating at 70ºC 
for 10 min. 200 µl of ethanol was added to the lysate, which was applied into the DNeasy spin 
column (placed in a 2 ml collection tube) and centrifuged for 1 min at 6 000 x g. The flow-
through was discarded, the DNeasy spin column was placed in a new collection tube and 
washed once with 500 µl AW1 buffer (1 min 6 000 x g) and once with 500 µl AW2 buffer (3 
min 14 000 rpm). The flow-through was discarded again and the DNeasy spin column was 
placed in a fresh 1.5 ml tube. In order to obtain a maximal yield of DNA, elution was 
performed in two steps. In each step 200 µl buffer AE was applied to the DNeasy column, 
incubated for 1 min at RT and DNA was collected by centrifugation (1 min at 6 000 x g). The 
isolated genomic DNA was stored at 4°C. 
 
2.2.9 RNA extraction  
 
Total RNA from adult mouse tissue, mouse embryo (2.2.19.1), cultured cell lines (2.1.10) and 
FACS sorted hematopoietic cell subpopulation (2.2.31) was isolated using the RNeasy® Mini 
Kit (Qiagen). For extraction from cultured cell lines, approx. 4 x 106 cells were lysed by the 
addition of 350 µl RLT buffer. For extraction from hematopoietic cells, the whole amount of 
sorted cells (from 807 cells to 2.4 x 105 depending on the cell subpopulation) was lysed in 350 
µl RTL buffer. For extraction from adult mouse tissue or whole mouse embryos, samples 
were first weight, 600 µl RLT buffer was added per 30 mg material and subsequently 
homogenized with a Tissuemizer (Tekmar-Dohrmann). For further homogenization, samples 
were passed through a QIAshredder spin column placed in a 2 ml collection tube (2 min at 14 
000 rpm). 1 vol. of 70 % ethanol was added to the homogenized lysate and mixed thoroughly 
by pipetting. The lysate was applied to a RNeasy mini column placed in a 2 ml collection tube 
and centrifuged for 15 sec at 8 000 x g. The flow-through was discarded and the total RNA 
bound to the column was washed once with 700 µl RW1 buffer and twice with 500 µl RPE 
buffer. The first and second centrifugation steps were carried out for 15 sec and the third for 2 
min at 8 000 x g, the flow-through was discarded after each washing step. Finally, to elute the 
RNA from the RNeasy column (placed in a fresh 1.5ml tube), 40 µl RNase-free H2O was 
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applied to the column and incubated for 1 min at RT. RNA was collected by centrifugation (1 
min at 8 000 x g). Yield was determined by measuring RNA concentration and quality was 
assayed by loading 2 µl of the isolated RNA on 1 % agarose gel (2.2.6) The isolated total 
RNA was stored at -80°C.  
 
2.2.10 Determination of nucleic acid concentration 
 
Concentration of DNA and RNA was determined in an UV spectrophotometer 
(BioPhotometer 6131, Eppendorf). 2 µl sample was diluted in 198 µl ddH2O and measured by 
absorption at 260 nm and 280 nm. The concentration was calculated according to the ratio 
A260/A280 . 1A260 unit of double-stranded DNA = 50 µg/ml and of RNA = 40 µg/ml.  
 
2.2.11 Reverse transcriptase reaction (synthesis of cDNA) 
 
Reverse transcriptase reaction followed by PCR (RT-PCR) is a sensitive technique used to 
determine the presence or absence of RNA templates or to quantify the level of gene 
expression. It is also an useful tool for amplification of genes of interest or determination of 
exon-intron boundaries. A cDNA strand, complementary to the RNA template is synthesized 
with the extension of oligo(dT) primers by the reverse transcriptase. Synthesized cDNA is 
used as template for subsequent PCR reactions as described in 2.2.12. In order to avoid 
genomic DNA contamination of the RNA and eventual amplification of these contaminants, 
RNA (2.2.9) was treated with DNAse I prior to cDNA synthesis as follows: 1 µg of RNA 
sample was mixed with 1 µl 10X DNase I reaction buffer, 1 µl DNase I (1 U/µl) and DEPC-
H2O to a final vol. of 10 µl. The reaction was incubated for 15 min at RT. The DNAse I was 
inactivated by adding 1 µl of 25 mM EDTA and heating at 65ºC for 10 min. For the first 
strand cDNA synthesis, 1 µg DNAse-free RNA (10 µl) was mixed with 1 µl dNTP (10 mM) 
and 1 µl oligo(dT) primer. The RNA mixture was denatured at 65ºC for 5 min, chilled on ice 
and the contents of the tube was collected by brief centrifugation. 4 µl of 5X First-Strand 
Buffer, 2 µl of 0.1 M DTT and 1 µl RNase inhibitor (40 U/µl) was added to the reaction, 
gently mixed and incubated for 2 min at 42ºC. Then 1 µl of SuperScript II enzyme was added 
and the reaction was incubated for 50 min at 42°C. Enzyme was inactivated by heating the 
reaction to 70ºC for 15 min. 1 µl of the synthesized cDNA (20 µl total vol.) was used for 
subsequent PCR reaction (2.2.12). 
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2.2.12 PCR 
 
The PCR technique is employed to amplify DNA. The amplification is achieved using 
synthetic oligonucleotides (primers), which flank the sequence to be amplified. These 
primers, under appropriate conditions, anneal to the denatured target sequence and, in the 
presence of DNA polymerase and excess dNTPs, synthesize a complementary strand of the 
target sequence. As a template 1 µl cDNA (2.2.11), 1 µl genomic DNA (2.2.8) or 0.5 ng 
plasmid DNA was used. The PCR reaction was performed by mixing template, 2 µl 10X PCR 
buffer, 0.6 µl MgCl2 (50 mM), 0.4 µl dNTP (10 mM), 0.5 µl forward primer (10 µM), 0.5 µl 
reverse primer (10 µM), 0.16 µl Taq polymerase (5 U/µl) and ddH2O to a final vol. of 20 µl. 
Alternatively, reactions were scaled up to 50 µl vol.. The reaction was incubated in a 
thermocycler with the following program: 
95°C 2 min (denaturation) 
94°C 45 sec (denaturation), 60°C 1 min (annealing), 72°C 45 sec (extension) (25-35 cycles) 
72°C 5 min (final extension) 
Depending the primer pair used in the reaction MgCl2 was adjusted to 1.2 mM final 
concentration instead of 1.5 mM. Annealing temperature varied depending on the primer pair 
used and extension time varied according to the expected size of the PCR product (1 min per 
kb). 
 
2.2.13 Sequencing 
 
Sequencing reaction was employed characterize and to confirm the identity of a clone, to 
check the fidelity of a PCR product or of a ligation junction. The cycle sequencing reaction 
consists of successive rounds of denaturation, annealing and extension in the presence of 
polymerase, dNTPs and dye-labeled terminator. For the sequencing reaction 4 µl BigDye 
terminator was added to the DNA to be sequenced together with 1 µl primer (10 µM) in a 10 
µl reaction. 10-100 ng or 1 µg DNA was used to sequence PCR products (0.2-5 kb) and 
plasmid DNA, respectively. The reaction was incubated in a thermocycler with the following 
program: 
96°C 2 min (denaturation) 
96°C 30 sec (denaturation), 50°C 15 sec (annealing), 60°C 4 min (extension) (25 cycles) 
After cycle sequencing has been completed, 10 µl ddH2O was added to complete 20 µl vol. 
followed by ethanol precipitation (2.2.3). Precipitated DNA was diluted in 20 µl ddH2O and 
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10 µl was injected into the capillary of a Genetic Analyzer automated sequencer ABI PRISM 
310 (PE Applied Biosystems). 
 
2.2.14 Agarose-gel electrophoresis for RNA 
 
Denaturing agarose-gel was employed in the separation of RNA. For electrophoresis, 1 % 
agarose-gel was prepared boiling 1 g of agarose in 74 ml DEPC-H2O plus 10 ml of 10X 
MOPS RNA running buffer (2.1.5), until completely dissolved. After gel has cooled to 
approx. 50°C, 16.6 ml Formaldehyde 37 % was added. The gel was poured onto a horizontal 
gel bed (RNase-free). 
To avoid degradation RNA probes were prepared on ice as follows: RNA samples (10 µg) 
and RNA Ladder were brought to a total vol. of 6 µl with DEPC-H2O (samples with bigger 
vol. were previously dried using SpeedVac®) and 12 µl of RNA sample buffer was added. 
The probes were denatured at 65°C for 13 min and then cooled on ice for 2 min. Finally, 6 µl 
of RNA loading buffer was added and the probes were loaded into the slots of the gel. The 
electrophoresis was carried out at RT, at 15 V for the first 15 min and at 60 V for approx. 4 
hr. 
 
2.2.15 Northern blot 
 
The technique transfer RNA from the gel to a nitrocellulose membrane, which can be 
hybridized. The Northern blotting was set up as follows: The membrane was soaked in 20X 
SSC (2.1.5) and placed onto a pile of blotting paper (20 x G003 and 1 x soaked G002 at the 
top). The RNA gel was then placed onto the membrane and covered by 4 more layers of G002 
(also pre-wet in 20X SSC), the last one having its ends in a 20X SSC-containing reservoir. 
The RNA was transfered from the gel onto the membrane by the difference of concentration 
gradient promoted by the salt. Transfer was performed O/N at RT, after that membrane was 
air dried and RNA was fixed onto the membrane by UV crosslinking with a GS Gene Linker™ 
UV Chamber (BioRad). 
 
2.2.16 Radioactive labeling of DNA 
 
DNA probes for the hybridization of Northern blots were labeled with Megaprime™ DNA 
labeling system (Amersham). In a 34 µl vol. reaction, 25 ng DNA probe and 50 pmol 
oligo(dN)9 random primers were denatured at 95°C for 5 min and subsequently placed on ice. 
After cooling down, 10 µl labeling buffer, 2 µl Klenow DNA polymerase I and 5 µl [∝-
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32P]dCTP were added. Labeling reaction was carried out for 1 hr at 37°C. Labeled probe was 
precipitated using Microspin S-400 HR column (Amersham), according to the manufacturer’s 
instructions and denatured for 10 min with 150 µl salmon testes DNA (10 mg/ml). 
 
2.2.17 Hybridization  
 
Northern blot membrane placed in a hybridization tube (nucleic acid facing inwards) was 
rinsed with 2X SSC and then pre-hybridized in 15 ml pre-warmed hybridization solution plus 
150 µl salmon testes DNA (10 mg/ml). Pre-hybridization was carried out for 3 hrs in a 
rotation oven at 65°C. Denatured 32P-labeled probe (2.2.16) was given to the pre-hybridized 
membrane, which was hybridized O/N under the same conditions. On the next day, 32P-
labeled probe/hybridization solution was replaced by 2X SSC. The membrane was then 
washed for 20 min at RT followed by 2 warm washes, carried out at hybridization 
temperature. First warm wash was performed with 2X SSC plus 0.1 % SDS for 3-10 min and 
the second with 0.2X SSC for 1-2 min. Finally, membrane was air dried, wrapped in cling 
film and placed in a x-ray cassette. For film exposure (2-5 days) cassette was kept at -80°C. 
Stripping the Northern blot membrane was performed in order to hybridize the same 
membrane with a different probe. In this case the membrane was washed in a large vol. of 
stripping solution for NB (2.1.5) for 2 hrs, rotating at 65°C. 
 
2.2.18 Screening of mouse genomic cosmid library 
 
The mouse genomic cosmid library 129/ola (2.1.16) was screened under stringent conditions 
according to RZPD’s recommendations. Basically, the 11 cosmid filters were pre-hybridized 
in 100 ml hybridization solution for RZPD filters (2.1.5) plus 500 µl salmon testes DNA (10 
mg/ml). Pre-hybridization was carried out for 2 hrs at 65°C in a water bath with gentle 
shaking. After that, pre-hybridization solution was replaced by 20 ml hybridization solution 
plus denatured 32P-labeled probe (2.2.16). Hybridization was carried out O/N under the same 
conditions. Next day filters were washed with 2X SSC for 20 min at RT and 20 min with pre-
heated 2X SSC and 0.2X SSC at 65°C. Filters were wrapped in cling film, placed in a x-ray 
cassette and exposed for 1-2 days at -80°C. Position of the positive signals were calculated 
according to RZPD’s instructions and corresponding clones were ordered on line 
(http://www.rzpd.de). 
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Cosmid clones, delivered as stabs were grown on LB agar plates/kanamycin (2.1.6) and Mini 
preparation of plasmid DNA (2.2.1.1) was used to recover the DNA. Clones were tested for 
false positive by PCR reaction (2.2.12), using Cats specific primers. 
 
2.2.19 Whole mount in situ hybridization (WISH) 
 
Whole mount in situ hybridization was employed to determine tempo-spatial pattern of Cats 
expression during mouse embryogenesis. Mouse embryos were prepared and hybridized by 
standard protocols according to Wilkinson, 1992; with some modifications. 
 
2.2.19.1 Preparation of mouse embryo 
 
BALB/c mice (2.1.9) were paired and the females checked the following day for the presence 
of a vaginal plug, indicating 0.5 days post coitum (d.p.c) embryos. On the 9.5-14.5 d.p.c, the 
pregnant female mice were dissected, embryos were collected and placed in cold PBS-DEPC. 
Extra-embryonic membranes were removed and embryos were fixed in 4 % PFA (in PBS-
DEPC), rocking O/N at 4°C. Next day embryos were gradually dehydrated (on ice) through 
25 %, 50 %, 75 % methanol (in PBS-DEPC) for 10 min each and bleached for 1 hr with 
freshly prepared 6 % H2O2 (in methanol), Treatment with H2O2 has been found to decrease 
considerably the amount of non-specific background. After bleaching, embryos were further 
dehydrated twice for 5-10 min in large amount of 100 % methanol and stored in this solution 
at -20°C. Treatment and storage of mouse embryos were carried out in scintillation vials. 
Embryos dissected for RNA extraction purpose (2.2.9), were stored  at -80°C (in 1.5 ml tube) 
immediately after removal of extra-embryonic membranes and PBS-DEPC wash. 
 
2.2.19.2 DIG-labeling RNA 
 
RNA probes labeled with Digoxigenin-UTP were synthesized by in vitro transcription of Cats 
cDNA templates. The DNA to be transcribed was first cloned into pGEM®-T Easy (2.1.11) 
which contains promoters for SP6 and T7 RNA polymerases (Figure 2.1). Prior to 
transcription, enzymes that created a 5’-overhang were used in a digestion reaction (2.2.2.1) 
to linearise the template avoiding transcription to continue over the insert onto the plasmid 
itself. Digestion was carried out for 2 hrs with 10 µg DNA template in a 30 µl reaction. 
Linearised DNA was then purified using a QIAquick® nucleotide removal column (Qiagen) 
according to manufacturer’s instructions and eluted in 32 µl Ampuwa® H2O. 
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PI clone (850 bp) was linearised with SalI and transcribed with T7 RNA polymerase to 
produce anti-sense probe and linearised with NcoI and transcribed with SP6 RNA polymerase 
to produce sense probe. PIII clone (300 bp) was linearised with NcoI and transcribed with SP6 
RNA polymerase to produce anti-sense probe (Figure 2.1).  
2700 2800 2900 3000 3100 3200 3300 3400 3500 3600 3700 3800
Exon 2 Exon 3 Exon 6Exon 4Exon 5
P I
T7 RNA…SP6 RNA pol promoter
mCATSF113 mCATSR942
NcoI (3823)SalI (2921)
 
100 200 300 400 500
Ex3 Ex2
PI I I
NcoI (37)
SP6 RNA pol promoter
mCATSF364 mCATSR630
 
Fig. 2.1: PI and PIII clones used to produce sense and anti-sense WISH probes. PI and PIII clones were 
generated by RT-PCR from thymus RNA using primer pairs mCATSF113-mCATSR942 and mCATSF364–
mCATSR630, respectively and by subsequent cloning of the 850 and 305 bp products into the pGEM®-T Easy 
vector. PIII was linearised with NcoI and transcribed with SP6 RNA polymerase to produce anti-sense probe and 
PI was linearised with NcoI and transcribed with SP6 RNA polymerase to produce sense probe. Arrows indicate 
binding position of CATS primers. 
 
For the in vitro transcription the following components were placed in a 1.5 ml tube. 
10 µl Template DNA (PI or PIII) prepared as described above 
3 µl Ampuwa® H2O 
2 µl TS-buffer 
2 µl rNTPs DIG-Mix 
1 µl RNase inhibitor 
2 µl RNA polymerase (T7 or SP6) 
Reaction was incubated for 2 hrs at 37°C. After that, 2 µl DNase I was added to the reaction, 
which was incubated for further 15 min. Transcribed RNA was then precipitated by adding 
400 µl 100 % ethanol, 1 µl tRNA (20 mg/ml) and 33 µl 7.5 M NH4Ac, gently mixing and 
incubating for 1 hr at -80°C. RNA was centrifuged at 15 000 rpm for 30 min at 4°C, pellet 
was washed with 70 % ethanol (15 000 rpm, 15 min, 4°C) and resuspended in 100 µl 
Ampuwa® H2O plus 1 µl RNase inhibitor. Quality and yield were checked, by loading 5 µl of 
the RNA probe on 1 % agarose-gel (2.2.6). RNA probe was stored at -20°C. 
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2.2.19.3 Hybridization of mouse embryos 
 
Embryos prepared as described above (2.2.19.1) were re-hydrated through 75 %, 50 %  and 
25 % methanol (in PBS-DEPC) incubation for 10 min each. Re-hydrated embryos were then 
washed for 10 min with PBT and transferred to the slots of the InsituPro robot (ABIMED), 
where an automated hybridization took place. In contrast to manual hybridization, the 
apparatus allowed rapid changes of solutions and constant temperature throughout all steps. 
All buffers used were listed in 2.1.5. Briefly, embryos were washed twice with PBT for 10 
min. For embryos older than 10.5 d.p.c., 5 min treatment with proteinase K buffer was 
needed. Proteinase K was used to improve the signal by increasing the accessibility of target 
RNA. After proteinase K treatment, embryos were washed twice with 2 mg/ml glycine in 
PBT (10 and 5 min, respectively), then twice with PBT. Prior to pre-hybridization, embryos 
were treated with RIPA-DEPC and 4 % PFA/ 0.1 % GA (10 min and 20 min, respectively), 
with two PBT washing steps (10 min) between and after treatments. Pre-hybridization was 
carried out with hybridization solution (WISH) plus 100 µg/ml tRNA for 3 hrs at 70°C. For 
hybridization, DIG-labeled RNA probe was previously denatured and then added to the same 
solution diluted 1:100 dilution. Hybridization was carried out for 16 hrs at 70°C. Post 
hybridization washes were performed to remove unbound probe. Firstly, embryos were 
washed for 1 hr (4 x 15 min) with hybridization solution (WISH) free from RNA probe, at 
70°C. Then treated with 100 µg/ml RNase A in TNT for 1 hr at 37°C. RNase A treated 
embryos were washed altogether for 5 hrs (5 min, 3 x 10 min and 9 x 30 min, respectively) in 
SSC/FA/ Tween® 20 at 70°C, then for 20 min in TBST and MABT (2 x 10 min, each) at RT. 
Before incubation with antibody, embryos were blocked with 2 % blocking reagent (Roche) 
in MABT for 3 hrs. Meanwhile a 1:5000 dilution of Anti-Digoxigenin-AP conjugate (Roche) 
was pre-incubated with 1 % blocking reagent (Roche) in MABT for 1 hr at 4°C with gentle 
rocking. Immuno-hybridization was carried out for 12 hrs in the AB solution described above. 
Immuno-hybridized embryos were washed altogether for 14 hrs with TBST (2 x 5 min, 7 x 30 
min and 10 x 1 hr, respectively). After washing, embryos were transferred to Cryotube™ vials, 
washed with NTMT (2 x 5 min) and stained using centrifuged BM purple AP substrate 
(Roche) O/N at 4°C. The staining reaction was kept in dark and the color development was 
monitored. When the desired extent was achieved, reaction was stopped and embryos were 
fixed in 4 % PFA for 1 hr at RT. Stained embryos were stored in the same solution for several 
month. For documentation, embryos were transferred to PBS and mounted on a thin layer of 
agarose (in Petri dishes) under a MZ APO stereomicroscope (Leica) in dark field illumination 
with additional diffuse light from above. All WISHs were recorded on a JVC KY-F70 digital 
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camera using a Leica QWin software (Leica Microsystems Imaging Solutions, Cambridge, 
UK) and pictures were adjusted for brightness and contrast in Adobe Photoshop® 7.0 (Adobe 
Systems, Mountain View, U.S.A). 
 
2.2.19.4 Dissection of hybridized mouse embryos and microscopy 
 
Mouse embryos hybridized and stored as described above (2.2.19.3) were incubated in 30 % 
sucrose solution (in PBS). After having sank to the bottom of the tube, embryos were 
incubated in 7.5 % gelatine solution (in 30 % sucrose solution) for 2 h at 42°C in a water bath. 
In a Petri dish, a thin layer of the 7.5 % gelatine solution was kept at RT until became solid 
and embryos were then embedded with the same solution onto this layer. After O/N 
incubation at 4°C, embryos were recovered into small gelatine blocks. Gelatine blocks were 
placed in alu-folio boxes (1 x 1 cm), which were filled with Jung Tissue Freezing Medium™, 
frozen in dry ice and stored at -80°C. Embedded embryos were sectioned in 35 µm slices with 
a Cryotome CM 1850 (Leica) at -30°C and placed onto pre-cooled slides. Cover slips were 
mounted on the slides with Kaisers Glyceringelatin and stored at RT. Sections were observed 
under an automated Axioplan 2 Imaging microscope (Carl Zeiss, Jena, Germany) equipped 
with an AxioCam HR digital camera. Images were recorded using the AxioVision 3.1 
software (Carl Zeiss, Jena, Germany) and pictures were processed as in 2.2.19.3. 
 
2.2.20 Culture of mammalian cells 
 
Cells (2.1.10) were grown either in DMEM or RPMI medium (2.1.6.3) supplemented with 10-
20 % heat inactivated FBS and 1 % penicillin/streptomycin, in some cases 1 % L-Glutamine 
was also added to the medium. Cells were grown at 37°C in a humidified incubator 
supplemented with 5 % carbon dioxide. Confluent cultures were split 1:3 - 1:5 every 2-3 days. 
Suspension cells were subcultured by simply aliquoting part of the growing culture in a new 
flask containing fresh growth medium. Cultures of adherent cells were washed with DPBS, 
incubated with trypsin/EDTA for approx. 5 min at 37°C, detached cells were resuspended in 
growth medium and replated in a new flask. For long-term storage, harvested cells were 
washed in DPBS, resuspended in freezing medium (70 % growth medium supplemented with 
20 % FCS and 10 % DMSO), aliquoted in Cryotube™ vials and stored in liquid nitrogen. 
 
2 Material and Methods 
 43 
2.2.21 Transient transfection of adherent cells  
 
Transient transfection of adherent cells was performed using Roti®-Fect transfection reagent. 
The day before the transfection, 3.2 x 105 cells were seeded per reaction, they were placed in 
6 well plates with 2 ml of the appropriate growth medium and incubated for 16 hrs at 37°C in 
a CO2 incubator until they were 60 % confluent. Cells, which were transfected with the 
purpose of colocalization and microscopy were grown on 18 x 18 mm coverslips placed in the 
wells. For the transfection the following reactions were mixed in parallel: 1-2 µg of plasmid 
DNA (2.2.1.3) plus 60 µl medium free of serum and antibiotic (reaction A) and 10 µl Roti®-
Fect transfection reagent plus 60 µl medium free of serum and antibiotics (reaction B). 
Reactions A and B were mixed and incubated at RT for 40 min in order to allow DNA-lipid 
complex formation. Meanwhile cells were washed once with DPBS and refilled with 0.8 ml 
antibiotica-free medium with serum. The DNA-lipid complexes were added to the cells and 
after 3 hrs incubation 1.2 ml of complete growth medium was added to the cells, which were 
incubated for another 20-48 hrs. After that, cells were either fixed for microscopy (2.2.21.2) 
or harvested for protein extraction (2.2.24.1) and reporter gene assay (2.2.23.1). Alternatively, 
when greater vol. of protein extracts from transfected cells was required, transfections were 
scaled up to be performed in a 100 mm or 150 mm Petri dish. 
 
2.2.21.1 Nuclear export inhibition of overexpressed protein 
 
Nuclear export inhibition was employed to determine cytoplasmic-nuclear shuttling of 
proteins. For that NIH-3T3 cells were transfected with YFP-CATS (both isoforms) (3.4.1), 
YFP-CALM (3.7) or YFP-CALM/AF10 (2.1.12) constructs as described in 2.2.21. 16 hrs 
after transfection, cellular medium was replaced by 100 nM Leptomycin B in fresh growth 
medium. Nuclear export inhibition was carried out for 4 hrs in cell culture conditions. Cells 
were subsequently fixed and mounted for microscopy as described below (2.2.21.2). 
 
2.2.21.2 Fixation of transfected cells and microscopy 
 
At different time points after transfection (2.2.21), the cells were washed with PBS (3 x 3 
min) and fixed for 10 min with freshly prepared 3.7 % formaldehyde (in PBS). After fixation, 
cells were washed with PBS and stained with 2 ml DAPI solution (5 mg/ml stock diluted 
1:20000 in PBS) for 5 min. DAPI solution was replaced by PBS and coverslips were mounted 
on slides with Dakocytomation Fluorescent Mounting Medium and sealed with Fixogum 
Rubber Cement (Marabu). Cells were observed under an automated Axiovert 200M 
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microscope (Carl Zeiss, Jena, Germany) equipped with single-band pass filter sets for 
visualization of DAPI, cyan (CFP) and yellow (YFP) fluorescence. Images were recorded 
using the Openlab 3.08 software (Improvision, Coventry, UK) and pictures were processed 
with Adobe Photoshop® 7.0 (Adobe Systems, Mountain View, CA) 
 
2.2.22 Yeast two-hybrid screen 
 
Y2H is a GAL4-based system that provides a transcriptional assay for detecting protein 
interactions in living yeast cells. This system can be employed to identify novel protein 
interactions, confirm suspected interactions, and to define interacting domains. The Y2H 
screen is based on the coexpression of the bait protein (CATS fused in frame to the GAL4-
DBD) and a prey protein (a library of random cDNA expressing protein X fused in frame to 
the GAL4-AD). If there is interaction between the bait and prey proteins the GAL4-DBD and 
-AD are brought into proximity thus a transcriptional activation complex is formed which 
activates the expression of reporter genes in the yeast (Figure 2.2). The yeast strain AH109 
(2.1.8), used for the screen, contains reporter constructs in which HIS3, ADE2 and MEL1/lacZ 
genes are under the control of distinct GAL4-UAS and TATA boxes. Expression of HIS3 and 
ADE2 provides nutritional selection which enable the yeast cells to grow on plates lacking 
certain nutrients (2.1.6.2) and MEL1 provides a catalytic color reaction on the same plates 
supplemented with X-∝-GAL (X-∝-GAL is converted into a blue color by MEL1 gene 
product).  
 
 
Fig. 2.2: The two-hybrid principle. The DBD is amino acids 1-147 of the yeast GAL4 protein, which binds to 
the GAL4-UAS upstream of the reporter genes. The AD is the amino acids 768-881 of the GAL4 protein and 
functions as a transcriptional activator. 
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Potential interaction between proteins identified with the screen should be confirmed by 
independent methods. Interaction was confirmed cotransforming the prey and bait plasmids 
into yeast strain AH109 (2.2.22.2) and assaying for growth on selective plates as well as by 
colocalization (2.2.21) and co-immunoprecipitation experiments (2.2.28). 
 
2.2.22.1 Test of bait plasmid for autonomous activation 
 
Some bait proteins may have intrinsic DNA-binding and/or transcriptional activating 
properties when fused to the GAL4-DBD activate the yeast reporter genes. Hence deletion of 
certain portions of the bait protein may be required to eliminate unwanted activity before the 
protein can be used in a two-hybrid screen. In order to test the bait protein, pGBT9-CATS 
construct was transformed in the yeast strain CG 1945 (2.1.8) as described in 2.2.22.2. As a 
control, CG 1945 cells were transformed with the empty pGBT9 plasmid (2.1.11). Since the 
bait expression plasmid pGBT9 harbor TRP1 gene, transformants were selected by growth on 
SD -Trp plates (2.1.6.2). The test of self-activation transformants were stricked onto SD -Trp, 
-His plates (2.1.6.2).  
 
2.2.22.2 Transformation in yeast cell 
 
A polyethylene/lithium acetate mediated transformation was performed to transform yeast 
strains AH109 or CG 1945 with plasmids expressing either/both GAL4-DBD and -AD fusion 
proteins (or cDNA library). Yeast cells were made competent as follow: one or more yeast 
colonies (≤ 4 weeks old) were resuspended in 1 ml YPD medium, mixed by vortexing and 
transferred to 20 ml culture medium (2.1.6). O/N culture grown at 30°C for 16-18 hrs shaking 
at 250 rpm (stationary phase OD600 >1.5) was transferred to 300 ml YPD and incubated for 
approx. 3 hrs to OD600 0.4-0.6. Cells were collected by centrifugation at 1 000 x g for 5 min at 
RT and resuspended in 30 ml ddH2O. After a second centrifugation step, the supernatant was 
discarded, and the cells were resuspended in 1.5 ml freshly prepared 1X TE/LiAc (2.1.5). For 
sequential transformation, 100 µl of the freshly prepared yeast competent cells were mixed 
with 10 µl carrier DNA (10 mg/ml), 100 ng bait or prey plasmid (or 1 µg library DNA) and 
600 µl PEG/LiAc. For simultaneous cotransformation both bait and prey plasmids were added 
together in the reaction above at a molar ratio of 2:1 (200 ng DNA-DBD: 100 ng DNA-AD). 
The reaction was incubated for 30 min shaking at 30°C (200 rpm). 70 µl DMSO was added 
and gently mixed by inversion. Cells were heat shocked for 15 min in a 42°C water bath, 
chilled on ice for 2 min, collected by centrifugation at 14 000 rpm at RT for 5 sec and 
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resuspended in 1 ml YPD. In order to allow cells to recover from the stress, they were 
incubated for 1 hr at 30°C, shaking at 230 rpm. After that, cells were washed twice in 1 ml 1X 
TE buffer (14 000 rpm, 5 sec at RT) and finally stricked onto SD plates lacking tryptophane 
and/or leucine (selection for the presence of plasmid expressing the GAL4-DBD and -AD, 
respectively). Colonies positive for both bait and prey plasmids were then assayed for protein 
interaction by re-plating transformants from the SD -Trp, -Leu plate onto SD -Trp, -Leu, -His, 
-Ade plate supplemented with X-α-GAL. Plates were incubated at 30°C and growth 
monitored for several days.  
Glycerin stocks were prepared for long-term storage of the yeast clones. Single colony was 
inoculated into 3 ml YPD and incubated O/N shaking at 30°C. 1 ml of the yeast culture plus 
300 µl glycerin were placed in a fresh 1.5 ml tube, mixed by vortexing and stored at -80°C. 
 
2.2.22.3 Large-scale cDNA library transformation 
 
For screening the HeLa S3-cDNA library thus obtaining a high number of cells expressing an 
individual prey protein, large-scale transformation of the yeast AH109 was performed. In a 
sequential transformation, the pGBKT7-CATS bait plasmid was firstly introduced through a 
small-scale transformation as described in 2.2.22.2. Colonies positive for pGBKT7-CATS 
were assayed by growth on SD -Trp plates. Selected transformants (pGBKT7-CATS/AH109 
cells) were then grown up and made competent as described in 2.2.22.2. In order to obtain a 
maximal amount of transformation efficiency (4x104 cfu /µg cDNA library), the amount of 
the library DNA was increased to 4X and reaction was scaled up to be performed in a 11X 
vol. of the small-scale reaction. Thus 1.1 ml of the freshly prepared bait-containing competent 
cells was mixed with 44 µg cDNA library, 1.1 mg carrier DNA and 6.6 ml PEG/LiAc. 
Transformation reaction, divided in 11 reaction tubes (1.5 ml) proceeded as described before. 
Selection of cotransformants was performed using medium-stringency conditions. For that, 
cells transformed with the library cDNA were plated on SD -Trp, -Leu, -His plates. 200 µl 
vol. was used to strick each of the 150 mm selective plates (42 plates in total). Plates were 
grown at 30°C for 7 days. Subsequently, His positive colonies were replicated onto SD -Trp, -
Leu, -His, -Ade plate supplemented with X-α-GAL to screen for ADE2 and MEL1 expression. 
After 7 days incubation at 30°C, the positive colonies were identified by the blue color. 
In order to assay the number of transformants screened in this experiment, 0.1 and 0.2 % of 
the transformation reaction (1 and 2 µl, respectively) was plated onto SD -Trp, -Leu plates 
and the number of cfu/ reaction vol. was determined. 
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2.2.22.4 Isolation of plasmid DNA from yeast cells 
 
Prey plasmids were recovered from positive colonies identified in 2.2.22.3 by a rapid isolation 
of plasmid-DNA. For that, single colonies were inoculated into 2 ml YPD medium and grown 
at 30°C, O/N at 200 rpm. 1.5 ml of the O/N culture was transferred to a 1.5 ml tube and spin 
down for 5 sec at high speed. Supernatant was removed and the pellet was briefly vortexed. 
Cells were lysed in 200 µl Lysis solution for yeast cells (2.1.5) plus 0.3 g glass beads and 200 
µl of phenol/chloroform/isoamyl (25:24:1), vortexed for 2 min and centrifuged for 5 min at 14 
000 rpm. Approx. 250 µl of supernatant was transferred to a fresh 1.5 ml tube and ethanol 
precipitated as described in 2.2.3. DNA was resuspended in 20 µl ddH2O and 5 µl was used 
for electroporation (2.2.5.4). 
 
2.2.23 GAL4-based transcription assay 
 
The GAL4-based transcription assay is based on the expression of GAL4-DBD fusion protein 
in the mammalian system. The hybrid protein is targeted to the cell’s nucleus by the GAL4 
NLS from the pM1 plasmid (2.1.11) where the GAL4-DBD of the fusion protein binds to the 
GAL4-UAS in the promoter region of the reporter gene plasmid. If the protein posses any 
function as a transcriptional regulator, a transcription activation or repression complex will 
induce or repress the expression of the luciferase reporter gene (Figure 2.3).  
 
Fig. 2.3: Principle of GAL-4-based transcription assay. Vectors expressing both the GAL4-DBD fusion 
protein and reporter gene are coexpressed in mammalian cells. The GAL4-DBD of the fusion protein binds to 
the GAL4-UAS in the promoter region of the reporter gene. (A) If the expressed protein has a function as 
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activator of transcription, it will induce the transcription of the luciferase reporter gene from the pGAL4LUC 
plasmid. (B) If the protein functions as repressor of transcription it will repress the constitutive expression of the 
luciferase reporter gene (under the transcriptional control of the Herpes simplex virus thymidine kinase 
promoter) from the pGAL45tkLUC plasmid. 
 
2.2.23.1 Luciferase reporter gene assay 
 
Human embryonal kidney 293T cells were transfected as described in 2.2.21. 48 hrs after 
transfection, cells were washed with 1 ml PBS and harvested in 200 µl to 1 ml of lysis buffer 
(PLB). Cell lysates were transferred to a 1.5 ml tube and alternately incubated for 5 min in ice 
and at 37ºC. Cell lysates were assayed for firefly and Renilla luciferase activities using a 
Dual-Luciferase® Reporter Assay System (Promega) and a Turner Designs TD-20/20 
luminometer. The luminometer was programmed to perform a 2-sec pre measurement delay, 
followed by a 10-sec measurement period for each reporter assay. Measurements were 
performed by transferring 8-20 µl of cell lysate into a luminometer tube containing 100 µl 
LAR II, placing the tube in the luminometer and initiating the reading for the firefly luciferase 
activity. The sample was removed from the luminometer and 100 µl of Stop & Glo® reagent 
was added. After briefly vortexing, the tube was placed in the luminometer again and the 
Renilla luciferase activity was read. Measurements of Renilla luciferase activity were used for 
normalization. Experiments were performed at least in triplicate.  
 
2.2.24 Protein extraction 
 
2.2.24.1 Protein extraction from mammalian cells 
 
Protein extraction from both transfected and nontransfected cells were performed as follows. 
Cells were harvested and washed twice in ice-cold PBS (1 100 rpm for 5 min). Cell pellets 
were lysed in an appropriate vol. of RIPA buffer (2.1.5) with freshly added protease inhibitors 
(protease inhibitor cocktail diluted 1:100). After 30 min. of incubation on ice, whole cell 
extracts were cleared by centrifugation at 10 000 x g for 10 min at 4º C. The supernatant was 
the total cell lysate.  
 
2.2.24.2 Protein extraction from human tissue 
 
Proteins were extracted from human tissue similarly to what described above (2.2.24.1). 
Maintaining the temperature at 4°C throughout all procedures, 60 mg of human thymus was 
homogenized in 200 µl RIPA buffer with freshly added protease inhibitor (in general approx. 
3 ml RIPA buffer per gram of tissue) with a Tissuemizer (Tekmar-Dohrmann). 200 µl of 
2 Material and Methods 
 49 
PMSF (100 mM) was added to the homogenized tissue, which was incubated on ice for 30 
min. Protein extract was cleared by centrifuging at 10 000 x g for 10 min at 4°C, twice. The 
supernatant fluid was the total protein extract. Protein extracts were mixed with an equal 
volume of 2X Laemmli sample buffer (2.1.5) and denatured at 95º C for 5 min. Lysates were 
stored at 20º C for several months. 
 
2.2.24.3 Protein extraction from yeast cells 
 
One or more yeast colonies (≤ 4 weeks old) were inoculated in 5 ml YPD medium, mixed by 
vortexing and incubated O/N at 30°C shaking at 230 rpm. The O/N culture was diluted in 5 
ml YPD medium (OD600 0.2) and further incubated for approx. 4-6 hrs to OD600 0.45-0.7. 1.5 
ml of the culture suspension was transferred to a fresh tube and centrifuged at 13 000 x g for 3 
min at RT. Cells were resuspended in 50 µl 2X Laemmli sample buffer, vortexed and frozen 
on dry ice (or liquid nitrogen). Samples were subsequently boiled for 5 min and centrifuged 
for 5 sec at 14 000 rpm. The supernatant was the total cell lysate. 25 µl of cell lysate was used 
per lane of SDS-PAGE gel (2.2.26). 
 
2.2.25 Determination of protein concentration using the Bradford method 
 
Standard BSA curve was calibrated by diluting the stock solution (1 µg/µl; 30 mg BSA in 30 
ml ddH2O) in the appropriate vol. of ddH2O as shown in the table below. 
 
BSA (µl) 0 1 5 10 15 20 25 
ddH2O (µl) 800 799 795 790 785 780 775 
 
In parallel, 1 µl of the protein extract was diluted in 799 µl of ddH2O and 200 µl of Bradford 
reagent was added to each reaction tube, both to the BSA and sample dilutions. Measurement 
of the protein against the BSA calibration curve was performed in an Eppendorf 
BioPhotometer 6131. 
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2.2.26 PAGE gel 
 
SDS-Polyacrylamide (SDS-PAGE) gel electrophoresis was used for separation of proteins 
under denaturing conditions. The concentration of the gels used was determined according to 
the effective range of separation of SDS-PAGE shown below: 
 
Acrylamide concentration (%) Linear range of separation (kDa) 
15 12-43 
10 16-68 
7.5 36-94 
5 57-212 
 
SDS-PAGE gel was prepared according to the range of protein separation desired. For the 
resolving gel the following components were mixed together: 
 
Components (5 ml) 8 % 10 % 12 % 
ddH2O 2.3 ml 1.9 ml 1.6 ml 
30 % Acrylamide mix 1.3 ml 1.7 ml 2.0 ml 
1.5 M Tris/HCl (pH 8.8) 1.3 ml 1.3 ml 1.3 ml 
10 % SDS 50 µl 50 µl 50 µl 
10 % APS 50 µl 50 µl 50 µl 
TEMED 3 µl 2 µl 2 µl 
 
Resolving gel solution was poured into the gap between glass plates placed at vertical position 
at RT. After polymerization of the resolving gel was completed (approx. 30 min at RT), 
stacking gel was prepared by mixing the following components:  
 
Components (2 ml) Stacking gel 5 % 
ddH2O 1.4 ml 
30 % Acrylamide mix 330 µl 
1 M Tris/HCl (pH 6.8) 250 µl 
10 % SDS 20 µl 
10 % APS 20 µl 
TEMED 2 µl 
 
Stacking gel solution was poured directly onto the surface of the polymerized resolving gel.  
2 Material and Methods 
 51 
2.2.26.1 Coomassie staining of PAGE gel  
 
Coomassie staining of PAGE gel was used for detection of proteins on the gel after 
electrophoresis. Gel was immersed in Coomassie® solution (BioRad) and incubated for 
approx. 1 hr at RT with shaking. Coomassie® solution bound unspecifically was removed by 
washing the gel with 10 % methanol plus 10 % acetic acid in ddH2O. Washing was performed 
until protein bands became visible. Gel was then washed in 90 % methanol/10 % acetic acid 
for approx. 10 min and fixed for 15 min with 20 % ethanol plus 2 % glycerol in ddH2O. 
Finally, gel was dried for approx. 1 hr between 2 sheets of cellophane using a Gel Air™ 
Drying System (BioRad). 
 
2.2.27 Western blot  
 
Immunocomplexes and cellular lysates were electrophoresed on 8-12 % SDS-PAGE gels and 
transferred to a nitrocellulose membrane using a semi-dry system, consisting of 3 sheets of 
blotting paper (GB003), a nitrocellulose membrane, the gel and 3 layers of blotting paper 
(GB003), one on the top of the other one laid on the surface of the Trans-Blot® SD Semi -Dry 
Transfer Cell (BioRad). Except for the gel, papers and membrane were pre-wet in transfer 
buffer (2.1.5). Transfer of protein from the gel to the membrane occurred under electric 
current from the negative to the positive pole at 0.15 A for 1 hour. The membranes were 
blocked for nonspecific binding sites with 5 % nonfat dried milk for 1 hr at RT (alternatively, 
O/N at 4°C). Immunoblotting was carried out with specific antibodies diluted in 5 % nonfat 
dried milk at optimal concentration. Incubation with primary antibody was carried out in most 
cases for 1 hr at RT (alternatively, O/N at 4°C) followed by extensive washing steps with 
TBST (rinse twice, wash 1 x 15 min and 3 x 5 min, respectively). Secondary antibodies 
conjugated with horseradish peroxidase (HPR) were used for detection of the primary 
antibody. Incubation was carried out for 45 min at RT followed by extensive washing steps as 
described above. Finally, proteins were detected by incubating the membrane with enhanced 
chemiluminescent reagent for 5 min at RT (ECL, Amersham Pharmacia biotech). The 
membrane was then wrapped in cling film and placed in an x-ray film cassette. 
Autoradiography films were exposed between 5 sec to 2 min. 
Stripping the immunoblotings was performed in order to probe the same membrane with a 
different antibody. Immunoblotings were stripped by immersing the membranes in stripping 
solution for WB (2.1.5) under shaking at 56°C for 30 min. Membranes were washed twice 
with TBST for 10 min at RT followed by blocking and probing as described above. 
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2.2.28 Immunoprecipitation 
 
Cell lysates (2.2.24.1) were precleared in order to remove proteins, which bind in an 
unspecific manner. For this, 2 µg of normal control IgG and 30 µl Protein A- or G-Agarose 
beads were incubated with 400 µg total cell lysate in 1 ml CoIP buffer (reaction A). Protein A 
was used to bind rabbit or mouse antibodies and G to bind rat antibody. In parallel antibody-
beads conjugates were formed by incubating 2 µg of specific antibody (100 µl when α-CATS 
2C4 was used for precipitation) or normal IgG control with 30 µl Protein A- or G-Agarose 
beads in 500 µl vol. of the same buffer (reaction B). After 1 1/2 hr incubation, reactions A and 
B were centrifuged at 2 200 rpm for 5 min at 4°C. Antibody-bead conjugates (reaction B) 
were washed in 1 ml CoIP buffer and pelleted by centrifugation at 2 200 rpm for 5 min at 
4°C. Precipitation of immunocomplexes was performed by incubating the precleared cell 
lysates (reaction A) with the antibody-beads conjugates (reaction B) for 5 hrs at 4°C with 10 
rpm rotation. Precipitates were washed 3 times with 1 ml CoIP buffer, resuspended in 15 µl 
2x Laemmli sample buffer and denatured for 5 min at 95°C before loading on SDS-PAGE gel 
for analysis. The CoIP buffer used for the immunopreciptation was determine according to the 
appropriate stringency necessary to detect the coimmunoprecipitates. When the high stringent 
CoIP buffer I was used for the precipitation reaction, the last two washing steps were 
performed with the CoIP buffer II without proteinase inhibitors. When the low stringent CoIP 
buffer 3 was used, all the washing steps were performed with the same buffer.  
 
2.2.29 Immunofluorescence 
 
2.5 x 105 U2OS cells were seeded and grown on 18 x 18 mm coverslips placed in 6 well 
plates. After 24 hrs incubation at 37°C in a CO2 incubator, cells were washed in PBS and 
fixed for 10 min in 2 % PFA (2.1.5). Cells were then washed three times with PBS (3 min 
each), incubated for 15 min with PBS plus 0.1 % Tween® 20 and blocked with 10 % FCS in 
PBS for 1 hr at RT with gentle rocking. For the immunofuorescence reaction, CATS antibody 
was diluted 1:10 in PBS plus 1.5 % FCS and incubation was carried out O/N at 4°C in a 
humidified chamber. Next day, cells were washed with PBS plus 0.1 % Tween® 20 (3 x 5 
min) at RT with gentle rocking. Secondary antibody Cy™ 3-conjugated diluted 1:250 was 
used for detection of the primary antibody for 30 min at RT in dark followed by washing as 
described above (also in dark). Finally, cells were stained for 2 min in DAPI solution (5 
mg/ml stock, diluted 1: 20 000 in PBS) and washed with PBS. Coverslips were mounted on 
slides with Dakocytomation Fluorescent Mounting Medium and sealed with nail varnish. 
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Cells were observed under an automated Axiovert 200M microscope (Carl Zeiss, Jena, 
Germany) equipped with single-band pass filter sets for visualization of DAPI and Texas red 
fluorescence. Image documentation was performed as described in 2.2.21.2.  
 
2.2.30 Expression and purification of GST-CATS fusion protein  
 
For expression of the GST-CATS fusion protein, the bacteria strain BL21 (2.1.7) was 
transformed with the pGEX4T-2-CATSv1 and pGEX4T-2-CATSv2CT constructs as 
described in 2.2.5.2. Transformed colony was inoculated into 10 ml LB medium plus 
ampicillin and incubated O/N at 37°C with vigorous shaking. The O/N culture was diluted 
into 100 ml LB medium plus ampicillin and further grown to OD600 0.6-0.8 at the same 
conditions. Induction of GST-fusion protein expression was performed incubating the cell 
culture for 2 hrs in the presence of 1 mM IPTG. As a control, a parallel culture grown at the 
same conditions was grown deprived from IPTG treatment. After induction, cells were 
harvested by centrifugation at 4 500 rpm for 15 min at 4°C and resuspended in 5 ml cold 
NETN buffer plus protease inhibitors (1 mM PMSF and 10 µg/ml pepstatin, leupeptin and 
aprotinin). Suspension was then sonicated for 1 min on ice. Cell lysate was transferred to 1.5 
ml tubes, centrifuged at 14 000 rpm for 5 min at 4°C and supernatant was transferred to a 
fresh tube. Protein extract was stored at -80°C. In order to check whether induction of protein 
expression has occurred, a PAGE gel electrophoresis was performed with 20 µl protein 
extract from both induced and non-induced cultures. Overexpressed protein was visualized by 
staining the gel with coomassie solution (2.2.26.1). GST fusion protein was purified from the 
bacterial lysate by affinity chromatography using glutathione immobilized to a matrix (such 
as agarose) and gravity flow. For that GST-CATS protein extract was incubated with 250 µl 
Glutathione-agarose beads (which had been firstly washed 3 times in NETN buffer) per ml of 
lysate. Incubation was carried out for 4 hrs at 4°C with 10 rpm rotation, protein-Glutathione 
beads were applied to the GST purification column followed by extensive wash with high salt 
buffer (2.1.5) (3 x 2.5 ml), PBS plus 0.1 % Triton X-100 (2 x 2 ml) and PBS plus 1 mM DTT 
and protease inhibitors (1 x 2 ml), respectively. Protein was finally recovered from the ligand 
through 3 elution steps with 500 µl elution buffer each. 
The integrity of the purified protein was examined in 12 % SDS-PAGE and Coomassie blue 
staining. GST-CATS fusion protein was stored at -80°C. 
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2.2.31 FACS sorting of hematopoietic cell sub populations 
 
Hematopoietic cells were obtained from the thymus and bone marrow of 4 weeks old mice. 
Bone marrow cells were flushed from both femurs and tibias with DMEM medium 
supplemented with 2 % FBS. Cell from thymus were obtained through smashing the tissue 
onto a cell strainer and recovering them with DMEM medium. Cellular suspensions (from 
thymus and bone marrow) were centrifuged for 3 min at 2 000 rpm and cell pellets were 
resuspended in 5 ml DPBS. For the cellular suspension originated from bone marrow, 
treatment with ammonium chloride was needed in order to lysate the red blood cells. For that, 
the same vol. of ammonium chloride solution was added to that suspension followed by 20 
min incubation on ice. Ammonium chloride treated cells were harvested by centrifugation and 
resuspended in 1 ml DPBS. Cellular suspensions were divided into 250 µl or 500 µl aliquots 
and each of them was incubated with the appropriated PE or/and APC conjugated antibody at 
optimal concentration (2.1.14). Antibody incubation was carried out for 30 min on ice 
protected from light. The cells were then washed with DPBS and pellets were resuspended in 
0.5 ml FACS buffer (2.1.5). Cells were sorted using FACSVantage SE System (BD 
Biosciences) and cell subpopulations were collected in DMEM medium supplemented with 
50 % FBS. After sorting, cells were rinsed in PBS and immediately lysate in RLT buffer for 
RNA extraction as described in 2.2.9. 
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3 Results 
 
3.1 Isolation and characterizing the CATS genes  
 
3.1.1 The human CATS gene 
 
In order to obtain the complete mRNA sequence of the human CATS gene, the human EST 
database was searched with the sequence (834 bp) from the pGADGH-CATSv2CT prey clone 
(2.1.12) isolated from a previous Y2H screen (Gläsner, 1999). Three overlapping ESTs were 
identified (GenBank AA604379, BE888231, BE799806) which were assembled into a 1532 
bp long contig. Two IMAGE cDNA clones (IMAGp998G039611, IMAGp998D169579) 
corresponding to the EST contig were obtained from RZPD, Berlin, Germany (2.1.15) and 
completely sequenced (2.2.13). Genbank searches revealed that the complete CATS genomic 
locus is contained in the sequence of a BAC (EMBL accession number AC055872). 
Alignment of CATS cDNA sequence to the whole human genomic sequence was used to 
characterize the genomic locus as well as to identify exon-intron boundaries and pseudogenes 
of CATS. 
CATS is located on chromosome 17 band p13, 6.29 megabase pairs from the telomere of the 
short arm (chromosome 17 genomic contig NT_010718). 4 processed pseudogenes of CATS 
were identified at other chromosomal locations. Two of them are located on chromosome 4 
(4p15; 4q24), one on chromosome 6 (6q15) and the fourth on chromosome 2 (2q33). The 
genomic locus of CATS spans 7 kb and contains 6 exons with a non-coding first exon. The 
splice donor and acceptor sites of the CATS are canonical except for the splice donor in the 
third intron (GC-AG (splice donor - splice acceptor)) (Table 3.1). At least three alternatively 
spliced variants of CATS were identified which code for two protein isoforms of 238 and 248 
amino acids in length (isoform 1 and 2, respectively) (Figure 3.1). The calculated molecular 
weight for isoform 1 is 26.24 kDa (pI 10.23) and for isoform 2 is 27.47 kDa (pI 10.56). Both 
isoforms share the same sequence from residues 1-228, encoded by exons 2-4. The two 
proteins differ in their C-terminus. The 10 last amino acids of isoform 1 are encoded by exon 
5, which is not present in the transcript coding for isoform 2. The last 20 amino acids of 
isoform 2 are encoded by exon 6 (Figure 3.2).  
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Fig. 3.1: Genomic organization, alternative splicing, and protein isoforms of CATS. Boxes represent exons, 
with filled parts symbolizing coding region. 5’ and 3’ UTRs are indicated by lighter coloring of the boxes. There 
are 3 splice variants (sizes are indicated in brackets). In splice variant 2, exon 5 is spliced out resulting in a 
longer protein (CATSv2) encoded by exons 2, 3, 4 and 6. The shorter isoform (CATSv1) is encoded by exons 2, 
3, 4 and 5 from splice variants 1 and 3. Both CATS isoforms are identical from amino acids 1-228, they differ in 
their last 10 and 20 C-terminal residues (CATSv1 and CATSv2, respectively). 
 
Intron splice acceptor Exon splice donor 
  Exon 1 (39 bp) GTGGTGTCGGgtgagtgcgg 
Intron 1 (588 bp) tcctccccagGGTCTAGTGG Exon 2 (328 bp) CGTGTCCCAGgtaatactga 
Intron 2 (2059 bp) cctgttccagAGAATCCAGG Exon 3 (295 bp) GCTCTCCCAGgcaagtggga 
Intron 3 (1554 bp) tttcatgcagCGAGTCTGAC Exon 4 (95 bp) CGGAAGAGAGgtgagttggc 
Intron 4 (621 bp) ttctctctagTGGTGACATC Exon 5 (44 bp) GTGCCTGCAGgtaatgccca 
Intron 5 (290 bp) tgtcttgaagGAAACAAGCC Exon 6 (702 bp)  
 
Table 3.1: Exon-intron boundaries of human CATS. Sequences of the splice donor and acceptor sites of CATS 
as determined by comparison of the cDNA and genomic sequences are underline. Exons are in upper-case and 
introns are in lower-case. The non-canonical splice donor in intron 3 is in bold. Exon and intron sizes are 
indicated in brackets. 
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Exon 1                                               Exon 2 
           10           20           30            40           50           60 
GCA GCT GTG CTG CGG CTG TGC TCG GCC TTA GTG GTG TCG GGG TCT AGT GGA CAG AGA AGA 
 
           70           80           90           100          110          120 
CTC TTG GCC AGG CAG ATG GCT TCT CGG TGG CAG AAC ATG GGG ACC TCC GTG CGC CGG AGA 
                     M   A   S   R   W   Q   N   M   G   T   S   V   R   R   R  
                     1                                                       15 
 
          130          140          150           160          170          180 
TCT CTC CAG CAC CAG GAG CAG CTG GAG GAC AGC AAG GAG CTG CAG CCT GTG GTC AGC CAT 
 S   L   Q   H   Q   E   Q   L   E   D   S   K   E   L   Q   P   V   V   S   H  
 16                                                                          35 
 
          190          200          210           220          230          240 
CAG GAG ACC TCT GTA GGG GCC CTG GGG TCC CTG TGC AGA CAG TTC CAA AGG AGG CTG CCC 
 Q   E   T   S   V   G   A   L   G   S   L   C   R   Q   F   Q   R   R   L   P  
 36                                                                          55 
 
          250          260          270           280          290          300 
CTG AGA GCC GTC AAC CTC AAC CTC CGC GCA GGG CCC TCC TGG AAA CGC CTG GAA ACC CCA 
 L   R   A   V   N   L   N   L   R   A   G   P   S   W   K   R   L   E   T   P  
 56                                                                          75 
 
          310          320          330           340          350          360 
GAG CCA GGT CAG CAG GGC CTC CAG GCT GCA GCT CGC TCA GCT AAG AGT GCT TTG GGT GCC 
 E   P   G   Q   Q   G   L   Q   A   A   A   R   S   A   K   S   A   L   G   A  
 76                                                                          95 
 
            Exon 3 
          370          380          390           400          410          420 
GTG TCC CAG AGA ATC CAG GAG TCC TGC CAA AGT GGC ACC AAG TGG CTG GTG GAG ACC CAG 
 V   S   Q   R   I   Q   E   S   C   Q   S   G   T   K   W   L   V   E   T   Q  
 96                                                                         115 
 
          430          440          450           460          470          480 
GTG AAG GCC AGG AGG CGG AAG AGA GGA GCA CAG AAG GGC AGT GGA TCC CCA ACT CAC AGC 
 V   K   A   R   R   R   K   R   G   A   Q   K   G   S   G   S   P   T   H   S  
116                                                                         135 
 
          490          500          510           520          530          540 
CTG AGC CAG AAG AGC ACC CGG CTG TCT GGA GCC GCC CCT GCC CAC TCA GCC GCA GAC CCC 
 L   S   Q   K   S   T   R   L   S   G   A   A   P   A   H   S   A   A   D   P  
136                                                                         155 
 
          550          560          570           580          590          600 
TGG GAG AAG GAG CAT CAC CGC CTC TCT GTC CGG ATG GGC TCA CAT GCC CAC CCA TTA CGG 
 W   E   K   E   H   H   R   L   S   V   R   M   G   S   H   A   H   P   L   R  
156                                                                         175 
 
          610          620          630           640          650          660 
CGA TCA AGG CGG GAG GCT GCC TTC CGG AGC CCC TAC TCC TCA ACA GAG CCC CTC TGC TCT 
 R   S   R   R   E   A   A   F   R   S   P   Y   S   S   T   E   P   L   C   S  
176                                                                         195 
 
      Exon 4 
          670          680          690           700          710          720 
CCC AGC GAG TCT GAC AGT GAC CTA GAG CCT GTG GGG GCG GGA ATT CAG CAT CTC CAG AAG 
 P   S   E   S   D   S   D   L   E   P   V   G   A   G   I   Q   H   L   Q   K  
196                                                                         215 
 
                                                      Exon 5 
          730          740          750           760          770          780 
CTG TCC CAA GAG CTA GAT GAA GCC ATT ATG GCG GAA GAG AGT GGT GAC ATC GTC TCT CTC 
 L   S   Q   E   L   D   E   A   I   M   A   E   E   S   G   D   I   V   S   L  
216                                             228                         235 
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                                  Intron 5 
          790          800          810           820          830          840 
ATT CAT GAC TGA GGA AGT GCC TGC AGg taa tgc cca cct ccc aag agt ctt tct cac tgt 
 I   H   D  STOP 
236     238 
 
          850          860          870           880          890          900 
cct tct cct cca tct cat gca tga gca agt taa aga aaa agc cca cag agc tga tgg gca 
 
          910          920          930           940          950          960 
cag cag agt agg tag tac cta ctt gcc gct tga agc cag agc tgc taa cct cac tga ccc 
 
          970          980          990          1000         1010         1020 
cgt cat taa cag cac gct ggg ggc ccc aag tag cta cag cca cct tcc agc acc ccc cac 
 
         1030         1040         1050          1060         1070         1080 
ccc gca gtg agc agg gaa agg cat ccc tac ttc tcc tac ctt gag cac agt gaa aaa ggc 
 
                    Exon 6 
         1090         1100         1110          1120         1130         1140 
agc tct gtc ttg aag GAA ACA AGC CCT GTC TGA CCG CCA AGG CTT CAT ACT CAA GGA TGT 
                    R   K   Q   A   L   S   D   R   Q   G   F   I   L   K   D   
                   229                                                     243 
 
         1150         1160         1170          1180         1190         1200 
CTA TGC TTC CCC GTG AGC TTC CTG GAA AAA ACC CCC GGG AGT CGT CAG TAC CCC TGG GCC 
V   Y   A   S   P STOP 
244            248 
 
         1210         1220         1230          1240         1250         1260 
ACT GCT AAC AAG CAC CTA ACA AGG GGC CCA GAG CCC CCT GCT CCA GCC ACA TCT GGA CCC 
 
         1270         1280         1290          1300         1310         1320 
ATC AGT GAC TGC CTG CCA TAG CCT GAG AGT GTC TTG GGG AGA CCT TGC AGA GGG GGA GAA 
 
         1330         1340         1350          1360         1370         1380 
TTG TTC CTT CTG CTT TCC TAG GGG ACT CTT GAG CTT AGA AAC TCA TCG TAC ACT TGA CCT 
 
         1390         1400         1410          1420         1430         1440 
TGA GCC TTC TAT TTG CCT CAT CTA TAA CAT GAA GTG CTA GCA TCA GAT ATT TGA GAG CTC 
 
         1450         1460         1470          1480         1490         1500 
TTA GCT GTG TAC CCG GGT GCC TGG TTT TTG GGG AGT CAT CCG CAG AGT CAC TCA CCC ACT 
 
         1510         1520         1530          1540         1550         1560 
GTG TTT CTG GTG CCA AGG CTC TTG AGG GCC CCA CTC TCA TCC CTC CTT TCC CTA CCA GGG 
 
         1570         1580         1590          1600         1610         1620 
ACT CGG AGG AAG GCA TAG GAG ATA TTT CCA GGC TTA CGA CCC TGG GCT CAC GGG TAC CTA 
 
         1630         1640         1650          1660         1670         1680 
TTT ATA TGC TCA GTG CAG AGC ACT GTG GAT GTG CCA GGA GGG GTA GCC CTG TTC AAG AGC 
 
         1690         1700         1710          1720         1730         1740 
AAT TTC TGC CCT TTG TAA ATT ATT TAA GAA ACC TGC TTT GTC ATT TTA TTA GAA AGA AAC 
 
         1750         1760         1770          1780         1790         1800 
CAG CAT GTG ACT TTC CTA GAT AAC ACT GCT TTC TCA TAA TAA AGA CTA TTT GCA TTT GAA 
 
         1810         
AAA AAA AAA AAA AAA A 
 
 
Fig. 3.2: Human CATS nucleotide and amino acid sequences: Splice variant 1, 2 and 3. The first nucleotide 
of each exon is underlined. The last 10 C-terminal amino acids of CATS isoform 1 coded by the alternatively 
spliced exon 5 (splice variant 1 and 3) are italicized and underlined. The last 20 C-terminal amino acids of CATS 
isoform 2 coded by exon 6 (splice variant 2) are underlined. Stop codons for the both isoforms are marked. Note 
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the presence of not removed intron 5 sequences (only present in splice variant 3), indicated in lower-case. Splice 
variant 1 (1527 nt) corresponds to cDNA clone IMAGp998D169579. Splice variant 3 (1817 nt) corresponds to 
the cDNA clone IMAGp998G039611. 
 
3.1.2 The murine Cats gene 
 
In order to obtain the full sequence of the murine Cats gene, the murine EST database was 
searched with the human cDNA sequence (3.1.1). Four overlapping ESTs were identified 
(GenBank W65832, AA103173, BF167691, W80053) and a contig of the murine Cats gene 
was assembled. Three IMAGE cDNA clones (IMAGp998E09899Q2, IMAGp998F103793Q2, 
IMAGp998H174619Q2) corresponding to the contig EST sequences were obtained from the 
RZPD, Berlin, Germany (2.1.15) and were completely sequenced (2.2.13) (Figure 3.3).  
 
3.1.2.1 Cloning of Cats cDNA (mCats cDNA F113-R942 fragment) 
 
The murine Cats contig sequence was used to design primers flanking the Cats ORF. A 850 
bp murine Cats cDNA fragment was amplified by RT-PCR from thymus RNA (2.2.11 and 
2.2.12) using the mCATSF113 and mCATSR942 primer pair (2.1.13). The RT-PCR product 
was cloned into the pGEM®-T Easy vector and fully sequenced (Figure 3.3). The cDNA 
fragment was radioactive labeled (2.2.16) and used as a probe for hybridization of the mouse 
cosmid library (3.1.2.2) and Northern blot (3.2.1). Moreover the cloned RT-PCR fragment 
was used to produce the anti-sense probe I (PI) for whole mount in situ hybridization 
(2.2.19.2).  
 
 
Exon 1 
           10           20           30            40           50           60 
GCT TTG ACA AAA CTA CTT ATC GTG GGA GAG AAG TTA GGC GGG GTG AAG GAC TGA AAG GGG 
 
           70           80           90           100          110          120 
CGC GTG CCC TGG GTG GCG GTG ACC TGA ACC CCC GCA GCA TCC TGC ACC CTG ACC TGC ATG 
 
          130          140          150           160          170          180 
CTT GAA GAA GAG AGC TTG GGA GAA CGA TGG ACT AGG CGC GGT CGC CTG GGA CCA AGC AGC 
 
          190          200          210           220          230          240 
CGG GAT GTA GGG AGG CGG GCT GGT CGG TAA CAG TGA TCC GGT GGC GAC CTG GAC CCC TCT 
 
                Exon 2  
          250          260          270           280          290          300 
GCG GCG AGC CAG GAT CTA GCG GGC AGC GGA AAC TGG ACC AAG CAC ATG GCG TCT CAG TGG 
                                                mCATSF113    M   A   S   Q   W  
                                                             1               5  
 
          310          320          330           340          350          360 
CAG GGC ATG AGG ACC TCT GTG CGC AGA CGA TCA CTC CTA AAG GAG GAA CAG CTA GAG AAG 
 Q   G   M   R   T   S   V   R   R   R   S   L   L   K   E   E   Q   L   E   K  
 6                                                                           25 
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          370          380          390           400          410          420 
AAG GAG GTG ACC CGG TCT GCT GGG GGT CAT CCG GAG ACC GGT CCC TTG GGC TCC CTG TGC 
 K   E   V   T   R   S   A   G   G   H   P   E   T   G   P   L   G   S   L   C  
 26                                                                          45 
 
          430          440          450           460          470          480 
AGA CAA TTC CAA AGG AGG CTG CCT CTG AGA GCG GTC AGC CTG AAC CTC GGT AAC GGC CCC 
 R   Q   F   Q   R   R   L   P   L   R   A   V   S   L   N   L   G   N   G   P  
 46                                                                          65 
 
          490          500          510           520          530          540 
TCC TGG AAA CGC CTG GAA AGT CCA GAG CCA GAG CAG CAA GGT CTT CAG GCT GCA GCT CGC 
 S   W   K   R   L   E   S   P   E   P   E   Q   Q   G   L   Q   A   A   A   R  
 66                                                                          85 
 
                                            Exon 3 
          550          560          570           580          590          600 
TCA GCC AAA AGC GCC TTG GGT GCC ATG TCC CAG AGG ATC CAG GAG TCC TGT CAG AGT GGC 
 S   A   K   S   A   L   G   A   M   S   Q   R   I   Q   E   S   C   Q   S   G  
 86                                                                         105 
 
          610          620          630           640          650          660 
ACC AAG TGG CTG ATG GAG ACA CAG GTG AAA GTG AGA AGG AAG CGA GGA GCC CAG AAA GAC 
 T   K   W   L   M   E   T   Q   V   K   V   R   R   K   R   G   A   Q   K   D  
106                                                                         125 
 
          670          680          690           700          710          720 
AGA GGG TCA CCA CCA CCC AGT CTG AGC CAG AAG AAC ACT CGG CTA TGC AGG GCC AAC CGG 
 R   G   S   P   P   P   S   L   S   Q   K   N   T   R   L   C   R   A   N   R  
126                                                                         145 
 
          730          740          750           760          770          780 
GAT GCT AGA GTC GGG GGA CAT CTT CGC CTC TCT GGC CAG ATG GGT CCG CAT GCC CAT CGC 
 D   A   R   V   G   G   H   L   R   L   S   G   Q   M   G   P   H   A   H   R  
146                                                                         165 
 
          790          800          810           820          830          840 
CGT CAG CGG CTA AGG AGG GAG TCT GCC CTC CGG AGC CCC TGT TCC TCC ACA GAA CCT CTC 
 R   Q   R   L   R   R   E   S   A   L   R   S   P   C   S   S   T   E   P   L  
166                                                                         185 
 
              Exon 4 
          850          860          870           880          890          900 
TGC TCT CCC AGT GAG TCT GAC AGT GAC CTA GAG CCT GTG GGA GCC GGA ATC CAG CAT CTT 
 C   S   P   S   E   S   D   S   D   L   E   P   V   G   A   G   I   Q   H   L  
186                                                                         205 
 
                                                              Exon 5 
          910          920          930           940          950          960 
CAG AAG CTG TCT CAA AGG CTG GAC AGA GCC ATC AAG GCT GAA GAG AGT GGT GAC ATG ACC 
 Q   K   L   S   Q   R   L   D   R   A   I   K   A   E   E   S   G   D   M   T  
206                                                                         225 
 
                                                      Exon 6 
          970          980          990          1000         1010         1020 
GTC TCC CTT ATC CGT GAA TGA GGA CAG CAA GCA TCC TAC AGG AAG CCG GCT CTG TCC AAC 
 V   S   L   I   R   E  STOP 
226                 231 
 
         1030         1040         1050          1060         1070         1080 
CAC CAA GCC ACC AGG ATG TCC ATG CTG CCC AAC CCA TGA ACT TCC TGG AGA CAG CAT TGG 
 
         1090         1100         1110          1120         1130         1140 
GTT TAT CAG CAT CCC CAG GCC ACT GCT AAC AAG GAT TTG ACT AAC ATA GGG TCC AGA ACC 
                                   mCATSR942 
 
         1150         1160         1170          1180         1190         1200 
CTT CTA CTT CAG CCA TAT CTG GGC CCA CTG GTA ACC ACT GGC CAC AGC CTG AGA GTT ATT 
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         1210         1220         1230          1240         1250         1260 
TAG GAA GAC CTT GAA GAG GTG ATG GGA ACT GCC CAT GTT CCC CCA GGG GAC TCC TGG ACT 
 
         1270         1280         1290          1300         1310         1320 
CGG GCA CAC CCA TCT GGC TCT CCA GCT TCA TAG TTG TCC ATC CAT ATT AGG AAT GTA CCA 
 
         1330         1340         1350          1360         1370         1380 
GAA GAT GCT AGA TAG TTC TGA GTC TGG AAA CTA GGA CCA AGG ACC TGC AGG AGT CAT CCC 
 
         1390         1400         1410          1420         1430         1440 
ACA AAC CCT CCC CCT GTA TTC CCA GGG CAG AGA TTC CGG AGG ACC CAC TTT CAC TGC TGC 
 
         1450         1460         1470          1480         1490         1500 
TTC CCA CCC CCA GGA CCC CAC AGG AAG AGA GGA GGT ATT TGC AGA CTG CAA GCC TCA GCT 
 
         1510         1520         1530          1540         1550         1560 
CAC GGA GCC TAC TTA TCT TCT CCA TGT AGG GGC ACT AGC GTG CCT GGA GGG GAA TGC TGT 
 
         1570         1580         1590          1600         1610     
TCG AAA GCA GTT TCT TCT CTT TGT AAA TTA TTT AAG ACA TCT GCT ATG TCA TT 
 
 
Fig. 3.3: Murine Cats nucleotide and amino acid sequences. The cDNA sequence (1613 nt) corresponds to the 
cDNA clone IMAGp998H174619Q2. The first nucleotide of each exon is underlined. The stop codon is marked. 
Yellow filled boxes indicate the primers used to amplify Cats ORF by RT-PCR from thymus RNA. The 
underlined and bold sequence is absent both in the RT-PCR product (italicized) and in the genomic clone 
L02EcoRI-2 (3.1.2.2). 
 
3.1.2.2 Cloning of the murine Cats genomic locus   
 
The arrayed mouse genomic cosmid library 129/ola was screened as described in 2.2.18 using 
the Cats cDNA F113-R942 fragment (3.1.2.1) as a probe. Nine clones were detected with the 
Cats probe and ordered from RZPD (2.1.16.1). PCR analysis using these clones as template 
and Cats specific primers mCATSF364 and mCATSF630 showed Cats amplification in six 
out of the nine clones (MPMGc121C1938Q2, MPMGc121C0434Q2, MPMGc121L02225Q2, 
MPMGc121H24352Q2, MPMGc121D13437Q2 and MPMGc121K17553Q2). Restriction 
mapping and further PCR analysis revealed the presence of the whole Cats genomic locus in 
an EcoRI fragment of approx. 7.9 kb from cosmid MPMGc121L02225Q5. This EcoRI 
fragment was subcloned into the EcoRI site of the pBluescript II KS (+/-) vector. The 
corresponding clone, named L02EcoRI-2 was fully sequenced and characterized in further 
detail. The murine Cats is located on chromosome 11 (genomic contig NT_096135) in a 
region which is syntenic to human chromosome 17. The murine Cats genomic locus spans 
approx. 6 kb and similarly to the human counterpart comprises 6 exons with a non-coding 
first exon. Coding exons are of similar size in both human and mouse genes. Except for intron 
1, introns are shorter in the murine locus (Figure 3.4). The non-canonical splice site of CATS 
is also found in the third intron of the murine Cats gene (Table 3.2). 
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Fig. 3.4: Murine genomic Cats locus in clone L02EcoRI-2. The EcoRI fragment (7.9 kb) was isolated from 
cosmid clone MPMGc121L02225Q5 and subcloned into the pBluescript II KS (+/-) vector. Ruler represents the 
nucleotide. Exons (Ex) are represented as filled boxes. Restriction enzymes used for cloning are depicted in blue. 
 
Intron splice acceptor Exon splice donor 
  Exon 1 (253 bp) GGCGAGCCAGgtggggggtc 
Intron 1 (714 bp) acctccccagGATCTAGCGG Exon 2 (317 bp) CATGTCCCAGgtaacaatga 
Intron 2 (1642 bp) aacccatcagAGGATCCAGG Exon 3 (279 bp) GCTCTCCCAGgcaagtagtc 
Intron 3 (422 bp) ttgtgttcagTGAGTCTGAC Exon 4 (97 bp) CTGAAGAGAGgtgagctgca 
Intron 4 (565 bp) ctgtccttagTGGTGACATG Exon 5 (55 bp) CATCCTACAGgtaatgaccc 
Intron 5 (293 bp) tgtcttacagGAAGCCGGCT Exon 6 (669 bp)  
 
Table 3.2: Exon-intron boundaries of Cats. Sequences of the splice donor and acceptor sites in murine Cats as 
determined by comparison of genomic sequence and RT-PCR product (3.1.2.1). Exons are in upper-case and 
introns are in lower-case. The non-canonical splice donor is in bold. Exon and intron sizes are indicated in 
brackets. 
 
3.1.3 CATS homology among different species 
 
Protein databases were searched with the CATS amino acid sequence in order to identify 
evolutionarily conserved domains in CATS. The Cats protein was identified in four other 
species, Bos Taurus (genomic contig BtUn_WGA322593_1), Rattus norvegicus (genomic 
contig Rn10_WGA1855_3), Fugu rubripes and Gallus gallus (genomic contig 
Gga19_WGA443_1) (Figure 3.5). Comparison of the amino acid sequences of the CATS 
proteins revealed that the human isoform 1 rather than isoform 2 has a higher overall 
homology to the Cats proteins of other species. Closest to the human CATS protein is the 
bovine (Bos taurus) protein, with an overall homology of 91 % and 85 % to the human 
isoform 1 and 2, respectively. Human CATS isoform 1 revealed to be 76 % homologous to 
both murine and rat Cats (Rattus norvegicus) proteins, 47 % homologous to the chicken 
(Gallus gallus) protein and 34 % homologous to the puffer fish (Fugu rubripes) protein 
(Table 3.3). Four regions within the proteins were conserved from Fugu to man suggesting 
that these regions are important for function protein (Figure 3.5). 
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hCATSv1         1 MASR-----WQNMGTSVRRRSLQHQEQLEDSKELQPVVSHQETSVGALGS  45 
hCATSv2         1 MASR-----WQNMGTSVRRRSLQHQEQLEDSKELQPVVSHQETSVGALGS  45 
mCats           1 MASQ-----WQGMRTSVRRRSLLKEEQLEKKEVTRSAGGHPET--GPLGS  43 
BtCats          1 MASR-----WPAVGASLRRRSLQNQERLEESEALQPVASHPDTSSGALGS  45 
RnCats          1 MASQ-----WQGMRTSVRRRSLLKEEQLEK-EVTRSAGGHLET--GPLGS  42 
FrCats          1 MASSVMDGVGKAVVGVWRAHTVLDESDGAESSPEAPDRFRKLRSSSSLNS  50 
GgaCats         1 MASM-----LQNVKATMGWQRRLLLADFDENESPVPDKFKRKASFSSLHT  45 
                  ***         .      .                   .       * . 
 
hCATSv1        46 LCRQFQRRLPLRAVNLNLR-AGPSWKRLETPEPGQQGLQAAARSAKSALG  94 
hCATSv2        46 LCRQFQRRLPLRAVNLNLR-AGPSWKRLETPEPGQQGLQAAARSAKSALG  94 
mCats          44 LCRQFQRRLPLRAVSLNLG-NGPSWKRLESPEPEQQGLQAAARSAKSALG  92 
BtCats         46 LCRQFQRRLPLRAVSLNLG-VGPSWKRLETPEPGQQGLQAAAHSAKSTLG  94 
RnCats         43 LCRQFQRRLPLRAVSLNLG-NGPSWKRLETPEPEQQGLQAAARSAKSALG  91 
FrCats         51 LRMSLRKRLPLRAVQTNSLPENP----TGEPVKEQPKTSTVRKLSRCARN  96 
GgaCats        46 ICMSLRKRIPLKQVELNFH-ETPLWENMEARNKSQ-VFQSITKTARNAFG  93 
                  .    ..*.**. *  *     *           *    .  . .. . . 
 
hCATSv1        95 AVSQRIQESCQSGTKWLVETQVKARRR---------KRGAQKGSGSP--- 132 
hCATSv2        95 AVSQRIQESCQSGTKWLVETQVKARRR---------KRGAQKGSGSP--- 132 
mCats          93 AMSQRIQESCQSGTKWLMETQVKVRR----------KRGAQKDRGSP--- 129 
BtCats         95 AMSQRIQESCQSGTKWLVETQVKARRR---------KRGAQKGSSPP--- 132 
RnCats         92 AMSQRIQESCQSGTKWLMETQVRVRR----------KRGAQKDRGSP--- 128 
FrCats         97 SVSEMYQRLQRTREFSREECLVQTPGRTDN---------VEQRAAST--- 134 
GgaCats        94 TVSQKIQKTCQSPVHSTVTFPAEDIGSSSATCFSKKRRTVQTPCLSVNSV 143 
                  ..*.  *   ..                            .          
 
hCATSv1       133 -THSLSQKSTRLSGAAPAHSAADPWEKEHHRLSVRMG----------SHA 171 
hCATSv2       133 -THSLSQKSTRLSGAAPAHSAADPWEKEHHRLSVRMG----------SHA 171 
mCats         130 -PPSLSQKNTRLCRANRDARVGG-----HLRLSGQMG----------PHA 163 
BtCats        133 -AHSLSQRSTRLSVAAPAHSTLGPWEKEYHRLSVQMS----------SRA 171 
RnCats        129 -PPSLSPKNTRLCRANRDARGGG-----LPRLSGQMG----------PHA 162 
FrCats        135 -----SRTPRRTPGRAATPRRTPGNANTPGRTPGSRGRRTPDAGVRGVKA 179 
GgaCats       144 TPAARSKCTLRSSRRSLLGPTTASEHKELRGFPSWHG----------EDA 183 
                       *    *                                      * 
 
hCATSv1       172 HPLRRSRRE-AAFRSPYSSTEPLCS-PSESDSDLEPVGAGIQHLQKLSQE 219 
hCATSv2       172 HPLRRSRRE-AAFRSPYSSTEPLCS-PSESDSDLEPVGAGIQHLQKLSQE 219 
mCats         164 HRRQRLRRE-SALRSPCSSTEPLCS-PSESDSDLEPVGAGIQHLQKLSQR 211 
BtCats        172 HPWRRSRRE-AAFRSPYSSAEPLCS-PSESDSDLEPVGAGIRHLQKVSQE 219 
RnCats        163 HRRQRLRRE-AALRSPCSSTDPLCS-PSESDSDLEPVGAGIQHLQKLSQK 210 
FrCATS        180 AGGRRHLVRMAALRSPYASPSAHSQ-RLKFDQDLESVSSGLRRLKHLSKV 228 
GgaCats       184 VPLLKSRTASAALKSLYSSPTPTCRRIEEFDCELELVSSGIHQLKHLFWA 233 
                      .     .* .*  .*    .      * .** * .*...*...    
 
hCATSv1       220 LDEAIMAEE-----SG-DIVSLIHD                          238 
hCATSv2       220 LDEAIMAEERKQALS--DRQGFILKDVYASP                    248 
mCats         212 LDRAIKAEE-----SGDMTVSLIRE                          231 
BtCats        220 LEEAIVAED-----SGDMTVSLIRD                          239 
RnCats        211 LDKAIKAEE-----SGDMTVSLISE                          230 
FrCats        229 FDDLIGRDDS---TSAKETCGGAVMRKLDPSGKLSRSNLARRATNLSDTL 275 
GgaCats       234 PDDAIVHGDR                                         243 
                   .  *   .                                          
 
hCATSv1       239                 238 
hCATSv2       249                 248 
mCats         232                 231 
BtCats        240                 239 
RnCats        231                 230 
FrCats        276 GGWANTAVNTIHKSI 290 
GgaCats       244                 243 
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Fig. 3.5: Alignment of Cats proteins. Comparison between Cats proteins from human, mouse, cow, rat, fugo 
and chicken. Asterisks and points under the alignment represent identical and similar amino acids, respectively. 
Regions conserved from Fugu to man are marked in yellow. hCATSv1 and hCATSv2 (human protein isoform 1 
and 2, respectively), mCats (M. musculus), BtCats (Bos taurus), RnCats (Rattus norvegicus), FrCats (Fugu 
rubripes) and GgaCats (Gallus gallus). 
 
 hCATSv1 hCATSv2 mCats 
mCats 76 % 71 %  
BtCats 91 % 85 % 77 % 
RnCats 76 % 70 % 96 % 
FrCats 34 % 35 % 30 % 
GgaCats 47 % 47 % 18 % 
 
Table 3.3: Homology between CATS proteins from different vertebrate species. 
 
3.2 Expression analysis of CATS at the RNA level in normal tissue 
 
3.2.1 CATS is predominantly expressed in lymphoid organs 
 
The complete CATS open reading frame (ORF) (exons 2-5) was amplified by PCR using the 
CATS cDNA IMAGp998G039611 clone (2.1.15) as template and the primer pair 
FhCATSXhoI and RhCATSHindIII (2.1.13). The 730 bp product was radioactively labeled 
and used to probe human multiple tissue Northern blots. The hybridization revealed a CATS 
transcript of approximately 1.6 kb expressed predominantly in lymphoid organs. High levels 
of expression can be seen in thymus and spleen and to a lesser extent in the small and large 
intestines. Low levels of transcript are also present in ovary and brain. No transcripts were 
detected in placenta, lung, liver, kidney, pancreas, prostate, testis or peripheral blood. In 
skeletal muscle and heart, transcripts of higher molecular weight (of approximately 4 kb and 
6.5 kb) are detected. These are most likely due to transcripts containing a longer 3’ 
untranslated region (Figure 3.6). 
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Fig. 3.6: Predominant expression of CATS in lymphoid organs. Multiple tissue Northern blots (Clontech) 
containing 2µg poly(A)+ RNA per lane from 16 different human adult tissues. Membranes were hybridized with 
a cDNA probe for CATS and human β-actin, which serves as a control for the loading and the integrity of the 
RNA preparation. 
 
3.2.2 Expression of the murine Cats in adult multiple tissue 
 
The complete Cats ORF was used as a probe for murine Northern blot analysis. The 
approximately 1.5 kb long murine transcript showed high levels of expression in thymus and 
ovary and low level of expression in heart. Cats transcripts were absent in brain, kidney, liver, 
bone marrow and surprisingly, in spleen of adult mice (Figure 3.7). 
 
Fig. 3.7: Expression of Cats in adult multiple tissue Northern blot. Northern blot containing 10 µg total RNA 
per lane from nine different tissues of adult mice was hybridized with Cats cDNA F113-R942 fragment (3.1.2.1). 
The 1.5 kb murine transcript is strongly expressed in thymus and ovary and to a much lesser extent in heart. 
Bottom panel shows Ethidium bromide staining as a control for loading and integrity of the RNA preparation. 
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Since the RT-PCR technique is far more sensitive than Northern blot analysis, it was used to 
analyze Cats expression in tissues with either low levels of gene expression or with small 
amount of material available (e.g. lymph nodes). In a semi quantitative RT-PCR analysis, 
equal amounts of cDNA were used from each tissue to be amplified with Cats specific 
primers mCATSF364 and mCATSR630 (2.1.13). Amplification of a 305 bp product under 
stringent conditions (1.2 mM MgCl final concentration) revealed stronger Cats expression in 
thymus and ovary, confirming the results obtained with Northern blot analysis. However, 
after 35 PCR cycles Cats expression is also clearly seen in bone marrow, lymph node and 
testis although not as strong as in thymus and ovary. Except for liver, low levels of Cats 
transcripts were also detected in brain, heart, kidney and spleen (Figure 3.8). 
 
 
Fig. 3.8: RT-PCR with total RNA from 10 different tissues of adult mice. Strong Cats expression is found in 
thymus and ovary. Less expression is detected in bone marrow, lymph node and testis. After 35 PCR cycles Cats 
transcripts could also be amplified from brain, heart, kidney and spleen but not from liver. Control RT-PCR 
amplification of a 443 bp mGapdh fragment from the same RNA samples reveals that comparable amounts of 
cDNA were used as template in the reactions. M: DNA size marker. C: negative control PCR reaction with no 
template shows no amplification. Tissues are: brain (B), heart (H), kidney (K), liver (Li), ovary (O), testis (T), 
thymus (Th), spleen (S), bone marrow (BM) and lymph node (Ly). 
 
3.2.3 Cats is strongly expressed throughout mouse embryogenesis  
 
Northern blot analysis of Cats with total RNA prepared from mouse embryos revealed a 
strong expression of Cats transcript in every stage of development tested. However, Cats 
expression decreased gradually while embryos developed to later stages. Stages 9.5-14.5 days 
post coitum (d.p.c.) used for this analysis correspond to the time of organogenesis, suggesting 
an important role for Cats during organ formation (Figure 3.9). 
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Fig. 3.9: Cats expression throughout mouse embryogenesis. Northern blot containing 10 µg total RNA per 
lane from whole mouse embryos of day 9.5 to 14.5 d.p.c.. The blot was hybridized with Cats cDNA F113-R942 
fragment (3.1.2.1). The 1.5 kb murine transcript is strongly expressed in all stages examined. Note reduction of 
Cats expression during the course of embryo development. Bottom panel shows Ethidium bromide staining as a 
control for loading and integrity of the RNA preparation. 
 
Whole mount in situ hybridizations (2.2.19) were performed to analyze the temporo-spatial 
expression pattern of Cats during mouse development. Hybridization with either the PI sense 
or the PIII anti-sense probe (2.2.19.2) revealed widespread expression of Cats at stage 9.5 
d.p.c with prominent expression in the neural tube, somites, posterior region of the midbrain, 
olfactory placode and the branchial arches but no expression in the primitive heart. At 10.5 
d.p.c there is a reduction of the widespread expression and stronger Cats expression is seen in 
the neural tube, branchial arches, developing limbs, telencephalon, nasal process, lense 
vesicle, anterior and posterior regions of the midbrain and hindbrain. From 11.5 d.p.c on 
strong staining is also seen in the genital tubercle and hair and vibrissae follicles. A reduction 
of Cats expression is seen from stage 12.5 d.p.c onwards with completely lack of Cats 
expression in the cephalic region and the neural tube in 14.5 d.p.c embryos (Figure 3.10). 
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Fig. 3.10: Whole mount in situ hybridization analysis during mouse embryonic development. Embryos 
hybridized with Cats PIII anti-sense RNA probe. (a, b, d, h, i) Expression of Cats at embryonic stage of 9.5 
d.p.c.. Widespread transcript distribution with prominent expression in the neural tube (nt), somites (sm), 
posterior region of the midbrain (pmb), olfactory placode (olp) and in branchial arches (bra). Note complete 
absence of Cats expression in the primitive heart (he). Otic pit: otp; optic vesicle: opt. Bars indicate the plane of 
section. (c) 9.5 d.p.c embryo hybridized with Cats PI sense RNA probe as a control for staining specificity. (e-g, 
p, q) At 10.5 d.p.c., there is a reduction of widespread Cats expression, transcripts are additionally detected in 
fore- and hindlimbs (fl and hl, respectively), telencephalon (te), nasal process (np), lens vesicle (le), anterior 
region of the midbrain (amb), hindbrain (hb) and mandibular and maxillary component of first branchial arch 
(md and mx, respectively). (j-l) Right lateral view of embryos from 11.5, 12.5 and 13.5 d.p.c.. Note reduction of 
Cats overall expression and prominent expression in the limbs. (m, n) Dorsal view of the cephalic region of 11.5 
and 12.5 d.p.c embryos. Note the abrupt reduction of Cats expression in the hindbrain and neural tube from stage 
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11.5 to 12.5 d.p.c.. (o) Remaining Cats expression in the midbrain of a 12.5 embryo. (p-v) Transcripts detected 
in the lense vesicle (le), genital tubercle (ge), hair follicles (hf), vibrissae follicles (vf) and neural layer of optic 
cup (nl). (d, h, i, o-q, t-v) Sagittal (d, h, o, t-v) and transverse (i, p, q) sections from whole mount stained 
embryos. Stage of development and imaging magnification are indicated on the left and right bottom, 
respectively. 
 
Cats is strongly expressed in limb development. In general, stronger expression is detected in 
hindlimbs rather than forelimbs and it is slightly more prominent in the posterior region of the 
limb buds. At 11.5 and 12.5 d.p.c., expression is observed at the distal domain and the 
underlying mesenchyme but it is not present in the apical ectodermal ridge (AER). Distally, 
expression of Cats becomes confined to the digits in stages 13.5 and 14.5 d.p.c. (Figure 3.11). 
 
 
Fig. 3.11: Cats expression during limb development. In all panels the dorsal side of the limb is facing, the 
anterior side is to the top. The upper half of each figure shows a forelimb, the lower a hindlimb. Sections were 
generated from whole mount stained limb buds with 10x magnification (b, d, f, h). Bars indicate the plane of 
section. Transverse sections (forelimbs) are orientated with posterior side to the left, sagittal sections (hindlimbs) 
with the proximal side to the left. (a) Limb buds of a 11.5 d.p.c. embryo. The expression of Cats is more 
prominent in the distal part of the paddle-shaped fore- and hindlimb buds. (b) The transverse section shows 
staining in the underlying mesenchyme (m) and the sagittal section in the dorsal and ventral mesenchyme (dm 
and vm, respectively) but not in the apical ectodermal ridge (AER). (c) At 12.5 d.p.c. Cats expression is still 
detected at the distal part of the polygonal-shaped fore- and hindlimb buds. (d) Note stronger staining in the 
posterior domain (pd) rather than in the anterior domain (ad). (e, g) Distally, expression of Cats becomes 
confined to the digits in stages 13.5 and 14.5 d.p.c.. 
 
3.2.4 Cats is widely expressed in hematopoietic cell subpopulations 
 
RT-PCR analysis with RNA from FACS sorted cells (2.2.31) was performed to determine 
Cats expression in the hematopoietic compartment. Amplification was performed under 
stringent condition with the same primer pair used in 3.2.2. The expression analysis revealed 
wide-spread expression of Cats in the different cell subpopulations found in the murine 
thymus and bone marrow. Transcripts were observed in all 3 tested T-cell subpopulations 
isolated from the thymus (CD4+, CD8+ and CD4+/CD8+) although lower levels of transcript 
are seen in CD8+ cells (Figure 3.12a). Similarly, extremely low levels of Cats were observed 
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in the CD8+ cells isolated from bone marrow. However, except for the pro-B cell 
subpopulation (B220+) where Cats expression was nearly absent, abundant levels of transcript 
were observed in macrophages (Mac1+), pro-erythrocytes (Ter119+), granulocytes (Gr-1+), 
mast cells (c-kit+) and progenitor cells (Sca-1+/c-kit+) (Figure3.12b).  
 
 
Fig. 3.12: RT-PCR with total RNA from hematopoietic cell subpopulations. (a) T-cell subpopulations 
isolated from murine thymus (CD4+, CD8+ and CD4+/CD8+). Note lower levels of transcript in CD8+ cells. (b) 
Abundant Cats expression was observed in Mac1+, Ter119+, Gr-1+, c-kit+ and Sca-1+/c-kit+, low in CD8+ and 
nearly absent in B220+ cell subpopulations from the murine bone marrow. In the control RT-PCR, a 311 bp 
murine HPRT fragment was amplified from the same RNA samples. M: DNA size marker. C: negative control 
PCR reaction with no template. Samples are: T-cells (CD4+, CD8+ and CD4+/CD8+), pro-B cells (B220+), 
macrophages (Mac1+), pro-erythrocytes (Ter119+), granulocytes (Gr-1+), mast cells (c-kit+), progenitor cells 
(Sca-1+/c-kit+) and bone marrow (BM). 
 
3.3 Expression analysis of CATS at RNA level in leukemia cells  
 
3.3.1 CATS is expressed in cells from leukemia patients carrying the 
CALM/AF10 rearrangement 
 
RT-PCR was performed in order to determine CATS expression in leukemic cells carrying the 
t(10;11)(p13;q14). For this analysis, the U937 cell line as well as cells from 4 different 
leukemia patients (2.1.17) were used. 3 different CATS transcripts could be amplified in both 
patients carrying the CALM/AF10 fusion (patients 1: T-ALL and patient 2: AML). Similar 
expression levels of CATS were observed in one of the T-ALL patients negative for the 
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CALM/AF10 fusion (patient 3). However CATS was nearly absent in patient 4 (T-ALL). High 
CATS expression was also observed in the CALM/AF10 fusion positive cell line U937 and in 
293T.  Sequence analysis revealed the 3 amplified fragments to be CATS splice variants 1, 2 
and 3. Interestingly, the splice variant 3 (775 bp band) is highly expressed in patient 1, 
whereas it is absent in the other patients and cell lines. Splice variant 1 seems to be more 
abundant than the splice variant 2, being more prominent in the cell lines than in the patient 
samples (Figure 3.13).  
 
Fig. 3.13: Expression analysis of CATS in cells from leukemia patients and cell line carrying the 
t(10;11)(p13;q14). CATS transcripts were amplified using primer pair CATSE1F1(364) and CATSE5R1(828) 
(2.1.13). Patients 1 and 2 as well as the U937 cell line are positive for CALM/AF10 fusion, whereas patients 3 
and 4 are negative. Sequence analysis revealed that the 3 amplified fragments corresponded to CATS splices 
variants 1, 2 and 3 (485, 441 and 775 bp, respectively). Strong expression of CATS splice variant 3 was observed 
only in the CALM/AF10 positive T-ALL patient 1. 293T cell line was used as positive control for CATS 
expression. Amplification of GAPDH fragment from the same RNA samples was used as control for RNA and 
cDNA integrity. (C) Negative control PCR reaction with no template. 
 
3.3.2 Cats is up-regulated in B220+ cells from a CALM/AF10 leukemic 
mouse 
 
Expression analysis was performed in leukemic cells derived from a CALM/AF10 murine 
bone marrow transplant model (2.1.17). PCR reactions were performed as in 3.2.2 and 3.2.4. 
For the analysis, Cats expression was determined in B220+/Mac1-, B220+/Mac1+, B220-
/Mac1+ populations and whole bone marrow from a CALM/AF10 leukemic mouse. Cats was 
strongly expressed in all 4 samples derived from the leukemic mouse. Moreover, an striking 
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increase of Cats transcripts was observed in B220+/Mac1- population in comparison to the 
same population from a non-leukemic mouse (Figure 3.14). 
 
Fig. 3.14: Analysis of Cats expression in leukemic cells derived from a CALM/AF10 murine bone marrow 
transplant model. Cats is expressed in the B220+/Mac1-, B220+/Mac1+, B220-/Mac1+ populations and whole 
bone marrow from a CALM/AF10 leukemic mouse. The controls used were B220 positive cells sorted from the 
spleen, Mac-1 sorted cells from the bone marrow and whole bone marrow from a non-leukemic mouse. Note the 
different levels of Cats expression in B220 positive cells derived from a non-leukemic and a leukemic mouse. 
Control RT-PCR amplified a 311 bp murine HPRT fragment from the same RNA samples. M: DNA size 
marker. C: negative control PCR reaction with no template. 
 
3.4 CATS subcellular localization 
 
3.4.1 Construction of plasmids expressing a fluorescent protein fusion of 
CATS  
 
For the subcellular localization experiments, plasmids expressing green, cyan or yellow 
fluorescent fusion proteins of CATS were constructed. For GFP-CATSv1 and CFP-CATSv1 
constructs, full length CATS was generated by PCR amplification using the CATS clone 
IMAGp998G039611 (3.1.1) as template and primers containing sites for XhoI and HindIII 
restriction enzymes (FhCATSXhoI and RhCATSHindIII). The 730 bp PCR product 
corresponding to CATS isoform 1 was digested with the appropriate restriction enzymes and 
cloned in frame with the green and cyan fluorescent proteins into the pEGFP-C1 and pECFP-
C1 vectors, respectively (2.1.11) (Figure 3.15 a). CFP-CATSv2 was constructed by replacing 
the 51 amino acids C-terminal of CATS isoform 1 by the corresponding 61 amino acids of 
CATS isoform 2 in the CFP-CATSv1 clone (described above). The C-terminal portion of the 
CATS isoform 2 was generated by PCR using the pGADGH-CATSv2CT prey clone (2.1.12) 
as a template and primers containing sites for the SalI restriction enzyme (hCATSf SalI 
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635(ex3) and hCATSr SalI 909(ex6)). The PCR product was digested with EcoRI (internal 
site within the sequence) and SalI, the resulting fragment corresponding to amino acids 188 to 
248 of isoform 2 was subcloned into the CFP-CATSv1 construct, from which the C-terminus 
had been excised with the same enzymes (Figure 3.15 b). YFP-CATS constructs were 
generated by excising the ORF of CATS isoforms from their respective CFP constructs with 
XhoI and KpnI and subcloned into the pEYFP-C1 vector (2.1.11) digested with the same 
enzymes (Figure 3.15 c; d). 
 a 
400 800 1200 1600 2000 2400 2800 3200 3600 4000 4400 4800 5200
KanamycinECFP CATSv1P CMV IE
fusion protein
pEGFPC-1240-1258
XhoI (1343) HindIII (2080)
SalI (2097)
KpnI (2107)
 
 b 
400 800 1200 1600 2000 2400 2800 3200 3600 4000 4400 4800 5200
KanamycinCATSv2 ECFPP CMV IE
fusion protein
pEGFPC-1240-1258
XhoI (1343)
EcoRI (1976)
SalI (2140)
KpnI (2150)
 
c 
400 800 1200 1600 2000 2400 2800 3200 3600 4000 4400 4800 5200
KanamycinEYFP CATSv1P CMV IE
fusion protein
pEGFPC-1240-1258
XhoI (1343) KpnI (2107)
 
d 
400 800 1200 1600 2000 2400 2800 3200 3600 4000 4400 4800 5200
KanamycinCATSv2 EYFP P CMV IE
fusion protein
pEGFPC-1240-1258
XhoI (1343) KpnI (2150)
 
3 Results 
 74 
Fig. 3.15: CFP-, GFP- and YFP-CATS constructs. (a) The CATSv1 ORF was amplified using primer pair 
FhCATSXhoI and RhCATSHindIII. The 730 bp product was cloned into pEGFP- and pECFP-C1 vectors 
digested with XhoI and HindIII. (b) CFP-CATSv2 was constructed by replacing the 51 aa C-terminal of CATS 
isoform 1 by the corresponding 61 amino acids of CATS isoform 2 in the CFP-CATSv1 clone (EcoRI and SalI 
sites were used). (c;d) CATS isoforms were excised from their respective CFP constructs with XhoI and KpnI 
and subcloned into the pEYFP-C1 vector. Restriction enzymes used for cloning are in bold. Numbers in brackets 
indicate nucleotide position, ruler indicates construct size. Arrow indicates binding position of the pEGFP-1240-
1258 sequencing primer. Kanamycin: kanamycin resistance gene. 
 
3.4.2 CATS is a nuclear protein with predominant nucleolar localization 
 
To determine the intracellular localization of CATS, NIH3T3 cells were transiently 
transfected (2.2.21) with plasmids expressing YFP-CATS and CFP-CATS fusion proteins. 
Expression of fluorescently tagged CATS revealed an identical intracellular distribution for 
the two CATS isoforms (Figure 3.16 g and h). CATS proteins were localized mainly to the 
nucleus and to a lesser extent to the cytoplasm (Figure 3.16 a-e). Within the nucleus, CATS 
was often detected in one or several nodular structures, and at a lower level diffusely in the 
nucleoplasm. These structures are devoid of DAPI staining (Figure 3.16 c) and were most 
probably the nucleoli. Coexpression of CFP-CATS with YFP tagged nucleostemin and 
nucleophosmin, which were used as markers for the nucleolar structures, revealed a 
colocalization of these proteins with CATS at the nucleoli (Figure 3.16 i-n). Some of the 
CATS protein detected in the cytoplasm was most probably localized at the plasma membrane 
(Figure 3.16 e).  
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Fig. 3.16: Localization of CATS isoforms and colocalization with nucleostemin and nucleophosmin. (a-e) 
NIH3T3 cells expressing CFP-CATS constructs revealed a predominantly nuclear localization of CATS. (b, e) 
Within the nucleus, the CATS accumulates in nodular structures (b), which are devoid of DAPI staining (c). 
Less intense fluorescent signals were also observed in the cytoplasm and at the cell membrane (e).  
(f-h) Coexpression of CFP-CATSv1 and YFP-CATSv2. CATS isoforms colocalize and have an identical 
subcellular distribution. (i-n) CFP-CATS colocalizes with the YFP tagged nucleolar markers nucleostemin and 
nucleophosmin in the nucleoli. Bar: 20 µm. 
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3.5 Mapping of CALM-CATS interaction in yeast 
 
3.5.1 Construction of vectors expressing GAL4-AD-CATS fusion proteins 
 
The CATS open reading frames of isoform 1 and 2 were excised from the CFP-CATSv1 and -
CATSv2 constructs (3.4.1) using XhoI and SalI. The CATSv1 C-terminus was amplified 
using the CATS clone IMAGp998G039611 as a template and primers containing sites for the 
SalI restriction enzyme (hCATSf SalI 635(ex3) and hCATSr SalI 909(ex6)). Complete CATS 
ORF and C-terminal PCR product were inserted into the XhoI site of the bacterial/yeast 
shuttle vector pGADT7 (Figure 3.17) for the expression of yeast GAL4 activation domain 
CATS fusions. 
 a   
600 1200 1800 2400 3000 3600 4200 4800 5400 6000 6600 7200 7800 8400
LEU2 AmpCATSv1/v2GAL4AD
fusion protein
Y2H2 primer Y2H3' AD primer
XhoI (2030)
S a l I / X h o I
 
b 
600 1200 1800 2400 3000 3600 4200 4800 5400 6000 6600 7200 7800 8400
LEU2 AmpCv1CTGAL4AD
fusion protein
Intr5
Ex4 Ex6Ex5
Y2H2 primer
Xho I /Sa l I
S a l I / Xho I
Y2H3' AD primer
 
Fig. 3.17: pGADT7-CATS constructs. (a) Constructs expressing the GAL4-AD-CATS fusion proteins (either 
isoform 1 or 2). (b) Construct expressing the GAL4-AD fused to the last 51 amino acids of CATS isoform1 
(from residue 188 to 238). In bold and blue: restriction enzymes used for cloning. Enzymes in red denote 
compatible sticky ends used for cloning, which are destroyed upon ligation. Numbers indicate construct size in 
base pairs. Arrow indicate binding position of the Y2H3’AD and Y2H2-729-751 sequencing primers. LEU2: 
gene coding for ß-isopropyl malate dehydrogenase an enzyme in the leucine biosynthesis, provides nutritional 
selection in yeast cells in medium lacking leucine. Amp: ampicillin resistance gene for selection in bacteria. 
 
3 Results 
 77 
3.5.2 CATS interacts with amino acids 221 to 294 of CALM 
 
To map the CATS interacting domain of CALM and to test whether this interaction occurs 
with both CATS isoforms, plasmids encoding CALM deletion mutants fused to the GAL4-
DBD (DNA binding domain of the yeast transcription factor GAL4) (2.1.12) were 
simultaneously transformed (2.2.22.2) with the CATS constructs described above into yeast 
strain AH109. The cotransformants were assayed for growth on selective plates in the 
presence of X-α-GAL. CALM(1-408), CALM(1-335), CALM(1-294) but not CALM(1-221) 
interacted equally with both CATS isoforms. However, there was no interaction of the 
CALM(1-294) deletion mutant with the C-terminal portions of CATS isoforms 1 (the last 51 
amino acids) and 2 (pGADGH-CATSv2CT construct (2.1.12) coding for the last 61 amino 
acids). These experiments demonstrate that CALM interacts equally with both CATS 
isoforms and that the N-terminal region of CALM from residues 1-221 does not interact with 
CATS. Moreover, the CATS interaction domain of CALM could be mapped to amino acids 
221 to 294 of CALM for both CATS isoforms. Interestingly, the region comprising amino 
acids 221 to 294 of CALM does not interact with the CATS C-termini (Figure 3.18 a, b). The 
data suggest, that the C-termini of CATS require amino acids 294 to 335 of CALM for 
interaction. 
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Fig. 3.18: Mapping of the CATS interaction domain of CALM in yeast. Yeast strain AH109 was 
cotransformed with the following CALM deletion mutants fused to the GAL4-DBD: pGBKT7-CALM(1-408); 
pGBT9-CALM(1-335); pAS2-CALM(1-294) and pAS2-CALM(1-221) and with the following CATS isoforms 
(FL) or their respective C-termini (CT) fused to the GAL4-AD: pGADT7-CATSv1FL; pGADT7-CATSv1CT; 
pGADT7-CATSv2FL and pGADGH-CATSv2CT. (a) Diagram representing the interaction between 
cotransformed constructs. ++ indicates interaction; Ø indicates no interaction. Gray bar denotes the CATS 
interaction domain of CALM. (b) Interaction between the proteins was assayed by yeast growth on SD -Trp, -
Leu, -His, -Ade plates supplemented with X-α-GAL. ANTH: AP180 N-terminal homology domain. 
 
3.6 CALM interacts with both CATS isoforms in vivo 
 
To establish whether endogenous CALM interacts with both CATS isoforms, fluorescently 
tagged CATS fusion proteins (isoform 1 and 2) were expressed in 293T cells and precipitated 
with antibody against GFP protein (2.2.28). The GFP antibody detected the 
immunoprecipitated CATS fusion proteins as shown in figure 3.19, upper lanes 2 and 4 
(isoform 1 and 2, respectively). The membrane was stripped and reprobed with goat 
polyclonal anti-CALM antibodies. The CALM antibody identified two bands of the expected 
size for endogenous CALM (66 and 72 kDa) in the lanes where immunoprecipitated CATS 
fusion proteins were present (Figure 3.19, lower lanes 2 and 4). Immunoprecipitation with 
normal rabbit IgG did not coprecipitate endogenous CALM (Figure 3.19, lanes 3 and 5). 
Similarly, endogenous CALM could not be coimmunoprecipitated with GFP antibody in 
293T cells lacking the GFP-CATS fusion protein (Figure 3.19, lane 1).  
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Fig. 3.19: Coimmunoprecipitation of CATS and the endogenous CALM protein. Lysate of cells 
overexpressing GFP-CATSv1 and YFP-CATSv2 were immunoprecipitated with α-GFP. Immunoprecipitated 
CATS fusion proteins are detected by immunoblotting using the same antibody (α-GFP), upper lanes 2 and 4 
(isoform 1 and 2, respectively). The membrane was stripped and reprobed with goat polyclonal α-CALM, which 
identified two bands of the expected size for endogenous CALM (66 and 72 kDa) in the CATS precipitates, 
lower panel lanes 2 and 4. Immunoprecipitates of a lysate from untransfected cells and immunoprecipitates with 
normal rabbit IgG were used as negative controls, lanes 1, 3 and 5. 50 µg cell extract was used as input control in 
lanes 6, 7 and 8. 
 
3.7 CATS influences the subcellular localization of CALM and 
CALM/AF10 
 
To further validate the CALM-CATS interaction and to study a possible influence that the 
expression of one protein might have on the subcellular localization of the other protein, a 
yellow fluorescent protein tagged version of CALM (YFP-CALM) and the CFP-CATS 
proteins were coexpressed in murine fibroblasts (NIH3T3). The construct expressing YFP-
CALM fusion protein was generated by digesting the CALM full length cDNA (clone 
pQE31-CALM) with XhoI and BamHI and subcloning the fragment into the pEYFP-C1 
vector digested with the same enzymes (Figure 3.20).  
 
500 1000 1500 2000 2500 3000 3500 4000 4500 5000 5500 6000 6500
CALM KanamycinEYFP
fusion proteinXhoI (1343) BamHI (3404)
pEGFPC-1240-1258
 
Fig. 3.20: YFP-CALM construct. The CALM ORF was cloned into the XhoI and BamHI sites of the EYFP-C1 
vector. Restriction enzymes used for cloning are in bold. Numbers in brackets indicate nucleotide position. The 
arrow indicates the binding position of the pEGFP-1240-1258 sequencing primer.  
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Colocalization experiments revealed that CATS (both isoforms) was able to influence the 
subcellular localization of CALM. CALM alone is predominantly localized in the cytoplasm 
and at the plasma membrane (Figure 3.21 b). However, in some cells, where CATS is 
coexpressed, CALM localization was observed both at the cytoplasm/membrane and in the 
nucleus at almost equal levels. On one hand the cytoplasmic portion of CATS colocalizes 
with CALM in the cytoplasm and at the membrane and on the other hand a portion of CALM 
is withdrawn from the cytoplasm towards the CATS-containing nucleus (Figure 3.21 d; e). 
Interestingly, the effect of CATS on the CALM protein is not found in every cotransfected 
cell. In the majority of cells coexpressing YFP-CALM and CFP-CATS, CALM still localizes 
only to the cytoplasm and at the membrane (data not shown). In order to address this varying 
effect of CATS on the subcellular localization of CALM, the transfected cells were examined 
at different time points after transfection. This experiment showed that the effect of CATS on 
CALM localization is partially dependent on the time after transfection. No effect of CATS 
on CALM localization was observed up to 20 hrs after transfection. The effect became only 
apparent after 22 hrs, 28 hrs and 48 hrs. However, among the time points 22, 28 and 48 hrs 
there was no significant difference in the proportion of cells in which CATS changed the 
subcellular localization of CALM. 
In order to test if CATS interacts also with the CALM portion of the leukemic fusion protein 
CALM/AF10 and if this interaction has an effect on the subcellular distribution of 
CALM/AF10, the same experiments as described above were performed using a YFP-tagged 
version of CALM/AF10 (2.1.12). Like CALM, CALM/AF10 alone is predominantly found in 
the cytoplasm (Figure 3.21 g). In the presence of CFP-CATS, most of the YFP-CALM/AF10 
fusion protein is localized in the nucleus and even colocalizes with CATS at the nucleolus in 
some cells (Figure 3.21 i; j).  The nuclear localization effect seems to be stronger for 
CALM/AF10 than for CALM alone. However, similarly to CALM, in some cells 
CALM/AF10 can also maintain its normal localization in the cytoplasm or be just partially 
relocalized to the nucleus in the presence of CATS (data not shown).  
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Fig. 3.21: Colocalization of CATS with CALM and the leukemic fusion protein CALM/AF10. (a-e) 
Colocalization of CFP-CATS and YFP-CALM. CALM alone is predominantly found in the cytoplasm (b). In 
cells expressing both YFP-CALM and CFP-CATS, the presence of CATS (e) influences the subcellular 
localization of YFP-CALM, which is then also present in the nucleus (d). Note that cytoplasmic portion of 
CATS also colocalizes with CALM at the plasma membrane (d, e). (f-j) Colocalization of CFP-CATS and the 
leukemic YFP-CALM/AF10 fusion protein. In cells expressing the YFP-CALM/AF10 fusion protein alone, the 
CALM/AF10 fusion protein localizes to the cytoplasm (g). In cells expressing both YFP-CALM/AF10 and CFP-
CATS, the YFP-CALM/AF10 fusion protein is nearly completely relocalized to the nucleus where it colocalizes 
with CATS both in the nucleoplasm and at the nucleoli (i, j). Bar: 20 µm. 
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3.8 Nuclear-cytoplasmic shuttling of CALM and CALM/AF10 but 
not of CATS 
 
The fact that CALM and CALM/AF10 accumulate in the nucleus of some CATS expressing 
cells together with the cytoplasmic and nuclear localization of CATS prompted us to 
investigate whether this is the result of a nuclear-cytoplasmic shuttling of the CATS protein. 
Leptomycin B (LMB) was used to inhibit CREM-mediated nuclear export (2.2.21.1) in 
NIH3T3 cells that had been transiently transfected with YFP-CATS (both isoforms), YFP-
CALM, or YFP-CALM/AF10. The relative distribution of nuclear and cytoplasmic CATS 
was not affected by LMB treatment, indicating that CATS does not shuttle between nucleus 
and cytoplasm. However, this treatment result in a much lower accumulation of YFP-CATS 
in nucleoli as evidenced in figure 3.22 d and c. In contrast to CATS, both CALM and 
CALM/AF10 strongly accumulated in the nucleus upon LMB treatment. Interestingly, the 
leukemic fusion protein was nearly completely absent from the cytoplasm and often revealed 
a speckled nuclear staining in LMB treated cells (Figure 3.22). These results show that in 
contrast to CATS, both CALM and CALM/AF10 proteins shuttle between nucleus and 
cytoplasm. 
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Fig. 3.22: Nuclear export inhibition by LMB. NIH3T3 cells were transiently transfected with YFP-CATS, 
YFP-CALM or YFP-CALM/AF10 and treated with 100 nM LMB for 4 hours. Both CALM and CALM/AF10, 
which normally localize almost exclusively to the cytoplasm, accumulate in the nucleus upon LMB treatment (f, 
h). Neither CATSv1 nor Catsv2 relative nuclear-cytoplasmic distribution was affected by the nuclear export 
inhibitor LMB however, the protein seems to be translocated from the nucleolus to the nucleoplasm (b, d). Bar: 
20 µm. 
 
3.9 Production of CATS monoclonal antibodies 
 
A panel of monoclonal antibodies raised against the CATS protein was generated in 
cooperation with Dr. Elizabeth Kremmer from the Institute of Molecular Immunology, 
National Research Center for Environment and Health, GSF, Munich. The GST gene fusion 
system was used to express a GST-CATS fusion protein, which was used to immunize rats. 
 
3.9.1 Expression of GST-CATS fusion proteins 
 
The GST fusion of CATS isoform 1 and the C-terminal portion of CATS isoform 2 (61 amino 
acids) were expressed and purified as described in 2.2.30. The resulting GST-CATSv1 fusion 
protein revealed a different size from expected. The reason for this is unknown. Possibly due 
to degradation or cleavage of the GST-CATSv1 fusion protein. Nevertheless, high expression 
of the pGEX4T-2-CATSv2CT construct (2.1.12) was achieved and the purified GST-
CATSv2CT fusion protein showed the expected size of approximately 36 kDa (28 kDa from 
the GST protein plus approx. 6 kDa from the C-terminus of CATSv2) (Figure 3.23). The 61 
amino acids of CATS from this fusion protein correspond to residue 188-228, common to 
both CATS isoforms, plus the last 20 amino acids specific to isoform 2.  
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Fig. 3.23: GST-CATS fusion proteins in Coomassie stained PAGE gel. (1) 10 µl of GST-CATSv2CT fusion 
protein expressed in BL21 cells and glutathione agarose purified. (2-4) BSA as a standard for protein 
quantification (0.2 µg, 0.5 µg and 1 µg). (5) 10 µl of glutathione agarose purified GST-CATSv1 fusion protein. 
Note that the GST-CATSv1 fusion does not correspond to the expected size (51 kDa) for the CATS full length 
fused to GST protein. (M) protein molecular weight standard. 
 
3.9.2 Monoclonal antibodies against CATS recognize specifically the CATS 
proteins 
 
50 µg of purified GST-CATSv2CT fusion protein was injected both i.p. and subcutaneously 
into Lou/C rats (Dr. Kremmer, IMI). Fusion of myeloma cell line (P3X63Ag8.653, mouse, 
BALB/c) with cells from the spleen of immunized rats was performed according to standard 
procedures. Hybridoma supernatants were tested in a solid phase immunoassay.  
Sixteen hybridomas designated CATS-4D2, -2F12, -6F10, -6E2, -4D8, -7F6, -4D10, -3G2, -
3H8, -2B5, -7H2, -2C4, -2C6, -4B7, -3A6 and -2A2 were obtained. Western blotting was 
used to test the specificity of the hybridoma supernatants against CATS proteins. Incubation 
with CATS hybridoma supernatants diluted 1:5 was carried out for 1 hr at RT, followed by 
incubation with the secondary antibody (goat or mouse α-rat HRP diluted 1:3000 and 1:2000, 
respectively) for 50 min at RT. The Western blot analyses revealed that 9 hybridomas 
detected the fluorescently tagged CATS protein (approx. 55 kDa) and 2 out of the 9 
specifically recognized CATS isoform 2 (CATS-7H2 and -3H8) (Figure 3.24).  
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Fig. 3.24: Western blot analysis testing CATS antibodies. Extracts of 293T cells (6 µg) overexpressing either 
the GFP-CATSv1 or YFP-CATSv2 fusion protein and lysate from bacteria expressing GST protein alone 
revealed that the antibodies CATS-7F6, -3G2, -3A6, -2A2, -2C4, -2C6, -4B7 recognize both CATS isoforms 
(approx. 55 kDa) while antibodies CATS-3H8 and -7H2 recognize exclusively CATS isoform 2. CATS-2F12 
and -6F10 recognize neither the CATS isoforms nor GST. CATS-4D2, -6E2, -4D8, -4D10 and -2B5 recognize 
specifically the GST protein (approx. 26 kDa). An α-GFP antibody was used as control for the detection of the 
CATS fusion proteins in the 293T cell extracts. 
 
Hybridomas producing antibodies which detected the tagged CATS proteins or specifically 
detected CATS isoform 2, were stably subcloned and used for further analysis (CATS-2A2, -
7F6, -2C4, -3H8 and -7H2). The immunoglobulin isotype was determined using antibodies 
against the rat IgG heavy and light chains. The CATS-2C4 antibody has the IgG subclass 
IgG2a while CATS-2A2, -7F6, -3H8 and -7H2 antibodies have the IgG subclass IgG1. The 
resulting monoclonal rat antibodies were tested for sensitivity on Western blots of 293T cells 
overexpressing either GFP-CATSv1 or YFP-CATSv2. These antibodies showed specific 
recognition of tagged CATS at much lower levels than in the Western blot described above 
(down to 1 µg of cell lysate) and no background detection of the GST protein. Antibody 2C4 
recognized both CATS isoforms most efficiently followed by 7F6, 2A2 and 7H2 (specific for 
isoform 2). 3H8 weakly recognized the overexpressed CATS isoform 2 (Figure 3.25). 
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Fig. 3.25: Western blot analysis using monoclonal CATS anti-sera. Extract of 293T cells (1-6 µg) 
overexpressing either GFP-CATSv1 or YFP-CATSv2 fusion protein and from bacteria expressing GST protein 
was blotted and probed with the recloned CATS monoclonal antibodies 7F6, 2A2, 2C4 (recognizing both tagged 
CATS isoforms of approx. 55 kDa), 7H2 and 3H8 (recognizing exclusively the CATS isoform 2). Antibodies are 
specific for CATS protein and do not recognize GST protein. (a) Blots with 3 µg cell lysate. (b) Blot was probed 
for 2C4, striped and reprobed with 3H8. Note the difference in the signal strength. The film was exposed for 10 
sec for 2C4 and 30 sec for 3H8. 
 
Further expression analysis revealed that CATS antibodies recognize both endogenous and 
overexpressed CATS proteins. Western blot with lysate from transfected 293T cells 
overexpressing the pM1-CATSv1 construct showed that CATS-2C4 antibody strongly 
recognizes both the overexpressed GAL4-DBD-CATS fusion protein (approx. 42 kDa) and an 
additional band of the expected size for the wild type CATS protein (28 kDa). A lysate of non 
transfected 293T cells was used as control for the expression of endogenous CATS. Similarly 
to what was observed by the detection of the overexpressed CATS proteins, antibody 2C4 
recognized the endogenous CATS most efficiently followed by 7F6 and 2A2. Both 7H2 and 
3H8 (specific for isoform 2) do not seem to detect the endogenous CATS isoform 2. 
However, we do not know whether these antibodies are not able to recognize the endogenous 
isoform 2 of CATS or if the endogenous expression levels of the isoform 2 are too low for 
detection (Figure 3.26).  
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Fig. 3.26: CATS antibodies recognize both endogenous and overexpressed CATS proteins in 293T cells. 30 
µg protein of transfected (pM1-CATSv1 construct) and non-transfected 293T cells were blotted and probed with 
the α-CATS 7F6, 2A2, 2C4, 7H2 and 3H8 antibodies (the last two recognize exclusively CATS isoform 2). α-
2C4 antibody strongly detected both the overexpressed GAL4-DBD-CATSv1 (approx. 42 kDa) and the 
endogenous protein (28 kDa). α-CATS 7F6 and 2A2 clearly detected the overexpressed CATS however 
detection of the endogenous protein was weak. Note that no detection of GAL4-DBD-CATSv1 protein was 
observed with α-CATS 7H2 and 3H8 since these antibodies are specific for CATS isoform 2. The faint bands 
observed in blots probed with α-CATS 7H2 and 3H8 are most likely background of the secondary antibody. 
 
3.9.3 CATS antibodies raised against human CATS also detect the murine 
Cats protein 
 
CATS antibodies generated against the human protein were tested for crossreactivity with 
Cats proteins from other species. Lysates from the murine cell lines NIH3T3 and BA/F3 were 
blotted and probed with α-CATS 7H2, 7F6, 2C4, 3H8 and 2A2 antibodies. Simultaneously, 
the 293T cell extract was used as a positive control for antibody detection. α-CATS 7H2, 7F6, 
2C4 and A2 clearly detected the murine protein, which has the same size (28 kDa) as the 
human protein. Similarly to what we observed on extract from human cell lines, the α-CATS 
2C4 antibody shows the strongest detection of Cats followed by 7F6 and then by 2A2. In 
order to select a secondary antibody which gives the best results in combination with CATS 
antibodies, blots probed for CATS were incubated with either goat or mouse anti-rat 
secondary antibody. As negative controls (ø) to test the specificity of the secondary 
antibodies, blots were incubated with either mouse or goat anti-rat alone. The best results 
were obtained with the mouse anti-rat secondary antibody since lower background was 
observed and the position of unspecific bands did not overlap with the Cats band. Using 
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mouse anti-rat as a secondary antibody, good detection of CATS was also achieved with α-
CATS 7F6 and 2A2 antibodies, which had previously given much weaker signals (Figure 
3.27). 
 
Fig. 3.27: CATS antibodies recognize the murine protein. 30 µl total cell lysate from murine cell lines 
NIH3T3 and BA/F3 was blotted and probed with α-CATS antibodies (7H2, 7F6, 2C4, 3H8 and 2A2). 293T cell 
extract was used as a positive control for antibody detection. (a) Blots with 50 µg of cell extract were probed 
with CATS antibodies followed by incubation with goat anti-rat secondary antibody. An α-beta actin antibody 
was used as a positive control to demonstrate the integrity of proteins in the cell lysates. (b) Blots with 30 µg of 
cell extract were probed with α-CATS antibodies followed by incubation with mouse α-rat secondary antibody. 
(ø) Negative control. Blots, which were not probed with α-CATS primary antibodies were incubated with either 
mouse or goat anti-rat secondary antibodies. Note that incubation with the mouse anti-rat antibody gives lower 
background resulting in a more specific detection of the weak Cats signals (as observed with α-CATS 7F6 and 
2A2). 
 
3.9.4 Expression of Cats protein in murine cell lines 
 
Western blot analysis performed with lysate from mouse (BA/F3, NIH3T3, MEF null for p53 
and ARF genes) and rat (TGR) cell lines revealed a high expression of Cats in murine pro B-
cells (BA/F3) and mouse embryonic fibroblasts (NIH3T3 and MEF). Similar levels of Cats 
expression was observed in MEF cells lacking either the p53 or ARF protein or when these 
cells, had been treated with Uv radiation (40 Joule). No detection of Cats protein was 
observed in the rat fibroblast cell line (TGR), most probably because our CATS antibody does 
not recognize the rat protein and not because this cell line lacks Cats expression. CATS is 
highly expressed in both human and mouse fibroblast cell lines (Figure 3.28). 
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Fig. 3.28: Expression analysis of Cats at protein level. Western blot with 30 µg lysate from BA/F3, NIH3T3, 
TGR and MEF cell lines probed with α-CATS 2C4. The CATS antibody recognizes the murine but not the rat 
protein. MEF p53-/-: MEF cell line with a targeted disruption of the TP53 gene. MEF ARF-/-: MEF cell line with 
a targeted disruption of the ARF gene. MEF cell lines were treated with 40 Joules of UV radiation.  
 
3.10 Expression analysis of CATS at the protein level 
 
3.10.1 Expression of CATS in human thymus  
 
Western blots with cellular extract from human thymus (2.2.24.2) were probed with α-CATS 
2C4 antibody. The antibody clearly recognized the 28 kDa CATS protein, confirming CATS 
expression in the human thymus (Figure 3.29). 
 
 
Fig. 3.29: CATS is expressed in the human thymus. Western blot with 20 µl cell lysate from human thymus 
was probed with α-CATS 2C4 antibody. α-CATS 2C4 detected the 28 kDa CATS protein. α-CD3 12, an 
antibody which detects CD3, was used as a positive control to demonstrate the integrity of proteins in the thymus 
lysate.  
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3.10.2 Expression analysis of CATS in hematopoietic cell lines 
 
A Western blot with 15 µg lysates from hematopoietic cell lines was probed with the α-CATS 
2C4 antibody. The expression analysis revealed that CATS is highly expressed in all cell lines 
tested. These cell lines represent different leukemia and lymphoma subtypes (B- and T-ALL, 
B- and T-lymphoma and AML FAB M2, M4 and M5). The levels of CATS expression did 
not seem to correlate with the differentiation stage of the cells as expression were similar for 
immature and mature T and B cell lines. Slightly lower expression was observed in myeloid 
leukemia cell lines than in the lymphoblastic leukemia cell lines. No CATS protein could be 
detected in the HL-60 cell line (AML FAB M2) although CATS expression was detected in 
another cell line of the same leukemia subtype (KASUMI-1). Interestingly, HL-60 was the 
only tumor cell line tested which did not show CATS expression. Additionally, in the 
CALM/AF10 fusion positive cell line U937, an additional band of lower molecular weight 
was detected with the α-CATS 2C4 antibody (Figure 3.30).  
 
Fig. 3.30: CATS is highly expressed in leukemia and lymphoma cell lines. Cellular extracts (15 µg) from 
human leukemia and lymphoma cell lines were blotted and probed with α-CATS 2C4 antibody. CATS is highly 
expressed in both immature (JURKAT) and mature T-cell lines (HUT 78) as well as in pre B (NALM6) and 
mature B cell lines (Granta 519, HBL-2, JeKo-1, Karpas 422). Lower expression is observed in MOLT-4 
(immature T-cell line) and NCEB-1 (mature B-cell line) which is comparable to the level of expression observed 
in cellular extract from myeloid leukemias of FAB subtypes M2, M4 and M5 (KASUMI-1, U937 and K-562, 
respectively). No CATS expression was observed in the HL-60 extract (AML M2). The arrow indicates the 
position of the smaller band present in the cellular extract of the CALM/AF10 fusion positive cell line U937. 
The blot was stripped and reprobed with α-beta actin antibody, which served as a control for the loading and 
integrity of the protein extracts.  Note that beta actin is not present in extracts from the HUT 78 cell line. 
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3.10.3 Expression analysis of CATS in normal and tumor cell lines 
 
Additional Western blot analysis with the α-CATS 2C4 antibody revealed high expression of 
the CATS protein in solid tumor cell lines (U2OS, SaOS, and HeLa), as well as in normal 
proliferating cell lines (293T) but not in normal non-proliferating T-cell lines (TYRF8 and 
JB4). Lower expression of CATS was observed in WI-38, a normal human fibroblasts cell 
line, which have a finite life-span of approx. 50 population doubling and display a lower 
proliferative rate (Figure 3.31). The fact that CATS expression was not observed in non-
proliferating cells but strong expression was seen in highly-proliferating cells, indicates that 
CATS might play a role in cell proliferation. Interestingly, similar to what we observed in 
U937, an additional band was also detected in protein extracts of HeLa cells. This band may 
correspond to an additional CATS isoform resulting from alternative splicing. 
 
Fig. 3.31: CATS expression in normal and tumor cell lines. Cellular extracts (30 µg) from human normal and 
tumor cell lines were blotted and probed with α-CATS 2C4 antibody. CATS is highly expressed in solid tumor 
cell lines (HeLa, U2OS and SaOS) and in the transformed embryonal kidney cell line 293T. Lower expression of 
CATS was observed in the normal human fibroblast cell line WI-38, a cell line with low proliferative rate. No 
CATS expression was detected in the non-proliferating T-cell lines TYRF8 and JB4. The arrow indicate the 
additional band in the cellular extract of the HeLa cell line. Blots were stripped and reprobed with α-beta actin 
antibody, which served as a control for the loading and integrity of the protein extracts. 
 
3.10.4 CATS is a marker for proliferation 
 
Expression analysis of CATS in lysates of serum starved and serum stimulated T98G 
(glioblastoma cell line) cells (2.1.18) revealed a strong correlation between CATS expression 
and proliferation. Low levels of CATS were observed in lysate from quiescent cells as well as 
from cells shortly after release from serum starvation. Gradual and progressive upregulation 
of CATS expression is seen after serum stimulation, especially from hour 12 onwards (Figure 
3.32). These results indicate that CATS is a marker for proliferation and is regulated in a cell 
cycle dependent manner (see also below). 
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Fig. 3.32: CATS expression in serum stimulated T98G cells. After 48 hrs of serum starvation, T98G cells 
were serum stimulated. Cell extracts, prepared every 3 hrs for up to 30 hrs after stimulation were blotted and 
probed with α-CATS 2C4 antibody. CATS is strongly upregulated in proliferating cells. Low levels of CATS 
expression were observed in quiescent cells (0) and in cells which, had shortly been released from serum 
starvation (3-9 hrs). Gradual increase in CATS expression is clearly seen from hour 12 onwards, with strongest 
expression detected 30 hrs after serum stimulation. Numbers indicate hours after serum stimulation. (0) starved 
cells. (P) proliferating cells, which have not gone through starvation. The blot was stripped and reprobed with 
the α-beta actin antibody, which served as a control for the loading and integrity of the protein extracts. Note 
that the low intensity of CATS signal in extracts from proliferating cells (P) is due to lower amount of protein as 
shown by the weak signal obtained with the beta actin control.  
 
3.10.5 CATS is regulated in a cell cycle dependent manner 
 
Lysates from U2OS and HeLa cells (2.1.18), which had undergone synchronization through a 
double thymidine block, were blotted and probed with the α-CATS 2C4 antibody. FACS 
analysis of the corresponding cell populations was used to confirm the quality of the cell 
cycle synchronization. Analysis of CATS expression in synchronized cells revealed that 
CATS expression varies throughout the cell cycle and is regulated in a cell cycle dependent 
manner. CATS is upregulated in samples corresponding to S-, G2- and G2/M- phases. Samples 
in which most of the cells were found in G1-phase showed lower expression of CATS (Figure 
3.33). 
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Fig. 3.33: CATS expression during the cell cycle. U2OS and HeLa cell were synchronized by a double 
thymidine block. Synchronization was confirmed by FACS. (a) Western blot with extracts from the same cell 
samples analyzed by FACS. CATS expression varies in the different stages of the cell cycle. Upregulation of 
CATS protein was observed in cell extracts corresponding the S, G2 and G2/M phases of the cell cycle (sample 4 
to 11 from U2OS and samples 5 to 10 from HeLa). Sample 1 from HeLa lysates is from a non-synchronized cell 
population, the arrow indicates the smaller CATS isoform expressed also in U937 cells (3.10.2). Blots were 
stripped and reprobed with α-beta actin antibody, which served as a control for the loading and integrity of the 
protein extracts. (b) FACS analysis of U2OS samples (1-13). 
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3.11 HL-60 cell line produces CATS mRNA but lacks CATS 
protein 
 
Among all the 17 cancer cell lines tested for CATS expression, only the HL-60 cell line did 
not express the protein. Since HL-60 has a deletion of part of chromosome 17 and lacks the 
TP53 gene (TP53 is located proximal to CATS on 17p13), we used PCR to examine whether 
the CATS genomic locus is deleted in this cell line. A deletion of the CATS locus would 
explain the lack of its protein in this highly proliferative cell line. However, PCR 
amplification of a 697 bp CATS fragment from HL-60 genomic DNA revealed the presence of 
an intact CATS locus. Moreover, CATS transcript could be amplified by RT-PCR from HL-60 
RNA. (Figure 3.34). These results suggest a posttranscriptional regulation of CATS in HL-60. 
 
Fig. 3.34: Amplification of the CATS genomic locus and of CATS transcript from the HL-60 cell line. (a) 
PCR was performed using primer pair CATSE1F1(364) and CATSE5R1(828) and genomic DNA of 293T, 
U2OS and HL-60 cell lines as template. Amplification of HL-60 DNA reveals an intact genomic locus of the 
CATS gene. DNA of 293T and U2OS were used as normal and tumor cell line control for CATS amplification. 
Amplification with primers for the interferon genes (INF 5’ and INF 3’, see in 2.1.13) was used as control for 
DNA integrity. (b) RT-PCR with total RNA from 293T, HeLa and HL-60 cell lines. Amplification from HL-60 
cDNA (primer pair CATSE1F1(364) and CATSE5R1(828)) reveals clear expression of CATS transcripts in this 
cell line. Note that the CATS protein cannot be detected in HL-60. RT-PCR with 293T and HeLa was used as 
control for CATS expression in normal and tumor cell line. Amplification of GAPDH fragment from the same 
RNA samples was used as control for RNA and cDNA integrity. (C) Negative control: PCR reaction with no 
template shows no amplification 
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3.12 Subcellular localization of endogenous CATS 
 
Immunofluorescence (2.2.29) was performed in U2OS cells in order to determine the cellular 
localization of endogenous CATS. α-CATS 2C4 antibody detected the endogenous protein 
only in the nucleus where different levels CATS expression was observed from cell to cell. 
Strong accumulation of endogenous CATS was also observed in the nucleolus of some U2OS 
cells. However, the nucleolar expression of CATS was not a constant feature, since in some 
cells with evident nucleolar structure either CATS was not expressed or did not accumulate in 
the nucleolus (Figure 3.35).  
 
 
 
 
Fig. 3.35: Subcellular localization of endogenous CATS. Endogenous CATS was visualized by 
immunofluorescence in non-synchronized U2OS cells. (a) CATS is a nuclear protein. Note the different levels of 
CATS expression from cell to cell. Asterisks indicate DAPI stained cells, which are free from CATS expression. 
Arrows indicate cells with nucleolar accumulation of CATS. (b) Upper panel: strong CATS expression at the 
nucleoli. Middle panel: strong CATS nuclear expression. Lower panel: despite visible nucleoli, CATS does not 
accumulate to a great extent in the nucleoli. Bars: 25 µm (a); 10 µm (b). 
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3.13 CALM does not activate transcription in a GAL4-based 
transactivation assay 
 
It has previously been reported that CALM is able to activate transcription when fused to a 
heterologous DNA-binding domain (GAL4-DBD) in a mammalian cell reporter gene assay 
(Vecchi et al., 2001). Here we show that CATS physically interacts with CALM and that 
CATS can affect the subcellular localization of CALM. We thus asked the question whether 
CATS might affect the transcriptional activity of CALM either as a co-activator or co-
repressor of transcription (Figure 3.36).  
 
Fig. 3.36: Model of transactivation in GAL4-based transcription assay. Mammalian cells are cotrasfected 
with the GAL4-DBD-CALM and CFP-CATSv1 expressing plasmids and a reporter construct. GAL4-DBD-
CALM binds to the GAL4-UAS in the promoter region of the reporter gene. CALM recruits proteins to form a 
transcription activation complex and induce transcription of the luciferase reporter gene. Through the CALM-
CATS interaction, CATS would be part of the transcription complex. This assay was used to examine whether 
CATS can enhance or repress the tanscriptional activity of the GAL4-DBD-CALM fusion protein. 
 
293T cells were cotransfected with 1.5 µg of the GAL4-CALM (1-652) construct (encoding 
the GAL4-DBD fused to CALM), 0.3 µg of CFP-CATS constructs (both isoforms), 0.3 µg of 
the reporter plasmid pGAL4LUC (encoding the luciferase gene under the transcriptional 
control of the GAL4-binding sites) or pGAL45tkLUC (encoding the luciferase gene under the 
transcriptional control of the Herpes simplex virus thymidine kinase promoter and 5 GAL4-
binding sites) and 6 ng of pRL-null co-reporter vector (encoding the Renilla luciferase 
protein) (Promega). Alternatively, the experiment was performed with a ratio of 1:1 of GAL4-
DBD construct to the reporter plasmid (Figure 3.37 b and d). Expression of GAL4-DBD-
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CALM fusion protein was confirmed by Western blot using antibody against the GAL4-DBD 
(2.1.14) (Figure 3.37 e). However, expression of GAL4-DBD-CALM protein either alone or 
together with CATS had no effect on the transcription of the reporter genes in all four 
duplicate transfection experiments. The luciferase activity stayed at basal levels, similar to the 
control experiments, in which cells expressed only the GAL4-DBD (Figure 3.37 a-d). Positive 
control experiments, in which the GAL4-DBD-STAT2 fusion was expressed, showed a 92 
fold activation of the luciferase activity over basal levels (data not shown). Surprisingly, the 
previously reported function of GAL4-DBD-CALM as a transcriptional activator could not be 
reproduced. 
 
 
Fig. 3.37: CALM does not activate transcription when fused to a heterologous DNA binding domain. 293T 
cells were transiently transfected with a GAL4-regulated luciferase reporter construct (pGAL4LUC or 
pGAL45tkLUC), GAL4-DBD-CALM and CFP-CATS expressing plasmids. pM1 (GAL4-DBD) and pECFP-C1 
empty vectors were used as negative controls. The GAL4-DBD-CALM fusion protein did not activate 
transcription of the luciferase reporter genes when compared to the GAL4-DBD empty vector (a-d). The 
expression of CATS (both isoforms) did not change level of luciferase expression, neither activating nor 
repressing transcription of the reporter gene. The luciferase activity was normalized for transfection efficiency 
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using the activity levels of the Renilla luciferase. Experiments were performed in duplicate. (e) Expression of 
GAL4-DBD-CALM was confirmed by Western blotting. 
 
3.14 CATS isoform 1 acts a transcriptional repressor in a GAL4-
based transactivation assay 
 
Since CATS localizes to the nucleus, a GAL-4-based transcription assay (2.2.23) was used to 
investigate a possible function of CATS as a transcriptional regulator. For that purpose, 
CATS was cloned into a mammalian expression vector to be expressed as GAL4-DBD fusion 
protein. The complete CATS ORF was excised from the CFP-CATSv1 clone (3.4.1 a) with 
XhoI and HindIII and cloned into the pM1 vector (2.1.11) digested with SalI and HindIII 
(Figure 3.38). 
300 600 900 1200 1500 1800 2100 2400 2700 3000 3300 3600 3900 4200
AmpCATSv1GAL4DBD
fusion protein
Y2H1 primer
Sa l I / Xho I HindIII (1610)
 
Fig. 3.38: pM1-CATSv1 construct. CATSv1 ORF was cloned into the SalI and HindIII sites of the pM1 vector 
to be expressed as GAL4-DBD-CATS protein in the mammalian system. In bold and blue: restriction enzymes 
used for cloning. Enzymes in red demonstrate compatible sticky ends used for cloning, which are destroyed upon 
ligation. Ruler indicates construct size. The arrow indicates the binding position of the Y2H1 sequencing primer. 
Amp: ampicillin resistance gene. 
 
293T cells were cotransfected (as described in 2.2.21) with 0.66 µg of pM1-CATS construct, 
0.33 µg of pGAL45tkLUC reporter plasmid and 6.6 ng of pRL-null co-reporter vector. 
Transfected cells were disrupted with 1 ml PLB lysis buffer and 8 µl of the lysate was used 
for measurement of the luciferase activity (2.2.23.1). Expression of GAL4-DBD-CATS 
repressed the luciferase expression about 4.6 fold in comparison to GAL4-DBD alone (Figure 
3.39). 
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Fig. 3.39: CATS acts as a repressor of transcription when fused to a heterologous DNA binding domain 
(GAL4-DBD). The upper diagram is a model of repression of transcription by the DBD-CATS protein. 293T 
cells were transiently transfected with a GAL4-regulated luciferase reporter plasmid and pM1-CATSv1 or empty 
pM1 vector. CATS represses luciferase activity about 4.6 fold in comparison to GAL4-DBD alone. The bar 
graph represents the average of normalized firefly luciferase values obtained from four independent triplicate 
experiments. Error bars show standard deviation. 
 
3.15 CATS interacting proteins 
 
3.15.1 Construction of the bait plasmid 
 
In order to gain further insights into CATS function, a yeast two-hybrid screen was performed 
to identify interaction partners of CATS. For this purpose the full length coding region of 
CATS isoform 1 (residues 1-238) was cloned into the pGBKT7 vector (2.1.11) to be 
expressed as GAL4-DBD fusion protein. The complete CATS ORF was excised from the 
CFP-CATSv1 construct (3.4.1) with XhoI and SalI and cloned into the yeast expression vector 
pGBKT7 digested with SalI (Figure 3.40).  
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Fig. 3.40: pGBKT7-CATSv1 bait plasmid. CATSv1 ORF was cloned into the pGBKT7 vector (at the SalI site) 
to be expressed as GAL4-DBD-CATS fusion protein in yeast. Restriction enzymes used for cloning are in bold. 
Enzymes in red demonstrate compatible stick ends used for cloning, which are destroyed upon ligation. Numbers 
indicate nucleotide position. The arrow indicates the binding position of the Y2H1 sequencing primer. TRP1: 
gene coding for phosphoribosylanthranilate isomerase, an enzyme in the tryptophan biosynthesis. Kanamycin: 
kanamycin resistance gene for selection in bacterial cells. 
 
3.15.2 Two-hybrid screen 
 
Test of the pGBKT7-CATS bait plasmid for autonomous activation (2.2.22.1) showed that the 
CATS isoform 1 does not activate the reporter genes of the yeast two-hybrid system when 
fused to GAL4-DBD. Therefore, the CATS full length ORF was used as a bait in a Y2H 
screen of a S3 HeLa cDNA library (2.2.22). A middle stringency screen of 1x106 
transformants yielded 230 independent clones containing potentially interacting prey 
plasmids. Forty-seven (20 %) of these clones were sequenced with vector primer Y2H2-729-
751 (2.1.13). BLAST analyses with these sequences against Genbank showed that these 
sequences matched to 12 different cDNAs. Ten of them (21.2 %) were found to code for 
CATSv2 protein, five (10.6 %) were found to code for PCBP1 and five for SIVA. Three 
clones (6.3 %) were found to code for CSNK2B, 2 (4.2 %) were found to code for HAX1 and 
two for UXT. Finally, single clones coding for KRT17, KIS, MCM3AP, MKRN3, RCN1 and 
ATP60C were found (2.1 %). Table 3.4 summarizes the potential CATS interacting proteins.  
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CATS interacting protein Frequency of the 
interacting clones 
hypothetical protein FLJ10491 (CATSv2) 10x 
poly(rC) binding protein 1 (PCBP1) 5x 
CD27-binding (Siva) protein (SIVA) 5x 
casein kinase type II beta subunit (CSNK2B) 3x 
HS1 binding protein (HAX1) 2x 
ubiquitously-expressed transcript (UXT), transcript variant 2  2x 
keratin 17 (KRT17) 1x 
kinase interacting with leukemia-associated gene (stathmin) (KIS) 1x 
minichromosome maintenance deficient 3 associated protein 
(MCM3AP) 
1x 
makorin, ring finger protein, 3 (MKRN3) 1x 
reticulocalbin1 (RCN1) 1x 
ATPase, H+ transporting, lysosomal 16 kDa, V0 subunit c (ATP60C) 1x 
 
3.15.3 First confirmation of potential protein interaction  
 
A initial test to confirm that the proteins from the screen are indeed CATS interacting partners 
was performed by co-transforming the individual prey plasmids containing the potential 
interacting partners and the CATS bait plasmid into yeast strain AH109. Except for CATSv2, 
all the prey proteins showed interaction with CATSv1 as assayed by cell growth on selective 
plates (Figure 3.41). The fact that the CATS prey clones did not activate the yeast reporter 
genes together with the CATS bait indicates that the CATS-CATS interaction is either very 
weak or that the result of the yeast two-hybrid screen was an artifact. 
 
 
Fig. 3.41: Interaction of CATS with 11 different proteins. Yeast strain AH109 was cotransformed with 
pGBKT7-CATSv1 and GAL4-AD-CATS clones (full length of both isoforms plus deletion mutants cloned into 
the pGADT7 vector; see in 3.5.1) or the prey clones isolated from the Y2H screen (HeLa cDNA library cloned 
into the pGADGH vector). Transformed cells were streaked out on high stringent SD -Trp, -Leu, -His, -Ade 
selection plates (a) supplemented with X-α-GAL (b, c). (a) CATS-CATS interaction assay. (1-7) Yeast cells 
expressing the GAL4-DBD-CATSv1 bait protein and the prey proteins (1): GAL4-AD-CATSv1. (2): GAL4-
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AD-CATSv1CT. (3): GAL4-AD-CATSv2. (4-6): independent GAL4-AD-CATSv2CT prey clones from the 
HeLa cDNA screen. (7): pGADGH-KRT17 used as positive control for CATS interaction. Note that yeast clones 
containing both CATS bait and prey plasmids did not activate the reporter genes indicating that CATS does not 
interact with itself. (b, c) Yeast clones containing the CATS bait plasmid and the prey clones isolated from the 
yeast two-hybrid screening. All the isolated proteins are potential CATS interacting proteins as shown by cell 
growth on SD -Trp, -Leu, -His, -Ade + X-α-GAL plates. (7): KRT17. (8): KIS. (9): PCBP1. (10): MCM3AP. 
(11): UXT. (12): MKRN3. (13): SIVA. (14): CSNK2B. (15): RCN1. (16): HAX1. (17): ATP6V0C.  
 
The potential interaction of CATS with proteins involved in so many different cellular 
pathways indicates that CATS might play a role in many different cellular processes. The 
most frequently found and most interesting CATS interacting partners were chosen for further 
analysis. Some interactions were further confirmed by colocalization experiments and/or co-
immunoprecipitation.  
 
3.15.4 CATS interacting protein PCBP1  
 
The poly r-C binding protein 1 (PCBP1) was identified among the most frequent CATS 
interacting protein in the Y2H screen. This protein is of particular interest because it also 
interacts with CALM (Pasalic, Z., CCG Leukemia, GSF, Munich; personal communication). 
PCBP1 is a ribonucleoprotein involved in post-transcriptional control pathways, such as 
mRNA stabilization and regulation of translation from both cellular and viral RNAs 
(Makeyev & Liebhaber, 2002; Ostareck-Lederer & Ostareck, 2004). 
None of the 5 independent PCBP1 clones isolated in the yeast two-hybrid screen, coded for 
the complete PCBP1 ORF (these clones started at nt position 287, 311 and 464, or amino acid 
residues 37, 45 and 96 of the PCBP1 coding region) (Figure 3.42).  
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Fig. 3.42: PCBP1 clones isolated in the Y2H screen. Diagram representing PCBP1 nucleotide and amino acid 
sequences. Red bars underneath represent amino acids coded by the cDNA clones 48/297 (aa residues 35-356), 
41 (aa residues 45-356) and 83/118 (aa residues 96-356) and its position related to the complete ORF. The 
arrows indicate binding position of sequencing primers.  
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The full length cDNA sequence deposited in Genbank (accession NM_006196) was used to 
design primers flanking the PCBP1 ORF. A 1106 bp cDNA fragments was amplified by RT-
PCR from HeLa RNA (2.2.11 and 2.2.12) using PCBP1 specific primers containing sites for 
the XhoI and HindIII restriction enzymes (PCBP1XhoIf and PCBP1HindIIIr). The PCR 
product was digested with the appropriate enzymes, cloned into the pECFP-C1 vector (2.1.11) 
and sequenced (Figure 3.43).  
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Fig. 3.43: CFP-PCBP1 construct. The PCBP1 ORF was amplified by RT-PCR from HeLa RNA using primer 
pair PCBP1XhoIf and PCBP1HindIIIr. The 1106 bp product was cloned into the pECFP-C1 vector digested with 
XhoI and HindIII. Restriction enzymes used for cloning are in bold. Numbers in brackets indicate nucleotide 
position. The numbers are position in base pairs. The arrow indicates the binding position of the pEGFP-1240-
1258 sequencing primer. 
 
To further validate the CATS-PCBP1 interaction, YFP-CATS (both isoforms) and the CFP-
PCBP1 protein were coexpressed in murine fibroblasts (NIH3T3). These experiments 
revealed a colocalization of CFP-PCBP1 and YFP-CATS mainly in the nucleus but also to a 
lesser extent in the cytoplasm (Figure 3.44). 
 
 
Fig. 3.44: Colocalization of YFP-CATS with CFP-PCBP1. NIH3T3 cells transiently transfected with YFP-
CATS and CFP-PCBP1 expressing plasmids revealed a predominantly nuclear co-localization of these proteins. 
Bar: 10 µm. 
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Cloning of PCBP1 ORF and detailed analysis of CATS-PCBP1 interaction were performed 
together with Moritz Middeke (CCG Leukemia, GSF, Munich), an MD student who is 
working under the supervision of Leticia Fröhlich Archangelo. 
 
3.15.5 The CATS interacting protein KIS  
 
The kinase interacting with stathmin (KIS or UHMK1) is a serine/threonine kinase that 
positively regulates cell cycle progression through phosphorylation of p27KIP on S10, thereby 
promoting nuclear export of p27KIP and reducing its inhibitory effect on cell cycle (Boehm et 
al., 2002; Maucuer et al., 1995). 
In the yeast two-hybrid screen described above (3.15) a single clone coding for KIS was 
identified as CATS interacting partner. The isolated clone 31 did not correspond to the 
complete KIS ORF as its sequence started at nucleotide position 243 of the KIS cDNA 
sequence (GenBank acc. Nr.: NM_175866/AJ536197), which corresponds to amino acid 
residue 33 of the coding region (Figure 3.45).  
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Fig. 3.45: KIS clone isolated in the Y2H screen. Red bar underneath represents the amino acid residues coded 
by the cDNA clone 31 (aa residues 33-419 of KIS ORF) and its position related to the complete ORF. The 
arrows indicate binding position of sequencing primers.  
 
The cDNA sequence from Genbank was used to design primers flanking the KIS ORF. A 
1328 bp cDNA fragments was amplified by RT-PCR from HeLa RNA (2.2.11 and 2.2.12) 
using KIS specific primers containing restriction enzyme sites for the XhoI and HindIII 
(KISXhoI5’new and RKISHindIII). The PCR product was digested with the appropriate 
enzymes, cloned into the pEYFP-C1 vector (2.1.11) and sequenced (Figure 3.46).  
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Fig. 3.46: YFP-KIS construct. The KIS ORF was amplified by RT-PCR from HeLa RNA using primer pair 
KISXhoI5’new and RKISHindIII. The 1328 bp product was cloned into the pEYFP-C1 vector digested with 
XhoI and HindIII. Restriction enzymes used for cloning are in bold. Numbers in brackets indicate nucleotide 
position. The numbers indicate the base pair positions. The arrows indicate primer binding positions.  
 
3.15.6 CATS interacting protein HAX1  
 
HAX1 has been found in anti-apoptotic signaling counteracting the pro-apoptotic effects of 
BAX. HAX1 was identified as a protein interacting partner of HS1 (hematopoietic lyn 
substrate 1), which is part of the B-cell and T-cell receptor signaling cascade (Sharp et al., 
2002; Suzuki et al., 1997). 
Two independent clones coding for HAX1 were identified in the Y2H screen. The longer 
clone (clone 12) started at nucleotide position 559 and the shorter (clone 305a) at nucleotide 
position 622 (GenBank acc. #: NM_006118), corresponding to residues 133-279 and 154-279 
of the HAX1 ORF, respectively (Figure 3.47). The results show that CATS interacts with the 
C-terminal region of HAX1 (residues 154-279) and the N-terminal residues 1 to 153 of the 
HAX1 ORF are not necessary for the interaction.  
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Fig. 3.47: HAX1 clones isolated in the Y2H screen. Diagram represents HAX1 nucleotide and amino acid 
sequences The red bars underneath represent amino acids coded by the cDNA clones 12 and 305a (residues 133-
279 and 154-279, respectively) and its position related to the complete ORF. Note that N-terminal residues 1-153 
are not necessary for the interaction with CATS.  
 
To establish whether CATS interacts with HAX1 in vivo, fluorescently tagged CATS and 
HAX1 (2.1.12) fusion proteins were coexpressed in 293T cells and precipitated in CoIP 
buffer I (2.1.5) with an antibody against the HAX1 protein (2.2.28). The α-HAX1 antibody 
detected the immunoprecipitated HAX1 fusion protein as shown in figure 3.48, upper lanes 1 
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and 2. The membrane was stripped and reprobed with α-CATS 2C4 antibody. The CATS 
antibody identified the expected sized band for overexpressed CFP-CATS (approx. 55 kDa) 
in the lanes where immunoprecipitated HAX1 fusion protein was present (Figure 3.48, lower 
lane 2). Immunoprecipitation with control mouse IgG did not coprecipitate overexpressed 
CFP-CATS (Figure 3.48, lane 3). Similarly, a CFP-CATS band was not detected in 
immunoprecipitate from cells which had been transfected with YFP-HAX1 plus the empty 
CFP vector (Figure 3.48, lane 1). These results confirm that HAX1 is indeed a CATS 
interacting protein. 
 
Fig. 3.48: Coimmunoprecipitation of CATS and HAX1 proteins. Lysates of cells overexpressing CFP-
CATSv1 and YFP-HAX1 were immunoprecipitated with α-HAX1 in CoIP buffer I. Immunoprecipitated HAX1 
fusion protein is detected by immunoblotting using the same antibody, upper lanes 1 and 2. The blot was 
stripped and reprobed with α-CATS 2C4 antibody, which identified a band of the expected size for the 
overexpressed CFP-CATS (approx. 55 kDa) in the HAX1 precipitate, lower lane 2. Immunoprecipitate of a 
lysate from cells transfected with YFP-HAX1 plus the empty CFP vector or immunoprecipitates with normal 
mouse IgG were used as negative controls, lanes 1 and 3, respectively. 10 µg cell extract was used as input 
control, lanes 4 and 5. 
 
3.15.7 CATS interacting protein SIVA  
 
Together with PCBP1, SIVA is the most frequent protein identified in the Y2H screen as 
CATS interacting partner. All five independent clones coded for the complete ORF of SIVA 
transcript variant 1 (GenBank acc. #: NM_006427) (Figure 3.49).  
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Fig. 3.49: SIVA clones isolated in the Y2H screen. All cDNA clones coded for the complete SIVA ORF (175 
aa). Red bars represent the coding region.  
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SIVA (from Shiva = the Hindu god of destruction) is a pro-apoptotic protein originally 
identified through its association with the cytoplasmic tail of CD27 (TNFRSF7), a member of 
the tumor necrosis factor receptor superfamily (Prasad et al., 1997). It is an important 
intracellular signaling molecule that transduces CD27-, GITR- and TCR-mediated apoptotic 
response (Gudi et al., 2006; Py et al., 2004; Spinicelli et al., 2002). 
To establish whether CATS interacts with SIVA in vivo, fluorescently tagged CATS and 
SIVA (2.1.12) fusion proteins were coexpressed in 293T cells and precipitated in CoIP buffer 
I (2.1.5) with antibody against the CATS protein (2.2.28). The α-CATS 2C4 antibody 
detected the immunoprecipitated CATS fusion protein as shown in figure 3.50, upper lanes 1 
and 2. The membrane was stripped and reprobed with the α-SIVA antibody. The SIVA 
antibody identified the expected sized band for overexpressed YFP-SIVA (approx. 43 kDa) 
protein in the lanes where immunoprecipitated CATS fusion protein was present (Figure 3.50, 
lower lane 2). Immunoprecipitation with normal rat IgG did not coprecipitate overexpressed 
YFP-SIVA (Figure 3.48, lane 3). Similarly, the YFP-SIVA band was not detected in the 
immunoprecipitate from cells which had been trasfected with CFP-CATS plus the empty YFP 
vector (Figure 3.48, lane 1). These results confirm that SIVA is indeed a CATS interacting 
protein. 
 
Fig. 3.50: Coimmunoprecipitation of CATS and SIVA proteins. Lysate of cells overexpressing CFP-CATS 
and YFP-SIVA were immunoprecipitated with 100 µl α-CATS 2C4 in CoIP buffer I. Immunoprecipitated CFP-
CATS fusion protein is detected by immunoblotting using the same antibody, upper lanes 1 and 2. The blot was 
stripped and reprobed with the α-SIVA antibody, which identified a band of the expected size for the 
overexpressed YFP-SIVA protein (approx. 43 kDa) in the CATS precipitate, lower lane 2. Immunoprecipitate of 
a lysate from cells transfected with CFP-CATS plus the empty YFP vector and immunoprecipitates with normal 
rat IgG were used as negative controls, lanes 1 and 3, respectively. 10 µg cell extract was used as input control, 
lanes 4 and 5. 
 
3 Results 
 108 
3.16 Conditional expression of the CATS protein 
 
Conditional expression systems are an important tool for dissecting the function and relevance 
of poorly characterized proteins. In order to further characterize CATS and obtain insights 
into its biological function we choose a tetracycline-inducible gene expression system (Tet 
system). Of particular interest is to examine the impact of CATS expression on cell 
proliferation. For that purpose both CATS isoforms were cloned into the reverse 
transactivator silencer-1 (pRTS-1) vector (2.1.11). In this Doxycyclin-regulatable (Dox) 
episomal “all-in-one” vector, the gene of interest is expressed from the bidirectional promoter 
Ptetbi-1 that allows simultaneous expression of two genes, of which one may be used as 
marker for the expression of the gene of interest. In addition, this vector constitutively 
expresses from a bicistronic expression cassette the Dox-sensitive reverse tetracycline 
controlled transactivator rtTA2S-M2 and the Tet repressor-KRAB fusion protein (tTSKRAB). 
Tight down regulation is achieved through binding of the silencer tTSKRAB to Ptetbi-1 in the 
absence of Dox. Addition of Dox releases repression and via binding of rtTA2S-M2 activates 
the Ptetbi-1 (Bornkamm et al., 2005) (Figure 3.51). 
 
 
Fig. 3.51: Principle of Dox-inducible gene expression.  
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3.16.1 Generation of an HA-tagged CATS fusion genes 
 
Human CATS cDNAs were amplified with the Pfu proof reading DNA polymerase and primer 
pair hCATS ATGf(PUC18) - hCATS∆TGAv1r(PUC18) or - hCATS∆TGAv2r(PUC18) in 
which a consensus Kozak sequence was added 5’ of the start codon of the forward primer. 
The CFP-CATSv1 and YFP-CATSv2 constructs were used as templates for the amplification 
of CATS ORF isoform 1 and 2, respectively. The blunt ended PCR products were cloned in 
frame with the 3’ HA tag from the pUC18-HA vector (2.1.11) which had been linearised with 
the EcoRV restriction enzyme. The orientation of the insert was determined by colony PCR 
using the pUC18-M13rev vector primer and CATSE1F1(364) primer internal to CATS 
sequences (Figure 3.52).  
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Fig. 3.52: pUC18-CATSv1/v2-HA tagged constructs. CATS ORF was amplified with Pfu polymerase and 
primer pair hCATSATGf(PUC18) - hCATS∆TGAv1r(PUC18) or - hCATS∆TGAv2r(PUC18). A consensus 
Kozak sequence was added 5’ to the start codon from the forward primer. Both 714 bp and 789 bp products 
(coding for isoform 1 and 2, respectively) were cloned into the EcoRV site of the pUC18-HA vector. In red is 
the enzyme used for cloning, the enzyme site is destroyed upon ligation. In bold and blue is the SfiI restriction 
sites used to excise the HA-tagged CATS in order to transfer the insert to the pRTS-1 vector. Numbers in 
brackets indicate nucleotide positions. The arrows indicate the binding position of the sequencing primers. The 
HA tag is shown in red. 
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3.16.2 Cloning of the HA-tagged CATS into pRTS-1 vector 
 
The HA-tagged version of both CATS isoforms were excised with SfiI from the constructs 
described above (pUC18-CATSv1/v2-HA) and cloned into the Dox-inducible episomal vector 
pRTS-1 digested with SfiI (Figure 3.53). The orientation of the insert was determined by 
colony PCR using the pEBNA_Sfi+55bp (rev) vector primer and the CATSE1F1(364) primer. 
 
Fig. 3.53: Schematic map of pRTS-1. pRTS-CATSv1/v2-HA tagged constructs were generated by excising 
both HA-tagged versions of CATS from the pUC18-CATSv1/v2-HA with SfiI restriction enzyme and 
subcloning into the pRTS-1 vector digested with the same enzyme. The SfiI restriction sites used for cloning are 
in blue boxes. Yellow boxes indicate genes of interest, either HA-tagged CATS or luciferase (Luc) from the 
control plasmid. The green box indicates the GFP gene, used as marker for CATS expression. Note that the 
bidirectional promoter Ptetbi-1 allows simultaneous expression of both CATS-HA (or Luc for control 
experiments) and GFP genes. pRTS-1 also contains the ampicillin resistance gene for bacterial selection and the 
hygromycin B resistance gene (hyg) for selection in mammalian cells. 
CATSv1/v2-HA 
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4 Discussion 
 
4.1 The novel CALM interactor CATS and the significance of the 
CALM-CATS interaction for CALM/AF10-mediated 
leukemogenesis  
 
4.1.1 CATS is a novel protein which interact with CALM and influence the 
subcellular localization of CALM/AF10 
 
The t(10;11)(p13;q14) translocation is found in patients with acute myeloid as well as acute 
lymphoblastic leukemias and in malignant lymphoma. This translocation results in the fusion 
of CALM on chromosome 11 band q14 to AF10 on chromosome 10 band p13. The 
CALM/AF10 fusion protein, which encompasses nearly all the protein domains of the two 
proteins, rather than the reciprocal AF10/CALM fusion protein, is critical for the malignant 
transformation. Desphande et al. have recently shown that the expression of CALM/AF10 is 
sufficient to induce leukemia in a murine bone marrow transplant model (Deshpande, 2003). 
CALM has been described as an important endocytic protein, which plays a pivotal role in 
clathrin-mediated endocytosis  (De Camilli et al., 2002; Evans & Owen, 2002; Ford et al., 
2001; Kalthoff et al., 2002; Meyerholz et al., 2005; Tebar et al., 1999). Recently, an 
MLL/CALM fusion has been described in a case of childhood AML (Wechsler et al., 2003). 
The involvement of CALM in two separate translocations with both MLL and AF10 as well as 
the fact that a number of other MLL and non-MLL fusion partners found in leukemia are 
proteins which play a role in clathrin-mediated endocytosis (CME) suggests that disturbing 
CME may be important in leukemogenesis (Bohlander, 2000; Di Fiore & De Camilli, 2001; 
Floyd & De Camilli, 1998; Polo et al., 2004; Wechsler et al., 2003). In order to further 
characterize CALM function and understand its contribution in CALM/AF10-mediated 
leukemogenesis we used the N-terminal portion of CALM (1-335) as a bait in a yeast 2 hybrid 
screen. The C-terminal end of a novel protein was identified. The corresponding gene was 
named CATS (CALM interacting protein expressed in thymus and spleen) because multiple 
tissue Northern blot analysis revealed a 1.6 kb transcript which is expressed predominantly in 
thymus, spleen and colon. The CATS gene is located on chromosome 17 band p13. The 
genomic locus spans approximately 7 kb and contains 6 exons. At least three alternatively 
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spliced versions of CATS could be identified which code for two protein isoforms of 238 or 
248 amino acids in length.  
Expression of fluorescent-tagged CATS proteins in NIH 3T3 cells showed that CATS 
localizes mainly to the nucleus where an accumulation of CATS is seen at the nucleoli (see 
below). However, a subfraction of CATS is also observed in the cytoplasm and at the cell 
membrane.  
The CATS interaction region of CALM was mapped to amino acids 221 to 294 of CALM. 
The interaction between CATS and CALM seems to be quite complicated since in contrast to 
the full length CATS the C-termini of CATS do not interact with CALM1-294 (which 
includes the interaction domain of for full length CATS) but need amino acids 1-335 of 
CALM for interaction.  
The N-terminal portion of CALM (150 aa) comprises the ANTH domain, which binds 
specifically to lipids (PtdIns(4,5)P2) in the membrane (De Camilli et al., 2002; Evans & 
Owen, 2002; Ford et al., 2002; Ford et al., 2001; Stahelin et al., 2003). In contrast to the N-
terminal domain of CALM, which is composed of α-helices, the C-terminal two thirds of 
CALM contains poorly ordered protein domains containing multiple copies of various short 
protein interaction motifs (e.g. NPF, DFP, DIF, DLL and FESVF; (Meyerholz et al., 2005)) 
and behaves like a flexible arm (Kalthoff et al., 2002). This organization of CALM is thought 
to permit the establishment of complex networks of interactions. Evan and Owen compared 
this structure to a long fishing line anchored to the membrane by the ANTH domain, with 
multiple hooks that can interact with various partners during clathrin-coated pit assembly 
(Evans & Owen, 2002). We were able confirm the CALM-CATS interaction (by 
cotransforming both the CALM bait and the CATS prey plasmids into yeast as well as by 
coimmunoprecipitation experiments) and determine the CATS interaction domain of CALM. 
The fact that CATS interacts within the central domain of CALM suggests an involvement of 
CATS in this complex network of interactions in the endocytic machinery. CATS might 
function as an adaptor protein which mediates the interaction of CALM with other endocytic 
proteins. The idea of CATS functioning in the cytoplasm as member of the endocytic 
machinery together with CALM is supported by the fact that expression of CFP-CATS and 
YFP-CALM resulted in the colocalization of both proteins in the cytoplasm and at the plasma 
membrane of transfected NIH3T3 cells. However, the majority of the CATS protein localizes 
to the nucleus, implying also a nuclear function for this protein. In reporter gene assays CATS 
functions as transcriptional repressor when it is fused to a DNA binding domain. Whether this 
observation is relevant for the physiological function of CATS needs to be explored further.  
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Interestingly, the CATS interaction domain of CALM is present in the CALM portion of both 
CALM/AF10 and the MLL/CALM fusion proteins. CATS not only colocalizes with 
CALM/AF10 in transient transfection experiments, but in some cells the subcellular 
localization of both CALM and CALM/AF10 can be affected by the presence of CATS. 
CATS was able to increase the nuclear fraction of both CALM and CALM/AF10 and this 
effect seems to be stronger for CALM/AF10. In contrast to CALM, which only partially 
shifted to the nucleus, CALM/AF10 was nearly completely relocalized to the nucleus and 
even accumulated at the nucleoli when CATS was coexpressed. Since we showed that not just 
CALM (as previously described; Vecchi et al., 2001) but also the CALM/AF10 fusion protein 
shuttle between nucleus and cytoplasm, it is tempting to speculate that the interaction between 
CATS and CALM or CALM/AF10 takes place in the nucleus, resulting in the accumulation 
of these proteins in the nucleus. These findings imply that in cells with high CATS expression 
a greater portion of CALM and CALM/AF10 might be present in the nucleus. Considering 
the high expression of CATS in lymphoid tissues, the CATS-CALM interaction might play an 
important role in CALM/AF10 mediated leukemogenesis. These findings have to be 
interpreted with caution at the present time, because the change in CALM and CALM/AF10 
localization was not observed in all cell coexpressing CATS and the two proteins. However, 
an analogous situation has been observed in a group of MALT lymphomas harboring the 
t(1;14)(p22;q32) translocation which results in the API2/MALT1 fusion protein. BCL10 
interacts with the non-rearranged MALT1 and some of the API2/MALT1 fusion proteins and 
MALT1 can regulate the subcellular localization of BCL10. Association of BCL10 with 
MALT1 and API2/MALT1 is thought to synergize the activation of NF-κB, the pathway 
underlying the anti-apoptotic effect of API2/MALT1 fusion protein (Nakagawa et al., 2006; 
Sanchez-Beato et al., 2003). 
 
4.1.2 Possible mechanisms underlying CALM/AF10-mediated 
leukemogenesis 
 
The mechanisms by which the CALM/AF10 fusion protein causes leukemia are not known. 
One possibility would be a gain of function mechanism by which the CALM/AF10 fusion 
functions as a CALM protein with additional functions or as an AF10 protein with additional 
functions. Alternatively, the CALM/AF10 fusion protein might exerts its effect through a 
dominant negative mode of action, i.e. disrupting normal AF10 and/or normal CALM 
function. Of course, a combination of both mechanisms could also be the case. 
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It is known that the localization of a protein (especially nuclear versus cytoplasmatic) is 
critical for its function (e.g. nuclear translocation of NF-κB causes transcription of target 
genes). It is tempting to speculate that the CALM/AF10 fusion resides predominantly in the 
cytoplasm and thereby causes mislocalization of the wildtype AF10 protein from the nucleus 
into the cytoplasm through AF10 homo-dimerization (Linder et al., 2000). In the light of the 
CATS–CALM interaction, which is able to change the subcellular localization of 
CALM/AF10 to the nucleus, this scenario appears less likely. However, it could still be that 
through its interaction with CATS, the CALM/AF10 fusion protein attains an abnormal 
subnuclear localization (e.g. a more nucleolar localization). In this context, it should be noted 
that CATS is highly expressed in lymphoid cells. Thus it can be hypothesized that the 
CALM/AF10 fusion exerts its leukemogenic effect through a disruption of AF10 function. 
Since AF10 is a putative transcription factor and the Drosophila AF10 homologue alhambra 
has been shown to affect transcriptional regulation through Polycomb group-responsive 
elements (PREs), disruption of AF10 function could lead to transcriptional deregulation of 
polycomb and trithorax target genes (Perrin et al., 2003). Indeed, leukemias involving 
CALM/AF10 fusion have been recently characterized by overexpression of HOXA genes and 
its co-factor MEIS1, and by overexpression of BMI1, a member of the polycomb (PcG) 
family (Dik et al., 2005; Krause, 2004; Soulier et al., 2005).  
On the other hand, it is conceivable that the CALM/AF10 fusion protein might disrupt the 
function of CALM through the mechanism of protein mislocalization. An altered CALM 
function might affect clathrin mediated endocytosis (CME) and protein trafficking in the 
trans-Golgi network. Endocytosis is well established mechanism of signal attenuation via 
receptor clearance from the plasma membrane. Tightly connected with signaling processes, 
endocytosis can itself be regarded as a signaling pathway, triggered by the activation of 
surface receptors and leading to their internalization. CME is involved then in propagating the 
intracellular signals, which continues within the cell until activated receptors have reached the 
end point of the endocytic journey where they undergo inactivation. For receptors whose fate 
is the lysosome, there is evidence that regulation of these steps may affect the duration of the 
stimulus (Di Fiore & De Camilli, 2001; Polo et al., 2004). Thus impairment of endocytosis 
will affect the down-regulation of activated transmembrane receptors resulting in prolonged 
growth factor signaling leading to an increase in proliferative stimuli to the cell (Di Fiore & 
De Camilli, 2001; Polo et al., 2004). There are several endocytic proteins which have been 
identified as parts of leukemic fusion proteins or which have been reported as mutated in 
various forms of cancer (Floyd & De Camilli, 1998). In this respect, a recent report that a 
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mutation in the murine CALM homologue Picalm results in altered hematopoiesis is 
interesting (Klebig et al., 2003). 
Indeed, Chao and coworkers have recently reported perturbed endocytosis by CALM-
containing fusion proteins, associated with prolonged growth factor signaling and enhanced 
cellular proliferation (Chao, 2005; Chao, 2004). Interestingly, the TSG101 tumor 
susceptibility gene (Li & Cohen, 1996) was found to interact with CALM at the same domain 
of CALM used for CATS interaction (Gläsner, 1999). TSG101 has an important role in 
ubiquitin-mediated endosomal sorting pathways and impairment of its function perturbs 
endosomal trafficking which is thought to contribute for the tumorigenic phenotype exhibited 
by suppressed expression of TSG101 in fibroblasts (Babst et al., 2000; Bishop et al., 2002). 
Similarly, increased expression of TSG101 in cells results in abnormal cell growth possibly 
mediated by the property of this protein to act as a dominant-negative inhibitor of the 
ubiquitination pathway controlling MDM2/p53 levels (Li et al., 2001; Ruland et al., 2001). 
Whether CATS and TSG101 are part of a complex with CALM or whether they compete for 
CALM interaction is not known. Nevertheless it is tempting to speculate that the 
mislocalization of CALM or CALM/AF10 through the interaction with CATS could interfere 
with the normal function of TSG101. On one side enhancing the effects of disrupted down 
regulation of activated growth factor receptors. On the other hand a greater portion of 
TSG101 protein would be free in the cytoplasm mimicking the overexpression situation 
where TSG101 inhibits MDM2 ubiquitination and degradation and consequently decreases 
the cellular level of p53. The hypothesis of an involvement of both CATS and TSG101 in 
CALM/AF10-mediated leukemogenesis is supported by the fact that TSG101, like the CATS 
interactor KIS (kinase interacting with stathmin; see bellow), interacts with stathmin, a 
phosphoprotein phosphorylation of which in important in diverse regulatory pathways 
including T-cell activation and cell cycle progression. Stathmin expression is also increased in 
acute leukemia and in malignant lymphoma (Li & Cohen, 1996; Maucuer et al., 1995 and 
references therein).  
As mentioned above, an alternative mode of action of the CALM/AF10 fusion protein would 
be a gain of function. In this scenario CATS, which could be shown to have transcriptional 
properties when fused to a heterologous DNA binding motif, would be recruited to AF10 
target genes through CALM thereby deregulating AF10 target gene expression. This 
transcriptional deregulation could also be caused directly by the CALM portion of the 
CALM/AF10 fusion protein. A transcriptional activation domain (TAD) could be delineated 
in CALM in the yeast system (Archangelo et al., 2006). It has also been reported that CALM 
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is able to upregulate transcription when fused to a GAL4-DBD in a mammalian reporter gene 
assay (Vecchi et al., 2001). However, we were unable to reproduce CALM-mediated 
transcriptional activation in a similar system. It should be noted that the CATS interaction 
domain of CALM and the CALM TAD map to distinct regions of the CALM protein. It 
remains to be tested which of these regions is critical for the transformation potential of the 
CALM/AF10 fusion protein. 
Structure function analyses of the MLL/AF10 fusion protein have shown that the critical 
region for transformation in AF10 is the octapeptide motif (OM) and the leucine zipper (LZ) 
of AF10 (DiMartino et al., 2002). The OM/LZ motif of AF10 was shown to interact with 
GAS41 a component of a chromatin remodeling complex and with the histone methyl 
transferase hDOT1L (Debernardi et al., 2002; Okada et al., 2005). The OM/LZ motif is also 
present in the CALM/AF10 fusion protein and it is very likely that this motif is critical for the 
transformation potential of the CALM/AF10 fusion protein. Since we could show that CATS 
is capable of recruiting the CALM/AF10 fusion protein to the nucleolus, there is the 
possibility that the AF10 portion of CALM/AF10 can affect the function of nucleolar 
proteins. Nucleolar proteins have been shown to regulate cell proliferation and growth by 
controlling ribosome biogenesis and p53 function and deregulation of these finely balanced 
mechanisms is a key event in the initiation and progression of malignant transformation 
(Maggi & Weber, 2005; Olson, 2004; Rubbi & Milner, 2003; Ruggero & Pandolfi, 2003). 
The significance of CATS nucleolar localization will be discussed below in more detail.  
In summary, we propose that CATS is a critical modulator of normal CALM function in 
lymphoid cells and that the interaction of CATS with CALM could be very important for 
understanding leukemogenic potential of the CALM/AF10 fusion protein. 
 
4.2 CATS is a nucleolar protein involved in proliferation control 
 
Nucleoli have been long known as the center of ribosome biogenesis, a major metabolic 
activity within the cell. This dynamic organelle dissociates during mitosis and assembles as 
cells renter cell cycle underlining the important relationship between cell cycle and ribosome 
production and the tight link between nucleolar function, cell growth and proliferation 
(Bernardi & Pandolfi, 2003; Du & Stillman, 2002; Schlosser et al., 2005; Schlosser et al., 
2003; Tsai & McKay, 2002). Recently, reports have suggested additional functions for the 
nucleolus in cell cycle control and cellular response to stress coupling nucleoplasmic levels of 
p53 to the functional state of ribosome biogenesis (Holzel et al., 2005; Kamijo et al., 1998; 
Kurki et al., 2004a; Kurki et al., 2004b; Olson, 2004; Rubbi & Milner, 2003; Tao & Levine, 
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1999). Not surprisingly subversion of nucleolar function has been associated with cancer 
progression (Maggi & Weber, 2005; Ruggero & Pandolfi, 2003) and much attention has been 
paid to this organelle as a potential target for anti-cancer drugs (Yao & Yang, 2005). 
Schlosser and colleges have indeed shown that many target genes of the proto-oncogene 
MYC are nucleolar proteins and conclude that MYC regulates cell growth and proliferation 
by the coordinated induction of cdk activity and ribosomal processing (Schlosser et al., 2005; 
Schlosser et al., 2003). Interestingly, proteomic analysis of the human nucleolus revealed that 
30  % of the identified proteins are encoded by previously uncharacterized genes (Andersen et 
al., 2005; Andersen et al., 2002). 
CATS is an example of this growing list of novel nucleolar proteins placing CATS in a 
defined molecular network. Consistent with the function as a nucleolar protein regulating cell 
proliferation, Cats is highly expressed throughout murine embryogenesis but not in 
differentiated cells of most adult tissues. Cats expression decreased gradually and 
proportionally similarly to the proliferative marker PCNA and the nucleolar nucleophosmin 
(Tsai & McKay, 2002), reflecting the increase in cells exiting cell cycle. Western blot 
analyses using CATS antibody have shown strong endogenous CATS expression in leukemia, 
lymphoma and tumor cell lines where CATS protein levels seems to be inversely correlated to 
cell doubling time, which in turn is known to be directly related to nucleolar function 
(Derenzini et al., 2000). In line with these findings, no expression of the CATS protein was 
observed in resting T-cells (JB4 and TYRF8). Furthermore, in cells induced to proliferate 
CATS showed an increasing and progressive upregulation with accumulation of CATS when 
cells entered S phase and maximum protein levels in G2 phase. Similarly, expression analysis 
on synchronized cells revealed an evident cell cycle dependent accumulation of CATS protein 
in the S and G2 phase of the cell cycle. These data clearly correlate accumulation of CATS 
protein with high nucleolar activity and thus a proliferative state of the cell. Thus CATS is a 
marker for proliferation and the amount of the protein is correlated to the cell cycle phases, 
being low in G1 and high in the S-G2 phase. 
Surprisingly, we failed to detect CATS protein in the leukemic cell line HL60. The fact that 
we found abundant amounts of CATS transcript in HL60 cells but not protein, suggests a post-
transcriptionally regulation of CATS and that CATS is not essential for proliferation in this 
cell line.  
Nevertheless, a function of CATS as a marker for proliferation was nicely demonstrated by 
Cats up-regulation in B220+ cells from a CALM/AF10 leukemic mouse population in 
comparison to the same population from a non-leukemic mouse. In this murine leukemia 
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model, the B220+ cells represent the leukemia propagating cells (Deshpande, 2005). These 
findings not only confirm CATS as a marker for proliferation but also suggest that CATS is 
an early player in CALM/AF10 mediated transformation. 
In this work, we described several monoclonal antibodies generated against the C-termini of 
CATS protein. The monoclonal antibody CATS 2C4 recognized the endogenous protein most 
efficiently followed by 7F6 and 2A2, all detecting both CATS isoforms. Differently from 
these antibodies, the antibodies specific for isoform 2 (7H2 and 3H8) did not seem to detect 
the endogenous CATS isoform 2 (only the overexpressed protein). Whether these antibodies 
are not able to recognize the endogenous isoform 2 of CATS or if the endogenous expression 
levels of the isoform 2 are too low for detection has to be determined. The observation that 
the transcript coding for isoform 2 are lower expressed than the ones coding for CATS 
isoform 1 supports the idea that the endogenous isoform 2 of CATS is less abundant. 
Immunofluorescence experiments of non-synchronized cells using the antibodies mentioned 
above showed levels of endogenous CATS expression, which were variable from cell to cell. 
There was also cell to cell variability of the nucleolar localization. To rule out that these 
observations were due to methodological problems different fixation protocols and 
experimental conditions were employed. In line with the results from the Western analysis, 
CATS failed to accumulate in the nucleoli of cells which grew at high density, i.e. growth 
arrested cells. These cell completely lacked nucleolar CATS staining, indicating that the 
nucleolar localization of CATS is associated with cell proliferation. Consistent with these 
observations, transiently expressed YFP-CATS did also not accumulate in the nucleoli of 
every cell expressing the plasmid. Moreover, YFP-CATS was not found in the nucleoli of 
cells which had been treated with the nuclear export inhibitor leptomycin B (LMB). LMB is 
one of the 13 agents described to disrupts nucleolar function and induce p53 (Rubbi & Milner, 
2003). Consistent with the nucleolar export model proposed by Rubbi and Milner, disruption 
of nucleolar function/structure caused by cellular stress promotes translocation of many 
nucleolar proteins to the nucleoplasm where they are able to interfere with p53 degradation 
and consequently with its stabilization and activation (Kamijo et al., 1998; Kurki et al., 2004a; 
Kurki et al., 2004b; Maggi & Weber, 2005; Olson, 2004; Rubbi & Milner, 2003; Tao & 
Levine, 1999). Interestingly, we identified two CATS interacting proteins, PCBP1and CSNK2 
in the nucleolar proteome database (Leung et al., 2006). The nucleolar localization of these 
proteins also decreases following the disruption of nucleolar function (upon treatment with 
the proteasome inhibitor MG132) (Andersen et al., 2005; Leung et al., 2006). These results 
strongly suggest that the proliferative function of CATS resides in the nucleolus while its 
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nucleoplasm localization could possibly be related stabilization of p53. However, this link to 
p53 has to be further investigated.  
Another question raised by our observations is whether CATS in one of the several MYC 
nucleolar targets that regulate cell proliferation. The fact that we found KIS as a CATS 
interacting partner further confirms this hypothesis. KIS positively regulates cell cycle 
progression by inhibiting p27KIP function, an important downstream target of MYC. It would 
be very important to address this question. 
 
4.3 CATS interacting proteins 
 
In order to gain further insights into CATS function we performed a yeast two-hybrid screen 
to identify interaction partners of CATS. Determining protein interactions we were able to 
indentify potential pathways that CATS might be involved thus placing CATS in a functional 
context within the living cell.  
 
4.3.1 PCBP1 
 
The poly(C)-binding protein 1 (PCBP1, also referred to as αCP1 or hnRNP-E1) is a RNA-
binding protein characterized by its triple KH structure and by its poly(c) binding specificity 
(Kiledjian et al., 1995; Leffers et al., 1995). It is a member of the PCBP family of proteins, 
which are involved in a wide spectrum of post-transcriptional control pathways. As for other 
PCBPs, the function of PCBP1 in mRNA stabilization, translation activation and translational 
silencing from both cellular and viral RNAs has been well characterized (for review; 
Makeyev & Liebhaber, 2002; Ostareck-Lederer & Ostareck, 2004; Ostareck-Lederer et al., 
1998). For example, PCBP1 is a component of a ribonucleoprotein complex that assembles on 
the 3’-UTR of a subset of long-lived mRNA to promote their stabilization. On the other hand, 
PCBP1/ hnRNP K-DICE complex formation at the 3’-UTR of the r15-LOX mRNA silences 
translation by blocking ribosome assembly at the translation initiation codon. PCBP1 not only 
affects the fate of cellular mRNA but it also stabilizes and enhance translation of poliovirus 
RNA via interaction with stem-loop IV of the internal ribosome entry site (IRES) (Gamarnik 
& Andino, 1997) and silences the translation of papillomavirus L2 (Collier et al., 1998). Most 
recently, several reports have described PCBP1-mediated enhancement of translation through 
stimulation of internal IRES element within cellular mRNAs, such c-myc, X-linked inhibitor 
of apoptosis (XIAP) and of the anti-apoptotic Bag-1 (Bcl-2 associated athanogene-1) (Evans 
et al., 2003; Nishimura et al., 2004; Pickering et al., 2003). Besides its function on mRNA 
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stability and translation, additional roles for PCBP1 in transcriptional control and apoptotic 
pathways have been proposed (Kim et al., 2005; Ko & Loh, 2005; Nishimura et al., 2004).  
We identified PCBP1 as a CATS interacting partner in a yeast two-hybrid screen. None of the 
5 independent PCBP1 cDNA clones isolated in the screen coded for the complete PCBP1 
ORF, but rather for PCBP1 proteins starting from different residues located within the first 
KH domain (KHI) or downstream of this motif, just 5’ of the KHII domain. The fact that two 
clones coded for PCBP1 lacking the complete first KH domain indicates that this motif is not 
necessary for the CATS-PCBP1 interaction. It has been described that both KHI and KHIII 
domain of PCBP1 confer the poly(c)-binding activity of the protein whereas all three KH 
domains exhibit binding activity towards other nucleic acids, albeit at significantly lower 
levels (Dejgaard & Leffers, 1996). Phosphorylation of PCBP1 results in a marked decrease in 
poly(c)-binding activity (Leffers et al., 1995), which for hnRNP K (member of the PCBP 
family and interacting partner of PCBP1 in the hnRNP K/PCBP1-DICE complex) results in 
the association with transcriptional repressors such as Eed and protein kinases such as Src, 
Erk and Lck and in the cytoplasmatic accumulation of the protein. The cellular distribution of 
the hnRNP K between nucleus and cytoplasm can be controlled by the MAP kinase signaling 
pathway. Serine phosporylation of hnRNP K by ERK kinase leads to its accumulation in the 
cytoplasm and enhances hnRNP K/PCBP1-DICE- dependent inhibition of mRNA translation  
(for review; Perrotti & Calabretta, 2004). This hnRNP K/PCBP1-DICE- dependent inhibition 
of mRNA can be abolished by tyrosine phosphorylation of hnRNP K by c-Src (PCBP1 is not 
an activator or substrate for c-Src) (Ostareck-Lederer et al., 2002). Although PCBP1 is itself a 
shuttling protein (Chkheidze & Liebhaber, 2003; Makeyev & Liebhaber, 2002), localization 
experiments have shown that CATS colocalizes with PCBP1 mainly in the nucleus and to a 
lesser extent in the cytoplasm. Interestingly, directed proteomic analysis of the human 
nucleolus has identified PCBP1 as one not previously described nucleolar protein (Andersen 
et al., 2005). It is tempting to speculate that the PCBP1-CATS interaction might take place in 
the nucleus or even in the nucleolus where most of CATS is localized. In the nucleus, CATS 
might function as regulator of transcription so one could postulate a role for the PCBP1-
CATS interaction in transcription control. Nevertheless, we cannot exclude a possible 
involvement of CATS in protein complexes controlling post-transcriptional pathways.  
In line with this idea, we have identified two protein kinases as CATS interacting partners, the 
kinase interacting stathmin (KIS) and casein kinase type II beta subunit (CSNK2B). KIS is a 
protein kinase with RNP-type recognition motif and is involved in regulating RNA associated 
factors and enhances formation of protein-RNA complexes. Thus suggesting that post-
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translational modifications on CATS or mediated by CATS could, for example, be involved 
in the activity of PCBP1. It would be of great value to investigate a possible kinase activity 
within the CATS protein and whether PCBP1 is a substrate for CATS. The involvement of 
CATS in RNA metabolism is further supported by the fact that the anti-apoptotic protein 
HAX1, also identified as CATS interacting partner is itself a RNA-binding protein suggesting 
its role in mRNA translation (Al-Maghrebi et al., 2002). Interestingly, PCBP1 is also a 
CALM interacting partner (Zlatana Pasalic, personal communication). The interaction 
between PCBP1 and CATS and these both proteins with CALM suggests that they form a 
protein complex. However, the biological significance of the interaction between these 
proteins, which function apparently in completely different cellular processes, has to be 
investigated.  
Intriguing is the implication that the CATS-CALM-PCBP1 interaction has in the leukemic 
context of CALM/AF10. By investigating the mechanism of leukemic transformation of 
hematopoietic cells, Perroti and coworkers (Perrotti & Calabretta, 2004 and references 
therein) have indeed found that expression and activity of several RNA-binding proteins was 
altered by the BCR/ABL fusion protein. Moreover, they identified MDM2 and CEBPA 
mRNAs as targets for these PCBPs, being directly relevant for the altered differentiation and 
survival of leukemic cells.  
A recent report by Giles et al. has described PCBP1 to bind and to regulate p21WAF1 mRNA 
stability. Moreover, multiple reports show that EGF induces p21WAF1 expression via 
stabilization of p21WAF1 mRNA (Giles et al., 2003 and references therein). Since clathrin 
mediated endocytosis (CME) is the major mechanism of down regulation of activated EGFR 
it is tempting to speculate that altered CALM function in CALM/AF10 leukemic cells would 
influence the normal function of PCBP1 and the post-transcriptional regulation of its target 
mRNAs. Supporting this idea is the fact that a down regulation of normal CALM mRNA is 
observed in leukemic cells from T-ALL patients carrying a CALM/AF10 rearrangement (Dik 
et al., 2005) and the observation that CALM/AF10 including the CALM portion of the fusion 
protein is mislocalized to the nucleus through the CATS-CALM/AF10 interaction 
(Archangelo et al., 2006).  
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4.3.2 KIS 
 
We have identified the kinase interacting with Stathmin (KIS) as a CATS interacting partner 
in the yeast two-hybrid screen. A first confirmation of this interaction was performed by 
cotransforming both CATS bait and KIS prey plasmids into yeast and assaying for growth on 
selective plates. The single KIS cDNA clone isolated in the screening coded for residues 33 to 
419 of the KIS ORF. Although, the first 10 aa N-terminal of the kinase core domain of KIS 
(Maucuer et al., 1997) were missing in the cDNA clone most of the core domain including the 
K54 kinase active site was still retained, indicating that CATS could be a substrate for KIS. 
The fact that KIS is a serine/threonine kinase suggests that CATS might be a substrate for KIS 
on these residues. In fact, CATS has three serine (S131, S185 and S195) and one threonine 
(T74) proline-directed residues, which are preferentially phosphorylated by KIS (Maucuer et 
al., 2000), with the S131 being a very good candidate site, since it lies within the SGSP 
consensus sequence for KIS phosphorylation. CATS seems to be involved in several 
regulatory pathways (such as signaling and control of apoptosis) controlled by post-
translational modifications implicating a possible role for CATS as a kinase substrate. 
Whether CATS is a substrate for KIS has to be further investigated. Nevertheless, the fact that 
both CATS and KIS share similar expression pattern and subcellular localization strengthens 
the biological relevance of this interaction in vivo.  
KIS was first identified as one of the proteins interacting with stathmin, a phosphoprotein 
phosphorylation of which correlates with diverse regulatory pathways including T-cell 
activation and cell cycle progression (Maucuer et al., 1995). The 46.5 kDa KIS protein 
localizes, like CATS, mainly to the nucleus and to a lesser extent to the cytoplasm. KIS has an 
N-terminal kinase core (282 aa) and a C-terminal domain that contains characteristic RPN-
type RNA recognition motif (RRM) with high sequence identity to U2AF65, a 65 kDa 
subunit of the splicing factor U2AF (Alam et al., 1996; Caldwell et al., 1999; Maucuer et al., 
1995; Maucuer et al., 1997). Because of its RNA recognition motif, KIS is thought to 
phosphorylate and regulate RNA associated factors (Maucuer et al., 1997). Recently, 
Manceau and colleges have indeed described a interaction between KIS and the splice factor 1 
(SF1). They showed that phosphorylation of SF1 by KIS increases binding of SF1 to U2AF65 
and enhances formation of ternary SF1-U2AF65-RNA complex (Manceau et al., 2006). The 
involvement of CATS in an interaction with KIS, a RNA-binding kinase which regulates the 
formation of protein-RNA complex, suggests a role for CATS in RNA metabolism. In line 
with this idea we have found PCBP1 (also known as hnRNPE1), a RNA binding protein 
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involved in translational regulation and/or mRNA stabilization in hematopoietic cells 
(Ostareck-Lederer & Ostareck, 2004) as CATS interacting partner (see above).  
The most well characterized function of KIS is however its ability to positively regulate cell 
cycle progression (Boehm et al., 2002; Le et al., 2005). KIS is the major kinase responsible 
for S10 phosphorylation on the cyclin-dependent kinase inhibitor p27Kip and phosphorylation 
on S10 by KIS promotes nuclear export of p27Kip reducing its inhibitory effect on cell cycle 
(Boehm et al., 2002). Thus abnormally elevated KIS activity, which is expected to relieve 
cells from growth inhibition dependent on p27Kip, might be involved in some aspects of tumor 
development. It was indeed shown that depletion of KIS significantly lowered the 
phosphorylation of p27Kip and enhanced growth arrest in leukemic cells suggesting that KIS 
promotes cell cycle progression in those cells (Nakamura, 2005). Moreover, elevated levels of 
KIS expression were observed in different types of neurological tumors (Bieche et al., 2003) 
and KIS expression has been shown to be targeted by the anti-HER2 antibody trastuzumab, 
used in treatment of human metastic breast cancer with HER2-overexpression (Le et al., 
2005). The KIS kinase activity is induced by mitogens during G0/G1, where it promotes cell 
cycle progression in G1 phase of the cell cycle. Interestingly, like KIS, CATS expression is 
also induced by mitogens with low levels of protein found in G0 cells and increased levels 
upon serum stimulation. Moreover, CATS is highly expressed in proliferating and tumor cells 
in a cell cycle dependent manner. Thus it is tempting to hypothesize that CATS is involved in 
the same cell cycle control pathway regulated by KIS and that CATS might modulate or be 
modulated by KIS kinase activity. It would be very interesting to investigate whether CATS 
overexpression or down regulation would mimic the effect of KIS and whether it has an effect 
on p27Kip. 
In this work we have shown that CATS function in the nucleus as a repressor of transcription, 
thus we cannot rule out that through the CATS-KIS interaction KIS can also have an 
additional role in the nucleus of modulating the transcriptional activity of CATS.  
Although KIS is a ubiquitous protein it displays a preferentially neural expression. (Bieche et 
al., 2003; Caldwell et al., 1999; Maucuer et al., 1995; Maucuer et al., 1997). Interestingly, 
KIS expression in the central nervous system (CNS) and dorsal ganglia of rat embryos has 
suggested a role for KIS in developing nervous system (Maucuer et al., 1997). Like KIS, 
CATS expression was detected enriched in the murine CNS suggesting a similar role for both 
proteins during embryogenesis. In the nervous system, a role for the cytoplasmic portion of 
KIS has also been described. Alam and coworkers have independently identified KIS as a 
PAM cytosolic interactor protein (they named KIS as P-CIP2) (Alam et al., 1996). 
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Phosphorylation of the cytosolic domain (CD) of PAM by KIS allows PAM to affect 
trafficking in the regulated secretory pathway it is involved (Alam et al., 1996; Alam et al., 
2001; Caldwell et al., 1999). CATS is not expressed in the adult neural cells, however this 
does not rule out a role for CATS through CATS-KIS interaction in post-translational 
modification of membrane protein, affecting signaling and protein trafficking in lymphoid 
cells where CATS is expressed. We have shown that CATS interacts with CALM, another 
membrane protein involved in clathrin mediated endocytosis and trafficking. Moreover, we 
have proposed that CATS is a critical modulator of normal CALM function in lymphoid cells 
and that CATS could be very important for understanding the leukemic potential of 
CALM/AF10 fusion protein (Archangelo et al., 2006). The fact that the KIS kinase activity 
modulates trafficking of membrane protein links CATS function with post-translational 
modification and protein internalization/trafficking in CATS expressing cells supporting a 
role for CATS in normal CALM function. 
All in all, we have shown strong evidences for the involvement of CATS in the 3 different 
nuclear as well as cytoplasmic cellular pathways modulated by KIS suggesting a close 
functional relationship between these proteins in all these cellular processes. 
 
4.3.3 HAX1 
 
We identified HAX1 as a CATS interacting partner in the yeast two-hybrid screen. This 
interaction was confirmed in vivo by cotransforming both the CATS bait and the HAX1 prey 
plasmids into yeast as well as by coimmunoprecipitation experiments in mammalian cells. 
Both HAX1 cDNA clones isolated in the yeast two-hybrid screen lacked sequences coding for 
the N-terminal portion of the protein (residues 1-132 or 1-153), indicating that the association 
between CATS and HAX1 is mediated through the C-terminal half of HAX1 (residues 153-
279).  
Although only a small proportion of the total cellular CATS protein was found in the 
cytoplasm, the fact that CATS was found to interact with two unrelated proteins that have a 
cytoplasmic localization and are known to function in the cytoplasm, such as CALM and 
HAX1, suggests a role for CATS in the cytoplasm.  
HAX1 was first identified as an interacting partner of the hematopoietic specific protein 1 
(HS1), a substrate of the Src family tyrosine kinase LYN which is part of the B-cell and T-cell 
receptor signaling cascade playing an important role in apoptotic and proliferative responses. 
HAX1 is a 35 kDa ubiquitously expressed protein that localizes to the mitochondria, 
endoplasmic reticulum and nuclear envelope and shows sequence similarity to the apoptosis 
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related protein NIP3 and BCL2 (Suzuki et al., 1997). To date, several other cellular and viral 
proteins have been described to interact with HAX1 including cortactin (the non-
hematopoietic homolog of HS1), polycystic kidney disease protein PKD2, EBNA-LP, 
interleukin-1α (IL-1α), Kaposi’s sarcoma-associated herpesvirus (KSHV) K15, IQGAP2, 
anti-apoptotic protein BCL2 and its Epstein-Barr virus homolog BHRF1, alpha-subunit of the 
G13 protein, HTRA2 (Omi) protease and the Human deficiency virus type 1 (HIV-1) viral 
protein R (Vpr). Thus HAX1 is implicated in modulating apoptosis and in actin cytoskeleton 
binding and motility functions (Cilenti et al., 2004; Dufva et al., 2001; Gallagher et al., 2000; 
Kawaguchi et al., 2000; Matsuda et al., 2003; Radhika et al., 2004; Sharp et al., 2002; 
Weissbach et al., 1998; Yedavalli et al., 2005; Yin et al., 2001). Among the different 
functions proposed for HAX1, its role in modulating apoptosis has been studied extensively. 
HAX1 was found in anti-apoptotic signaling counteracting the pro-apoptotic effects of BAX 
(Sharp et al., 2002) and down regulation of HAX1 was shown to induce apoptosis in HaCat 
cells (Mirmohammadsadegh et al., 2003). Recently, Cilenti et al. reported a mechanism of 
HAX1 regulation by the HTRA2 (Omi) serine protease. Evidence was presented that the anti-
apoptotic function of HAX1 might be mediated through its ability to regulate the 
mitochondrial membrane potential and that the cleavage of HAX1 by HTRA2 in 
mitochondria would allow the depolarization of the mitochondrial membrane leading to the 
release of pro-apoptotic proteins to the cytoplasm. In such a way, HAX1 and its regulation by 
HTRA2 would play a central role in mammalian cell death (Cilenti et al., 2004). 
The interaction between CATS and the anti-apoptotic protein HAX1 suggests a possible role 
for CATS in B-cell receptor mediated signaling leading to apoptotic and proliferative 
responses. Like HS1, CATS is also expressed specifically in lymphoid tissues and 
hematopoietic cells. Furthermore, expression of the CATS protein strongly correlates with the 
proliferative state of the cells. Thus it is tempting to speculate that CATS and HAX1 are part 
of the same cellular circuit and that the ability of HAX1 to promote cell survival might 
correlate with CATS expression in proliferating cells. The fact that CATS was found to 
interact with SIVA, another apoptosis-related protein, further supports the idea of CATS 
functioning in the control of apoptotic pathways. 
Nevertheless it is also interesting to consider a function for the CATS-HAX1 interaction other 
than in regulating apoptosis. We showed that CATS interacts with the RNA-binding protein 
PCBP1, a protein involved in stabilization and translational control of mRNAs suggesting a 
role for CATS in this processes. Interestingly, Al-Maghrebi et al. have recently reported 
HAX1 as a new RNA-binding protein which can strongly and specifically bind to the 3’ 
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untranslated region of the human vimetin mRNA suggesting a role for HAX1 in post-
transcriptional control pathways (Al-Maghrebi et al., 2002). In summary, the interaction 
between CATS and HAX1 suggests a role for CATS in important regulatory pathways, but 
the biological significance of this interaction and the possible effect that one protein might 
have on the function of the other has to be further investigated.  
 
4.3.4 SIVA 
 
We identified the pro-apoptotic protein SIVA1 together with PCBP1 as the most frequent 
CATS interacting partner in the yeast two-hybrid screen. Interaction between CATS and 
SIVA1 was confirmed in vivo by cotransforming both the CATS bait and the SIVA1 prey 
plasmids into yeast as well as by coimmunoprecipitation experiments in mammalian cells.  
SIVA1 is a pro-apoptotic protein which was initially identified using the cytoplasmic tail of 
CD27 (TNFRSF7), a member of the tumor necrosis factor receptor (TNFR) superfamily, as 
the bait in a yeast two-hybrid screen (Prasad et al., 1997). Since then a role for SIVA in 
various receptor (extrinsic) and nonreceptor (intrinsic) mediated apoptosis pathways has been 
described (Cao et al., 2001; Chu et al., 2005; Chu et al., 2004; Gudi et al., 2006; Henke et al., 
2000; Henke et al., 2001; Lin & Ying, 1999; Padanilam et al., 1998; Py et al., 2004; Qin et al., 
2002; Spinicelli et al., 2002; Xiao et al., 2000; Xue et al., 2002; Yoon et al., 1999). The full 
length main isoform of SIVA (SIVA1) is a 175 aa protein with a putative 20 aa amphipathic 
helical region (SAH) at the NH2 terminus and cysteine zinc-finger towards the C-terminus. 
The the minor isoform (SIVA2) lacks exon 2 that codes for the SAH region and is much less 
pro-apoptotic (Chu et al., 2004; Prasad et al., 1997; Yoon et al., 1999). Recently, several 
reports have looked into the mechanism of SIVA-mediated apoptosis. SIVA1 was shown to 
be a downstream target for post-translational modification by the ABL2 (ARG) tyrosine 
kinase signaling in the apoptotic response to oxidative stress (Cao et al., 2001) and to be a 
direct transcriptional target of the tumor suppressor gene TP53 and the transcription factor 
E2F1 (Fortin et al., 2004). Prasad, and co-workers showed that SIVA1 binds to the anti-
apoptotic members of the BCL2 family (Bcl2/Bcl-XL) through the SAH domain and that this 
interaction abrogates the Bcl2/Bcl-XL cell survival function (Chu et al., 2004; Xue et al., 
2002). Moreover, the SIVA1-mediated apoptotic pathway results in the activation of both 
initiator and effector caspases, such as caspase-8, -9 and -3, it involves loss of mitochondrial 
integrity through the activation of BID and cytochrome c release and this activity can be 
modulate by overexpression of BCL2 or BCL2L1 (Bcl-XL) (Py et al., 2004).  
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Additionally to its expression in normal tissues, several studies demonstrated SIVA 
overexpression in various pathologic circumstances, such as acute ischemic (Padanilam et al., 
1998) or neuronal injury (Fortin et al., 2004), virus infection (Henke et al., 2000; Henke et al., 
2001), and tumor cells exposed to genotoxic agents that induce a TP53 death response (Daoud 
et al., 2003; Qin et al., 2002). However, the main role of SIVA induced apoptosis has been 
characterized in response to TNFR signaling cascade in the immune system (Chu et al., 2004; 
Gudi et al., 2006; Prasad et al., 1997; Py et al., 2004; Spinicelli et al., 2002; Xue et al., 2002; 
Yoon et al., 1999). SIVA is the intracellular signaling molecule that associates with CD27 
(TNFRSF7) and GITR (TNFRSF18), two TNFR transmembrane receptors expressed on 
lymphoid cells. CD27 is known to provide important co-stimulatory signals for T- and B-cell 
growth and B-cell Ig production and the GITR signal transduction pathway counteracts T cell 
apoptosis. Through interaction with SIVA1 these receptors are able to transduce their 
apoptotic response (Py et al., 2004; Spinicelli et al., 2002). SIVA association with these 
receptors and its participation in their receptor-mediated apoptosis pathways suggests an 
important role for SIVA in the regulation of T cell homeostasis. In line with these findings, is 
the fact that natural SIVA1/Bcl-XL complexes are found in murine thymocytes and HUT78 
cells. Moreover, Gudi et al. have very recently demonstrated a significant role for SIVA1 in 
TCR-mediated AICD (activation-induced cell death), through an inhibitory effect on NF-κB 
activity further underpinning to the role of SIVA1 in T-cell homeostasis (Gudi et al., 2006; Py 
et al., 2004; Xue et al., 2002).  
The fact that CATS is specifically expressed in lymphoid tissues and interacts with SIVA, a 
pro-apoptotic protein involved in receptor-mediated apoptotic pathways and T-cell 
homeostasis, suggests a role for CATS in TNF receptor signaling and regulation of apoptotic 
response in lymphoid cells. However, we also showed that CATS is strongly expressed in 
proliferating cells and that CATS is likely to play a role in the regulation of cell proliferation. 
In line with these findings, we identified HAX1, PCBP1 and CSNK2 (involved in anti-
apoptotic function, enhancement of translation of anti-apoptotic genes, and cell 
growth/proliferation and suppression of apoptosis, respectively) as CATS interacting proteins. 
Thus it is intriguing that CATS should be involved in a protein–protein interaction with a pro-
apoptotic protein. Although the biological relevance to this interaction has to be further 
investigated it is tempting to speculate that through the interaction with SIVA CATS is able to 
sequester SIVA and modulate its pro-apoptotic function for example by inhibiting its 
association with the BCL2 members or by abrogating the inhibitory function of SIVA on NF-
κB activation. Similar mechanisms have been reported for other apoptotic proteins, for 
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instance the apoptotic protein BIM is prevented from associating with BAX after 
phosporylation and thereby has a pro-apoptotic function (Harada et al., 2004). Whether CATS 
is able to modulate SIVA function just by forming complex or by posttranslational 
modification has to be investigated.  
 
4.4 CATS can be placed in key pathways involved in 
tumorigenesis 
 
In summary, CATS is a novel protein which was identified to interact with and influence the 
subcellular localization of CALM/AF10. However, the involvement of CATS in malignant 
transformation seems to go beyond its interaction with the leukemogenic fusion protein 
CALM/AF10. CATS is highly expressed in nearly all tumor cell lines examined and its 
nucleolar localization connects CATS function with proliferation and possibly to TP53 
regulation. Moreover, evidence presented in this work suggests an involvement of CATS in 
signaling, apoptosis and cell cycle control. Thus, CATS function might be tightly linked to 
cancer initiation and/or progression. It will be very interesting to investigate to which extent 
CATS contributes to or determines cell proliferation and what effect its depletion might have 
on tumor cells.  
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5 Summary 
 
The Clathrin Assembly Lymphoid Myeloid leukemia gene (CALM) was first identified as the 
fusion partner of AF10 in the t(10;11)(p13;q14) translocation. The CALM/AF10 fusion 
protein plays a crucial role in t(10;11)(p13;q14) associated leukemogenesis.  Using the N-
terminal half of CALM as a bait in a yeast two-hybrid screen a novel protein named CATS 
(CALM interacting protein expressed in thymus and spleen) was identified as CALM 
interacting partner. Multiple tissue Northern blot analysis showed predominant expression of 
CATS in lymphoid tissues. CATS codes for two protein isoforms of 238 and 248 amino acids. 
The interaction between CALM and CATS was confirmed by co-immunoprecipitation and 
colocalization experiments. The CATS interaction domain of CALM was mapped to amino 
acids 221 to 294 of CALM. This domain is contained in the CALM/AF10 fusion protein. 
CATS localizes to the nucleus and shows a preference for nucleoli. Expression of CATS was 
able to markedly increase the nuclear localization of CALM and of the leukemogenic fusion 
protein CALM/AF10. This effect of CATS seems to be stronger on CALM/AF10 than on 
CALM. Several monoclonal antibodies against the C-terminus of human CATS were 
generated. These antibodies recognize both the human and the murine CATS protein. Western 
blot analyses showed that CATS is strongly expressed in different human leukemia, 
lymphoma and tumor cell lines but not in resting T-cells. High CATS expression in 
proliferating cells as well as its nucleolar localization suggest a role of CATS in the control of 
cell proliferation.  
In order to gain further insight into CATS function we used CATS as a bait in a yeast two-
hybrid screen. Several CATS interacting proteins with apparently unrelated function were 
identified. Interestingly, on closer scrutiny these proteins could be associated with three key 
regulatory pathways: signaling, apoptosis and cell cycle control. We discuss in detail the 
biological relevance of the CATS interaction with the two apoptosis-associated proteins 
HAX1 and SIVA, the cell cycle regulator KIS and the CALM interacting ribonucleoprotein 
PCBP1. 
Our results indicate that the subcellular localization of CALM and CALM/AF10 could 
depend in part on the presence of CATS with a greater fraction of CALM or CALM/AF10 
being present in the nucleus of cells with high CATS expression (e.g. lymphoid cells have 
high CATS expression). Moreover we provide evidences that CATS function might be tightly 
linked to cancer initiation and/or progression. The CALM-CATS interaction might thus play 
an important role in CALM/AF10 mediated leukemogenesis. 
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6 Zusammenfassung 
 
Das Clathrin Assembly Lymphoid Myeloid leukemia gene (CALM) wurde zuerst als 
Fusionspartner von AF10 bei der t(10;11)(p13;q14) Translokation identifiziert. Das 
CALM/AF10 Fusionsprotein spielt eine entscheidende Rolle bei der t(10;11)(p13;q14) 
assoziierten Leukämieentstehung.  Mit der N-terminalen Hälfte von CALM als Köder in 
einem Yeast-Two-Hybrid-Screen, wurde ein neues Protein namens CATS (CALM interacting 
protein expressed in thymus and spleen) als CALM Interaktionspartner indentifiziert. 
Multiple-Tissue-Northern-Blot-Analysen zeigten, dass CATS überwiegend in lymphatischen 
Geweben exprimiert wird. Das CATS-Gen kodiert für zwei Proteinisoformen, die aus 238 
bzw. 248 Aminosäuren bestehen. Die Interaktion zwischen CALM und CATS wurde durch 
Koimmunoprezipitations- und Kolokalisationsexperimente bestätigt. Die CATS-
Interaktiosdomäne von CALM konnte den Aminosäuren 221 bis 294 von CALM zugeordnet 
werden. Diese Domäne ist auch Bestandteil des CALM/AF10-Fusionsproteins. Das CATS-
Protein ist im Zellkern, überwiegend in den Nucleoli, lokalisiert. Die Überexpression von 
CATS führte zu einer deutlichen Anreicherung von CALM und dem leukämischen 
Fusionsprotein CALM/AF10 im Zellkern. Dieser Effekt von CATS ist stärker bei 
CALM/AF10 als bei CALM. Es wurden mehrere monoklonale Antikörper gegen den C-
terminus von CATS hergestellt. Diese Antikörper erkennen spezifisch sowohl das humane als 
auch das murine CATS-Protein. Western-Blot Analysen zeigten, dass CATS in verschiedenen 
Leukämie-, Lymphom- und Tumorzelllinien, allerdings nicht in ruhenden T-Zellen exprimiert 
wird. Die hohe Expression von CATS in proliferierenden Zellen sowie seine nucleoläre 
Lokalization sprechen für eine regulierende Rolle von CATS bei der Zellproliferation.  
Um weitere Einblicke in die Funktion von CATS zu erlangen, haben wir CATS als Köder in 
einem Yeast-Two-Hybrid-Screen verwendet. Dabei haben wir mehrere interagierende 
Proteine mit unterschiedlichen Funktionen gefunden. Bei genauerer Betrachtung dieser 
Proteine, konnten wir sie nach ihren Funktionen in drei Gruppen einteilen, nämlich 
Signaltransduktion, Apotose und Regulation des Zellzyklus. Die Interaktionen zwischen 
CATS und den Apoptose-assoziierten Proteinen HAX1 und SIVA, dem Zellzyklusregulator 
KIS sowie dem Ribonucleoprotein PCBP1 werden auführlich diskutiert. 
Unser Ergebnisse zeigen, dass die zelluläre Lokalisation von CALM und CALM/AF10 
teilweise von der Anwesenheit von CATS abhängt, da größere Mengen CALM oder 
CALM/AF10 im Zellkern von Zellen mit hoher CATS-Expression (z.B. haben lymphatische 
Zellen eine hohe CATS-Expression) vorhanden sind. Darüber hinaus liefern wir 
Anhaltspunkte dafür, dass die Funktion von CATS mit der Entstehung bzw. dem 
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Fortschreiten von Krebserkrankungen eng zusammenhängen könnte. Die CALM-CATS 
Interaktion könnte also eine wichtige Rolle bei der CALM/AF10 vermittelten 
Leukämieentstehung spielen. 
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